Citation Report
List of articles citing

Targeting HIF-1 for cancer therapy

DOI: 10.1038/nrc1187
Nature Reviews Cancer, 2003, 3, 721-32.

#	Paper	IF	Citations
2250	Glycolysis module activated by hypoxia-inducible factor 1 is related to the aggressive phenotype of hepatocellular carcinoma. **1992**, 33, 725		4
2249	Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. **1994**, 20, 1561		3
2248	The C1772T genetic polymorphism in human HIF-1 gene associates with expression of HIF-1 protein in breast cancer. **1994**, 20, 1181		0
2247	Rapid detection of the hypoxia-regulated CA-IX and NDRG1 gene expression in different glioblastoma cells in vitro. **1994**, 20, 413		1
2246	Environmental impact. *Nature Reviews Cancer*, **2003**, 3, 713-714	31.3	
2245	Mechanism of action of 2-methoxyestradiol: new developments. **2003**, 6, 355-61		139
2244	Parallels in invasion and angiogenesis provide pivotal points for therapeutic intervention. **2004**, 48, 583-98		59
2243	HIF-1alpha: a valid therapeutic target for tumor therapy. **2004**, 36, 343-53		55
2242	The hypoxia-inducible factor and tumor progression along the angiogenic pathway. **2005**, 242, 157-213		61
2241	The Eker rat: establishing a genetic paradigm linking renal cell carcinoma and uterine leiomyoma. **2004**, 4, 813-24		38
2240	Multiple roles of vascular endothelial growth factor (VEGF) in skeletal development, growth, and repair. **2005**, 65, 169-87		169
2239	H2AX may function as an anchor to hold broken chromosomal DNA ends in close proximity. **2004**, 3, 149-53		214
2238	Regulation of endothelial cell death and its role in angiogenesis and vascular regression. **2004**, 1, 305-15		32
2237	Proceedings of the Oxygen Homeostasis/Hypoxia Meeting. **2004**, 64, 3350-6		28
2236	Regulation of transcription and translation by hypoxia. **2004**, 3, 492-7		151
2235	Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (FIH) in regulating hypoxia-inducible factor (HIF) transcriptional target genes [corrected]. **2004**, 279, 42719-25		127
2234	Positron emission tomography-based molecular imaging in human cancer: exploring the link between hypoxia and accelerated glucose metabolism. **2004**, 10, 2203-4		23

2233	Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. **2004**, 64, 6845-8	176
2232	Exploitation of the HIF axis for cancer therapy. **2004**, 3, 608-11	29
2231	Targeting Topoisomerase 1 to inhibit Hypoxia Inducible Factor 1. **2004**, 3, 167-170	34
2230	Oxygen and the cell. **2004**, 385, 203-4	
2229	Defective acidification of intracellular organelles results in aberrant secretion of cathepsin D in cancer cells. **2004**, 279, 39982-8	65
2228	9-beta-D-arabinofuranosyl-2-fluoroadenine inhibits expression of vascular endothelial growth factor through hypoxia-inducible factor-1 in human ovarian cancer cells. **2004**, 66, 178-86	23
2227	Acute myocardial hypoxia increases BNP gene expression. **2004**, 18, 1928-30	158
2226	Glucose utilization is essential for hypoxia-inducible factor 1 alpha-dependent phosphorylation of c-Jun. **2004**, 24, 4128-37	22
2225	Dysregulation of ferroportin 1 interferes with spleen organogenesis in polycythaemia mice. **2004**, 131, 4871-81	33
2224	c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1alpha-dependent P-glycoprotein expression in hypoxia. **2004**, 64, 9057-61	99
2223	Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function. **2004**, 10, 4158-64	16
2222	DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. **2004**, 24, 5757-66	79
2221	Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates. **2004**, 101, 8132-7	182
2220	Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. **2004**, 96, 946-56	207
2219	Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. **2004**, 10, 8603-12	60
2218	HIF-1: an oxygen and metal responsive transcription factor. **2004**, 3, 29-35	193
2217	Raising the Bar: How HIF-1 Helps Determine Tumor Radiosensitivity. **2004**, 3, 1105-1108	35
2216	Siah: new players in the cellular response to hypoxia. **2004**, 3, 1345-7	36

2215	Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade. **2004**, 3, 503-4	17
2214	Functional integrity of nuclear factor kappaB, phosphatidylinositol 3'-kinase, and mitogen-activated protein kinase signaling allows tumor necrosis factor alpha-evoked Bcl-2 expression to provoke internal ribosome entry site-dependent translation of hypoxia-inducible factor 1alpha. **2004**, 64, 9041-8	55
2213	Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. **2004**, 279, 40337-44	236
2212	Hypoxia-induced nucleophosmin protects cell death through inhibition of p53. **2004**, 279, 41275-9	117
2211	Lack of correlation between expression of HIF-1alpha protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix. **2004**, 64, 5876-81	81
2210	Carbonic anhydrase IX in early-stage non-small cell lung cancer. **2004**, 10, 7925-33	74
2209	Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. **2004**, 64, 1475-82	275
2208	Properties of switch-like bioregulatory networks studied by simulation of the hypoxia response control system. **2004**, 15, 3042-52	50
2207	Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. **2004**, 10, 938-49	51
2206	Targeting hypoxia-inducible factor-1 for therapy and prevention. **2004**, 14, 951-966	
2205	VEGFA is necessary for chondrocyte survival during bone development. **2004**, 131, 2161-71	301
2204	6-Phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia. **2004**, 279, 53562-70	171
2203	ProBNP-derived peptides in cardiac disease. **2004**, 64, 497-510	19
2202	Kigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells' tolerance to nutrient starvation. **2004**, 95, 547-52	92
2201	ETS transcription factors: possible targets for cancer therapy. **2004**, 95, 626-33	145
2200	Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-quinolinium pamoate salt, showing preferential cytotoxicity during glucose starvation. **2004**, 95, 685-90	105
2199	Molecular regulation of the VEGF family -- inducers of angiogenesis and lymphangiogenesis. **2004**, 112, 463-80	111
2198	mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. **2004**, 10, 594-601	821

2197	Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. **2004**, 10, 858-64		2166
2196	Cancer genes and the pathways they control. **2004**, 10, 789-99		3175
2195	Cancer as a robust system: implications for anticancer therapy. *Nature Reviews Cancer*, **2004**, 4, 227-35	31.3	361
2194	Exploiting tumour hypoxia in cancer treatment. *Nature Reviews Cancer*, **2004**, 4, 437-47	31.3	1987
2193	Integrated global profiling of cancer. *Nature Reviews Cancer*, **2004**, 4, 638-44	31.3	116
2192	Structural disruption. *Nature Reviews Cancer*, **2004**, 4, 660-660	31.3	
2191	Why do cancers have high aerobic glycolysis?. *Nature Reviews Cancer*, **2004**, 4, 891-9	31.3	3535
2190	Oxygen sensing by HIF hydroxylases. **2004**, 5, 343-54		1535
2189	Multiple cell death pathways as regulators of tumour initiation and progression. **2004**, 23, 2746-56		263
2188	Prospective strategies to enforce selectively cell death in cancer cells. **2004**, 23, 2967-75		78
2187	HIF-1 and p53: communication of transcription factors under hypoxia. **2004**, 8, 423-31		138
2186	Clinical studies of hypoxia modification in radiotherapy. **2004**, 14, 233-40		70
2185	The relationship between hypoxia and angiogenesis. **2004**, 14, 215-21		67
2184	The hypoxic tumor microenvironment and gene expression. **2004**, 14, 207-14		90
2183	Antiangiogenic therapy and tumor progression. **2004**, 5, 13-7		220
2182	Intratumoral hypoxia, radiation resistance, and HIF-1. **2004**, 5, 405-6		179
2181	Engineered embryonic endothelial progenitor cells as therapeutic Trojan horses. **2004**, 5, 406-8		15
2180	Novel therapeutic targets in squamous cell carcinoma of the head and neck. **2004**, 31, 755-68		15

2179	Targeting HIF-alpha: when a magic arrow hits the bull's eye. **2004**, 9, 869	2
2178	New anticancer strategies targeting HIF-1. **2004**, 68, 1061-9	136
2177	HIF-1: master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs. **2004**, 68, 971-80	122
2176	Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. **2004**, 6, 485-95	450
2175	Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. **2004**, 279, 38458-65	757
2174	A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia. **2004**, 31, 1530-8	48
2173	Hypoxia-inducible factor-1 and oncogenic signalling. **2004**, 26, 262-9	163
2172	Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. **2004**, 40, 667-76	697
2171	Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. **2004**, 110, 838-44	63
2170	NS398 reduces hypoxia-inducible factor (HIF)-1alpha and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms. **2004**, 112, 585-95	48
2169	Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors. **2004**, 92, 491-501	173
2168	Locus of fragility in robust breast cancer system. **2004**, 92, 1020-4	14
2167	Manipulation of hypoxia-inducible factor-1 transactivation by mutation of C-TAD residues. **2004**, 14, 257-259	
2166	Hydroxylation of HIF-1: oxygen sensing at the molecular level. **2004**, 19, 176-82	639
2165	The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. **2004**, 57, 1009-14	525
2164	Upstream and downstream of mTOR. **2004**, 18, 1926-45	3169
2163	The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. **2004**, 18, 2183-94	266
2162	Laurenditerpenol, a new diterpene from the tropical marine alga Laurenciaintricata that potently inhibits HIF-1 mediated hypoxic signaling in breast tumor cells. **2004**, 67, 2002-7	70

2161	Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. **2004**, 18, 1039-57, viii		34
2160	Cellular oxygen sensing need in CNS function: physiological and pathological implications. **2004**, 207, 3171-88		191
2159	Hypoxia-inducible factor-1 activation by (-)-epicatechin gallate: potential adverse effects of cancer chemoprevention with high-dose green tea extracts. **2004**, 67, 2063-9		77
2158	Oxidation in rheumatoid arthritis. **2004**, 6, 265-78		417
2157	Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. **2004**, 36, 1-12		636
2156	Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis. **2004**, 18, 1143-59, ix-x		9
2155	The relationship between the tumor physiologic microenvironment and angiogenesis. **2004**, 18, 973-90, vii		13
2154	Regulation of malignant progression by the hypoxia-sensitive transcription factors HIF-1alpha and MTF-1. **2004**, 139, 495-507		16
2153	Versatile pharmacological actions of YC-1: anti-platelet to anticancer. **2004**, 207, 1-7		48
2152	Regulating cell survival by controlling cellular energy production: novel functions for ancient signaling pathways?. **2004**, 577, 1-4		17
2151	Targeting hypoxia tolerance in cancer. **2004**, 7, 25-40		68
2150	Cancer cell death by programmed necrosis?. **2004**, 7, 321-4		31
2149	Developmental and metabolic implications of the hypoxic ventilatory response. **2004**, 5, 173-81		5
2148	Physiological and pathological responses to hypoxia. **2004**, 164, 1875-82		332
2147	Angiogenesis and hepatocellular carcinoma. **2004**, 41, 864-80		286
2146	The neurovascular unit and its growth factors: coordinated response in the vascular and nervous systems. **2004**, 26, 870-83		96
2145	Molecular-targeted antitumor agents: the Saururus cernuus dineolignans manassantin B and 4-O-demethylmanassantin B are potent inhibitors of hypoxia-activated HIF-1. **2004**, 67, 767-71		101
2144	The STATs of cancer--new molecular targets come of age. *Nature Reviews Cancer*, **2004**, 4, 97-105	31.3	1845

2143	Persistent HIF-1alpha activation in gut ischemia/reperfusion injury: potential role of bacteria and lipopolysaccharide. **2004**, 22, 270-7	46
2142	Angiogenesis and lymphangiogenesis: highlights of the past year. **2004**, 11, 262-71	17
2141	Angiogenic signaling in Alzheimer's disease. **2004**, 15, 1507-10	59
2140	Endogenous 2-oxoacids differentially regulate expression of oxygen sensors. **2004**, 380, 419-24	93
2139	Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities. **2004**, 57, 188-96	146
2138	Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. **2004**, 114, 744-754	493
2137	Optical Imaging of Tumor Hypoxia and Evaluation of Efficacy of a Hypoxia-Targeting Drug in Living Animals. **2005**, 4, 153535002005051	74
2136	Chapter 14 Chronic lung vascular hyperpermeability. **2005**, 401-422	
2135	Involvement of hypoxia-inducible factor 1 in pulmonary pathophysiology. **2005**, 128, 592S-594S	48
2134	Real-time imaging of hypoxia-inducible factor-1 activity in tumor xenografts. **2005**, 46, 93-102	38
2133	PI3K/Akt/mTOR pathway as a target for cancer therapy. **2005**, 16, 797-803	354
2132	Hypoxia-inducible factor-1 (HIF-1). **2005**, 33, S423-5	52
2131	Hypoxia inducible factor-1: a novel target for cancer therapy. **2005**, 16, 901-9	100
2130	Hypoxia-reoxygenation induces premature senescence in FA bone marrow hematopoietic cells. **2005**, 106, 75-85	54
2129	Identification and characterization of the human ARD1-NATH protein acetyltransferase complex. **2005**, 386, 433-43	138
2128	In response to Dr. Dewhirst et al. **2005**, 63, 971	
2127	In regard to Arvold et al. (Int J Radiat Oncol Biol Phys 2005;62:207-212). **2005**, 63, 970-1; author reply 971	1
2126	Semi-synthetic mammalian gene regulatory networks. **2005**, 7, 241-50	41

2125	Nitric oxide signalling and cellular adaptations to changes in oxygenation. **2005**, 208, 235-48		35
2124	New insight into the transcriptional regulation of vascular endothelial growth factor expression in the endometrium by estrogen and relaxin. **2005**, 1041, 233-47		35
2123	Hemangioblasts representing a functional endothelio-hematopoietic entity in ontogeny, postnatal life, and CML neovasculogenesis. **2005**, 1, 277-84		10
2122	Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. **2005**, 46, 31-6		153
2121	Inhibition of immunoglobulin E synthesis through Fc gammaRII (CD32) by a mechanism independent of B-cell receptor co-cross-linking. **2005**, 115, 407-15		8
2120	Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. **2005**, 96, 183-90		101
2119	Hypoxia and anaemia in head and neck squamous cell carcinoma - mechanisms of therapy failure and provision of new therapeutic targets. **2005**, 30, 99-104		3
2118	In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo. **2005**, 93, 1356-63		52
2117	HIF, a missing link between metabolism and cancer. **2005**, 11, 1047-8		51
2116	Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. **2005**, 11, 992-7		366
2115	The anaemia of cancer: death by a thousand cuts. *Nature Reviews Cancer*, **2005**, 5, 543-55	31.3	128
2114	Alternative pathways. *Nature Reviews Cancer*, **2005**, 5, 667-667	31.3	
2113	Mitochondrial tumour suppressors: a genetic and biochemical update. *Nature Reviews Cancer*, **2005**, 5, 857-66	31.3	512
2112	Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. **2005**, 5, 712-21		417
2111	Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression. **2005**, 24, 3846-58		119
2110	VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha. **2005**, 6, 373-8		147
2109	Hypoxic preconditioning and tolerance via hypoxia inducible factor (HIF) 1alpha-linked induction of P450 2C11 epoxygenase in astrocytes. **2005**, 25, 939-48		85
2108	Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha. **2005**, 19, 1239-47		75

2107	REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. **2005**, 24, 1138-49	105
2106	HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. **2005**, 24, 3110-20	323
2105	Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent depletion. **2005**, 24, 4829-38	54
2104	Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. **2005**, 24, 5552-60	456
2103	Array-based comparative gene expression analysis of tumor cells with increased apoptosis resistance after hypoxic selection. **2005**, 24, 5914-22	25
2102	ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERalpha: a combination therapy potentially targeting hypoxic and dormant tumor cells. **2005**, 24, 6835-41	37
2101	Akt-regulated pathways in prostate cancer. **2005**, 24, 7465-74	297
2100	Hypoxia-inducible factor 1alpha in oral cancer. **2005**, 34, 385-9	44
2099	Mutation analysis of the HIF-1alpha oxygen-dependent degradation domain in invasive breast cancer. **2005**, 163, 168-72	19
2098	Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. **2005**, 8, 99-110	317
2097	HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. **2005**, 8, 143-53	740
2096	Genetic evidence for a tumor suppressor role of HIF-2alpha. **2005**, 8, 131-41	157
2095	Engaging the vascular component of the tumor response. **2005**, 8, 89-91	336
2094	Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. **2005**, 17, 1-9	177
2093	TOR signaling: an odyssey from cellular stress to the cell growth machinery. **2005**, 15, R139-41	33
2092	Negative and positive regulation of HIF-1: a complex network. **2005**, 1755, 107-20	137
2091	Monitor □hemistry. **2005**, 10, 1201	
2090	Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies. **2005**, 75, 41-6	7

2089	Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. **2005**, 15, 57-63	263
2088	HIF-1alpha and p53: the ODD couple?. **2005**, 30, 426-9	53
2087	Cellular reaction to hypoxia: sensing and responding to an adverse environment. **2005**, 569, 87-100	54
2086	Molecular mechanisms of breast cancer metastases to bone. **2005**, 5 Suppl, S46-53	139
2085	Clinical significance of hypoxia-inducible factor-1a messenger RNA expression in locally advanced non-small-cell lung cancer after platinum agent and gemcitabine chemotherapy followed by surgery. **2005**, 6, 299-303	5
2084	HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. **2005**, 5, 84	97
2083	Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1alpha (HIF-1alpha)-related expression of vascular endothelial growth factor (VEGF) in cancer cells overexpressing her-2/neu oncogene. **2005**, 94, 857-63	27
2082	Angiostatin's molecular mechanism: aspects of specificity and regulation elucidated. **2005**, 96, 242-61	106
2081	Hypoxia suppresses the production of matrix metalloproteinases and the migration of human monocyte-derived dendritic cells. **2005**, 35, 3468-77	42
2080	Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. **2005**, 42, 1339-48	276
2079	Macrophage migration and gene expression in response to tumor hypoxia. **2005**, 117, 701-8	153
2078	Cellular life histories and bow tie biology. **2005**, 17, 66-80	23
2077	Augmenting tumor sensitivity to topotecan by transient hypoxia. **2005**, 56, 473-80	6
2076	Succinate dehydrogenase deficiency in human. **2005**, 62, 2317-24	60
2075	When hypoxia signalling meets the ubiquitin-proteasomal pathway, new targets for cancer therapy. **2005**, 53, 115-23	28
2074	Upregulation of BNIP3 by 5-aza-2'-deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death. **2005**, 40, 504-10	56
2073	Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. **2005**, 131, 205-13	52
2072	Genomics of pancreatic cancer: does it make any improvement in diagnosis, prognosis and therapy?. **2005**, 11, 69-73	6

2071	Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. **2005**, 12, 229-41	82
2070	Critical role of microenvironmental factors in angiogenesis. **2005**, 7, 227-34	59
2069	Employing tumor hypoxia for oncolytic therapy in breast cancer. **2005**, 10, 311-8	14
2068	[Isolation of mitochondrial DNA binding proteins which are specific for maize cox1 promoter]. **2005**, 39, 394-402	2
2067	Tumoral micro-blood vessels and vascular microenvironment in human astrocytic tumors. A transmission electron microscopy study. **2005**, 73, 211-7	29
2066	Targeting STAT3 affects melanoma on multiple fronts. **2005**, 24, 315-27	240
2065	Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. **2005**, 63, 215-21	87
2064	Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: estrogen-induced recruitment of both estrogen receptor alpha and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter. **2005**, 19, 2006-19	97
2063	Down-regulation of the expression of the FIH-1 and ARD-1 genes at the transcriptional level by nickel and cobalt in the human lung adenocarcinoma A549 cell line. **2005**, 2, 10-3	28
2062	Ascorbate depletion: a critical step in nickel carcinogenesis?. **2005**, 113, 577-84	56
2061	HO-1 induction by HIF-1: a new mechanism for delayed cardioprotection?. **2005**, 289, H522-4	55
2060	Targeting hypoxia-inducible factor (HIF) as a therapeutic strategy for CNS disorders. **2005**, 4, 85-92	40
2059	Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. **2005**, 65, 6178-88	233
2058	Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. **2005**, 65, 5881-9	120
2057	Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. **2005**, 97, 1272-86	89
2056	A novel adenoviral vector which mediates hypoxia-inducible gene expression selectively in neurons. **2005**, 12, 1369-76	15
2055	Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. **2005**, 65, 5325-36	87
2054	Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade. **2005**, 8, 127-32	14

2053	Current Issues in the Utility of Blood Oxygen Level Dependent MRI for the Assessment of Modulations in Tumor Oxygenation. **2005**, 1, 229-243	43
2052	Adaptive myogenesis under hypoxia. **2005**, 25, 3040-55	113
2051	Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. **2005**, 170, 49-59	132
2050	Enzyme-linked immunosorbent assay for pharmacological studies targeting hypoxia-inducible factor 1alpha. **2005**, 12, 660-4	2
2049	Involvement of transforming growth factor-beta 1 signaling in hypoxia-induced tolerance to glucose starvation. **2005**, 280, 31557-63	43
2048	Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulation. **2005**, 79, 4479-91	92
2047	Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. **2005**, 4, 1465-74	173
2046	The oxygen sensing signal cascade under the influence of reactive oxygen species. **2005**, 360, 2201-10	43
2045	Roles of the HIF-1 hypoxia-inducible factor during hypoxia response in Caenorhabditis elegans. **2005**, 280, 20580-8	153
2044	Microregional expression of glucose transporter-1 and oxygenation status: lack of correlation in locally advanced cervical cancers. **2005**, 11, 2768-73	65
2043	Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors. **2005**, 65, 4918-28	128
2042	Loss of the von Hippel Lindau tumor suppressor disrupts iron homeostasis in renal carcinoma cells. **2005**, 280, 30120-8	32
2041	Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. **2005**, 105, 659-69	857
2040	Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation. **2005**, 65, 5498-505	76
2039	Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. **2005**, 65, 11676-88	56
2038	A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. **2005**, 65, 7267-75	111
2037	siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. **2005**, 33, 4527-35	288
2036	Angiogenic and antiangiogenic gene therapy. **2005**, 12 Suppl 1, S159-69	24

2035	Cytosolic action of thyroid hormone leads to induction of hypoxia-inducible factor-1alpha and glycolytic genes. **2005**, 19, 2955-63	107
2034	A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. **2005**, 65, 3257-63	84
2033	Pelvic malignancy: integrating form and function. **2005**, 78 Spec No 2, S86-93	1
2032	The impact of tumor physiology on camptothecin-based drug development. **2005**, 5, 1-13	34
2031	Functions of the Per/ARNT/Sim domains of the hypoxia-inducible factor. **2005**, 280, 36047-54	65
2030	New antiangiogenic strategies for the treatment of proliferative synovitis. **2005**, 14, 1-17	28
2029	How Cancer Could be Cured by 2015. **2005**, 4, 268-277	35
2028	Attenuation of oxidative stress in HL-1 cardiomyocytes improves mitochondrial function and stabilizes Hif-1alpha. **2005**, 39, 1273-84	17
2027	Thyroid hormone responsive genes in cultured human fibroblasts. **2005**, 90, 936-43	64
2026	Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?. **2005**, 14, 569-89	23
2025	Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. **2005**, 65, 9021-8	157
2024	Restoration of normoxia by ozone therapy may control neoplastic growth: a review and a working hypothesis. **2005**, 11, 257-65	26
2023	Expression of N-acetyl transferase human and human Arrest defective 1 proteins in thyroid neoplasms. **2005**, 15, 1131-6	39
2022	Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. **2005**, 280, 22473-81	251
2021	Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. **2005**, 280, 41928-39	290
2020	Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia. **2005**, 19, 1422-30	79
2019	Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. **2005**, 25, 7546-56	86
2018	Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. **2005**, 65, 5221-30	255

2017	The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor (HIF). **2005**, 102, 7481-6	146
2016	Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. **2005**, 280, 9336-44	103
2015	Prediction of radiation sensitivity using a gene expression classifier. **2005**, 65, 7169-76	155
2014	Ozone. **2005**,	2
2013	Drugs to suppress cough. **2005**, 14, 19-27	34
2012	The effects of L-arginine on neurological function, histopathology, and expression of hypoxia-inducible factor-1 alpha following spinal cord ischemia in rats. **2005**, 37, 323-9	5
2011	Microenvironmental Effects on Tumour Progression and Metastasis. **2005**, 1-22	1
2010	Hypoxia stimulates carcinoma invasion by stabilizing microtubules and promoting the Rab11 trafficking of the alpha6beta4 integrin. **2005**, 65, 2761-9	180
2009	Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. **2005**, 65, 7259-66	106
2008	Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. **2005**, 11, 2785-808	512
2007	Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. **2005**, 58, 172-7	175
2006	Molecular targets from VHL studies into the oxygen-sensing pathway. **2005**, 5, 345-56	15
2005	An Emerging Molecular Target in Melanoma: Cellular Carbonyl Stress and the Inhibition of Mitochondrial Survival Pathways by Carbonyl Scavenger Agents. **2005**, 1, 271-276	6
2004	Activation of HIF-prolyl hydroxylases by R59949, an inhibitor of the diacylglycerol kinase. **2005**, 280, 24238-44	44
2003	Suppression of hypoxia-inducible factor 1alpha (HIF-1alpha) transcriptional activity by the HIF prolyl hydroxylase EGLN1. **2005**, 280, 38102-7	74
2002	YC-1 [3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl Indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G0-G1 in human hepatocellular carcinoma cells. **2005**, 312, 917-25	48
2001	Regulation of hypoxia-inducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor I. **2005**, 19, 1304-17	99
2000	Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. **2005**, 25, 4853-62	210

1999	Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. **2005**, 4, 1222-5	67
1998	Teratogens as anti-cancer drugs. **2005**, 4, 1518-21	88
1997	A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia. **2005**, 65, 6151-8	10
1996	Cancer scene investigation: how a cold virus became a tumor killer. **2005**, 1, 247-58	16
1995	How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. **2005**, 4, 1307-10	66
1994	Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment. **2005**, 4, 1068-74	17
1993	Regulation of HIF by prolyl hydroxylases: recruitment of the candidate tumor suppressor protein ING4. **2005**, 4, 1153-6	33
1992	Genetic instability: the dark side of the hypoxic response. **2005**, 4, 881-2	27
1991	Mechanism of Taurine: □Ketoglutarate Dioxygenase (TauD) from Escherichia coli. **2005**, 2005, 4245-4254	159
1990	Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. **2005**, 75, 89-98	114
1989	The hypoxic proteome is influenced by gene-specific changes in mRNA translation. **2005**, 76, 177-86	89
1988	Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. **2005**, 77, 18-24	777
1987	Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. **2005**, 24, 6555-63	68
1986	Hypoxia in breast cancer: role of blood flow, oxygen diffusion distances, and anemia in the development of oxygen depletion. **2005**, 566, 333-42	57
1985	The unfolded protein response: a novel component of the hypoxic stress response in tumors. **2005**, 3, 597-605	254
1984	Hypoxia-Inducible Factor-1 Signaling System. **2005**, 311-323	
1983	Hsp27 upregulation by HIF-1 signaling offers protection against retinal ischemia in rats. **2005**, 46, 1092-8	105
1982	Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. **2005**, 25, 5675-86	754

1981	Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. **2005**, 65, 9047-55	399
1980	Evidence for the presence of a guanine quadruplex forming region within a polypurine tract of the hypoxia inducible factor 1alpha promoter. **2005**, 44, 16341-50	236
1979	Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. **2005**, 48, 4834-41	192
1978	Terpenoid tetrahydroisoquinoline alkaloids emetine, klugine, and isocephaeline inhibit the activation of hypoxia-inducible factor-1 in breast tumor cells. **2005**, 68, 947-50	51
1977	CXC Chemokines in Cancer. **2005**, 55, 255-288	
1976	Mitochondrial regulation of oxygen sensing. **2005**, 5, 322-32	100
1975	OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1alpha. **2005**, 17, 503-12	195
1974	HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. **2005**, 17, 793-803	296
1973	An expanding role for mTOR in cancer. **2005**, 11, 353-61	431
1972	Saururus cernuus lignans--potent small molecule inhibitors of hypoxia-inducible factor-1. **2005**, 333, 1026-33	59
1971	Epigallocatechin gallate inhibits HIF-1alpha degradation in prostate cancer cells. **2005**, 334, 543-8	73
1970	Signalling hypoxia by HIF hydroxylases. **2005**, 338, 617-26	269
1969	Dioxygenases as O2-dependent regulators of the hypoxic response pathway. **2005**, 338, 639-47	47
1968	The metal-responsive transcription factor-1 contributes to HIF-1 activation during hypoxic stress. **2005**, 337, 860-7	33
1967	Targeting key steps in metastatic tumour progression. **2005**, 15, 77-86	62
1966	Virus-based reporter systems for monitoring transcriptional activity of hypoxia-inducible factor 1. **2005**, 350, 89-98	26
1965	Transcription factors and drug resistance. **2005**, 41, 2577-86	60
1964	Is the hypoxia-inducible factor pathway important in gastric cancer?. **2005**, 41, 2792-805	65

1963	Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. **2005**, 37, 535-40	393
1962	Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors. **2005**, 87, 1005-10	62
1961	Enhanced antitumor activity of xanthohumol, a diacylglycerol acyltransferase inhibitor, under hypoxia. **2005**, 219, 215-22	38
1960	Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. **2005**, 218, 1-14	108
1959	Negative regulation of hypoxia inducible factor-1alpha by necdin. **2005**, 579, 3797-801	31
1958	The role of adrenomedullin in angiogenesis. **2005**, 26, 1670-5	58
1957	Hypoxia and anemia: effects on tumor biology and treatment resistance. **2005**, 12, 5-10	111
1956	Hypoxia and HIF-1 alpha in chondrogenesis. **2005**, 16, 539-46	82
1955	The interaction between HIF-1 and AP-1 transcription factors in response to low oxygen. **2005**, 16, 502-13	44
1954	Hypoxia-induced dedifferentiation of tumor cells--a mechanism behind heterogeneity and aggressiveness of solid tumors. **2005**, 16, 554-63	223
1953	Control of the hypoxic response through regulation of mRNA translation. **2005**, 16, 487-501	133
1952	Role of coactivators in transcriptional activation by the aryl hydrocarbon receptor. **2005**, 433, 379-86	248
1951	The "emigration, migration, and immigration"of prostate cancer. **2005**, 4, 24-30	45
1950	Akt-directed metabolic alterations in cancer. **2005**, 2, 255-262	8
1949	Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. **2005**, 49, 325-35	146
1948	Antineovascular therapy, a novel antiangiogenic approach. **2005**, 9, 63-76	17
1947	A3 adenosine receptors modulate hypoxia-inducible factor-1alpha expression in human A375 melanoma cells. **2005**, 7, 894-903	70
1946	Over expression of hypoxia-inducible factor-1alpha in renal and bladder cancer cells increases tumorigenic potency. **2005**, 173, 1762-6	23

1945	Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. **2005**, 54, 2277-86	870
1944	Redox regulation of the hypoxia-inducible factor. **2006**, 387, 1337-46	142
1943	Phenanthroquinolizidine alkaloids from the roots of Boehmeria pannosa potently inhibit hypoxia-inducible factor-1 in AGS human gastric cancer cells. **2006**, 69, 1095-7	45
1942	Breast Cancer and Molecular Medicine. **2006**,	2
1941	Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. **2006**, 82, 699-757	506
1940	Principles of Radiation Oncology. **2006**, 41-57	4
1939	Cancer Drug Resistance. **2006**,	17
1938	Cobalt induces hypoxia-inducible factor-1alpha (HIF-1alpha) in HeLa cells by an iron-independent, but ROS-, PI-3K- and MAPK-dependent mechanism. **2006**, 40, 847-56	86
1937	Tumor-associated Carbonic Anhydrases and Their Clinical Significance. **2006**, 42, 167-216	107
1936	Proteases in Gastrointestinal Tissues. **2006**,	
1935	Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. **2007**, 28, 858-64	160
1934	Lysyl oxidase mediates hypoxic control of metastasis. **2006**, 66, 10238-41	163
1933	Hypoxia signalling in cancer and approaches to enforce tumour regression. **2006**, 441, 437-43	1318
1932	Hypoxia protects HepG2 cells against etoposide-induced apoptosis via a HIF-1-independent pathway. **2006**, 312, 2908-20	49
1931	Immunophilin-ligands FK506 and CsA inhibit HIF1alpha expression by a VHL- and ubiquitin-independent mechanism. **2006**, 580, 6182-6	10
1930	CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. **2006**, 8, 394-401	121
1929	Role of the NEDD8 modification of Cul2 in the sequential activation of ECV complex. **2006**, 8, 956-63	30
1928	Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. **2006**, 5, 56	138

1927	Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase. **2006**, 5, 66	32
1926	Targeting the ERK signaling pathway in cancer therapy. **2006**, 38, 200-11	318
1925	Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. **2006**, 49, 5544-51	93
1924	Total synthesis and stereochemical confirmation of manassantin A, B, and B1. **2006**, 8, 5477-80	49
1923	Tumor-associated macrophages (TAMs) as new target in anticancer therapy. **2006**, 3, 361-366	10
1922	Targeting transcription factors in cancer: Challenges and evolving strategies. **2006**, 3, 261-7	16
1921	The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. **2006**, 60, 576-81	68
1920	Vascular endothelial growth factor in the lung. **2006**, 290, L209-21	303
1919	Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. **2006**, 4, 61-70	282
1918	Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. **2006**, 76, 217-57	191
1917	Gene expression profiling reveals the profound upregulation of hypoxia-responsive genes in primary human astrocytes. **2006**, 25, 435-49	104
1916	Sodwanone and yardenone triterpenes from a South African species of the marine sponge Axinella inhibit hypoxia-inducible factor-1 (HIF-1) activation in both breast and prostate tumor cells. **2006**, 69, 1715-20	41
1915	Lipopolysaccharide from Escherichia coli induces the expression of vascular endothelial growth factor via toll-like receptor 4 in human limbal fibroblasts. **2006**, 83, 1373-7	19
1914	Proteasome-dependent regulation of signal transduction in retinal pigment epithelial cells. **2006**, 83, 1472-81	27
1913	Cancer metastasis: building a framework. **2006**, 127, 679-95	3126
1912	Chronic in vivo hypoxia in various organs: hypoxia-inducible factor-1alpha and apoptosis. **2006**, 342, 875-80	33
1911	AMPK activation inhibits the expression of HIF-1alpha induced by insulin and IGF-1. **2006**, 342, 1197-202	47
1910	Knockdown of hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate. **2006**, 342, 1341-51	57

1909	Desferrioxamine, an iron chelator, enhances HIF-1alpha accumulation via cyclooxygenase-2 signaling pathway. **2006**, 343, 8-14	78
1908	Inhibition of cytochrome c oxidase subunit 4 precursor processing by the hypoxia mimic cobalt chloride. **2006**, 344, 1086-93	32
1907	Reconstitution of human hypoxia inducible factor HIF-1 in yeast: a simple in vivo system to identify and characterize HIF-1alpha effectors. **2006**, 346, 1289-96	8
1906	Suppression of hypoxia inducible factor-1alpha (HIF-1alpha) by YC-1 is dependent on murine double minute 2 (Mdm2). **2006**, 348, 1443-8	44
1905	mTOR and cancer: reason for dancing at the crossroads?. **2006**, 16, 78-84	60
1904	An alternatively spliced transcript of the PHD3 gene retains prolyl hydroxylase activity. **2006**, 233, 131-8	31
1903	Tumor hypoxia and cancer progression. **2006**, 237, 10-21	222
1902	Hypoxia confers protection against apoptosis via PI3K/Akt and ERK pathways in lung cancer cells. **2006**, 242, 231-8	60
1901	Transcriptional anti-angiogenesis therapy of human pancreatic cancer. **2006**, 17, 147-56	61
1900	Patterns of tumor oxygenation and their influence on the cellular hypoxic response and hypoxia-directed therapies. **2006**, 9, 185-97	31
1899	Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. **2006**, 66, 8814-21	260
1898	Cancer's molecular sweet tooth and the Warburg effect. **2006**, 66, 8927-30	954
1897	Mitochondrial disorders in renal tumors. **2006**, 6, 105-17	23
1896	p53 stabilization and transactivation by a von Hippel-Lindau protein. **2006**, 22, 395-405	197
1895	Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathy. **2006**, 116, 3266-76	177
1894	[Hypoxia inducible factor 1a is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells]. **2006**, 22, 10-3	5
1893	Hypoxia-inducible factor-1□nduces the epithelialmesenchymal transition of human prostatecancer cells. **2006**, 119, 713-718	32
1892	Radiation Therapy and Apoptosis. 1049-1086	2

1891	Scatter Factors in Tumor Progression. **2006**, 111-142	
1890	Inhibition of angiogenesis and HIF-1alpha activity by antimycin A1. **2006**, 29, 1344-8	20
1889	Anthracyclines, small-molecule inhibitors of hypoxia-inducible factor-1 alpha activation. **2006**, 29, 1999-2003	11
1888	Crinamine from Crinum asiaticum var. japonicum inhibits hypoxia inducible factor-1 activity but not activity of hypoxia inducible factor-2. **2006**, 29, 2140-2	20
1887	Hypoxia in Cancer. 777-798	
1886	Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. **2006**, 107, 2705-12	202
1885	Biology and Impact of Signal Transducers and Activators of Transcription and Their Regulators as Targets in Cancer Therapy. **2006**, 1, 337-351	1
1884	Noscapine inhibits hypoxia-mediated HIF-1 expression andangiogenesis in vitro: a novel function for an old drug. **2006**, 28, 1121	3
1883	Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1). **2006**, 7, 355-69	75
1882	Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells. **2006**, 9, 346-57	73
1881	Chemokines in Lung Cancer. **2006**, 13, 356-364	
1880	Leukocyte's Hif-1 expression and training-induced erythropoietic response in swimmers. **2006**, 38, 1410-7	18
1879	Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells. **2006**, 16, 275-83	27
1878	Oxygen-sensing in tumors. **2006**, 9, 366-78	23
1877	Proliferating cell nuclear antigen, survivin, and CD34 expressions in pancreatic cancer and their correlation with hypoxia-inducible factor 1alpha. **2006**, 32, 159-63	18
1876	Comparative proteomic analysis of hypoxia-treated and untreated human leukemic U937 cells. **2006**, 6, 3262-74	34
1875	Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma. **2006**, 6, 3880-93	58
1874	Intrarenal oxygenation in chronic renal failure. **2006**, 33, 989-96	109

1873	The host cell transcription factor hypoxia-inducible factor 1 is required for Toxoplasma gondii growth and survival at physiological oxygen levels. **2006**, 8, 339-52		84
1872	Over-expression of hypoxia-inducible factor-1alpha increases the invasive potency of LNCaP cells in vitro. **2006**, 98, 1315-9		37
1871	Angiogenesis in gliomas: biology and molecular pathophysiology. **2005**, 15, 297-310		254
1870	Angiogenesis in gliomas: imaging and experimental therapeutics. **2005**, 15, 342-63		44
1869	Induction of transcription factor CEBP homology protein mediates hypoglycaemia-induced necrotic cell death in human neuroblastoma cells. **2006**, 99, 952-64		12
1868	Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma. **2006**, 97, 313-21		56
1867	Expression of Ets-1 in human clear cell renal cell carcinomas: implications for angiogenesis. **2006**, 97, 875-82		27
1866	Invasive growth: a MET-driven genetic programme for cancer and stem cells. *Nature Reviews Cancer* , **2006**, 6, 637-45	31.3	440
1865	The place of VEGF inhibition in the current management of renal cell carcinoma. **2006**, 94, 1217-20		15
1864	HIF-1 and tumour radiosensitivity. **2006**, 95, 1-5		146
1863	Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. **2006**, 147 Suppl 2, S144-52		58
1862	Vascular defects and liver damage by the acute inactivation of the VHL gene during mouse embryogenesis. **2006**, 86, 664-75		24
1861	Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. **2006**, 86, 1221-32		313
1860	PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. **2006**, 442, 779-85		320
1859	Hypoxia and HIF-1alpha protect A549 cells from drug-induced apoptosis. **2006**, 13, 1611-3		38
1858	Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. **2006**, 25, 1114-25		278
1857	Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. **2006**, 25, 1231-41		164
1856	Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. **2006**, 25, 4650-62		185

1855	The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repression. **2006**, 25, 4784-94	95
1854	Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. **2006**, 20, 1759-66	95
1853	Proline oxidase activates both intrinsic and extrinsic pathways for apoptosis: the role of ROS/superoxides, NFAT and MEK/ERK signaling. **2006**, 25, 5640-7	128
1852	Hypoxia-inducible factor-1alpha expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas. **2006**, 25, 6123-7	48
1851	Role of ABCG2/BCRP in biology and medicine. **2006**, 46, 381-410	299
1850	Development of novel therapeutic strategies that target HIF-1. **2006**, 10, 267-80	94
1849	Involvement of Niemann-Pick type C2 protein in hematopoiesis regulation. **2006**, 24, 1549-55	13
1848	Antitumor protein therapy; application of the protein transduction domain to the development of a protein drug for cancer treatment. **2006**, 13, 16-26	45
1847	Hypoxia-inducible factor-1 (HIF-1). **2006**, 70, 1469-80	1089
1846	Hypoxia and HIF-1alpha in chondrogenesis. **2006**, 1068, 66-73	43
1845	Antioxidant enzymes during hypoxia-anoxia signaling events in Crocus sativus L. corm. **2006**, 1091, 65-75	16
1844	Physiological roles for ecto-5'-nucleotidase (CD73). **2006**, 2, 351-60	377
1843	Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials. **2006**, 11, 41-52	66
1842	Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. **2006**, 99, 135-41	87
1841	Molecular targeting of the lymphovascular system for imaging and therapy. **2006**, 25, 185-201	28
1840	Role of tumor-associated macrophages in tumor progression and invasion. **2006**, 25, 315-22	667
1839	Involvement of HIF-1 in invasion of Mum2B uveal melanoma cells. **2006**, 23, 87-96	30
1838	Distinct patterns of hypoxic expression of carbonic anhydrase IX (CA IX) in human malignant glioma cell lines. **2007**, 81, 27-38	25

1837	Hypoxia, angiogenesis and apoptosis markers in locally advanced rectal cancer. **2006**, 21, 248-57	28
1836	Expression of hypoxia-inducible factor (HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas. **2006**, 449, 673-81	45
1835	Tumor-associated carbonic anhydrases are linked to metastases in primary cervical cancer. **2006**, 132, 302-8	52
1834	Tumor angiogenesis and antiangiogenic therapy: current status and perspective. **2006**, 11, 71-2	2
1833	Role of hypoxia-inducible factor-1□n formation of multidrug resistance induced by microenvironment in hepatocellular carcinoma. **2006**, 5, 178-183	2
1832	Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells". **2006**, 58, 725-34	58
1831	Endogenous hypoxia markers in locally advanced cancers of the uterine cervix: reality or wishful thinking?. **2006**, 182, 501-10	23
1830	Vascular network remodeling via vessel cooption, regression and growth in tumors. **2006**, 241, 903-18	93
1829	Regulation of angiogenesis by hypoxia-inducible factor 1. **2006**, 59, 15-26	374
1828	Tumor metabolism: new opportunities for cancer therapy. **2006**, 8, 711-6	34
1827	A precious metal: Iron, an essential nutrient for all cells. **2006**, 1, 25-39	151
1826	Erythropoietin disrupts hypoxia-inducible factor signaling in ovarian cancer cells. **2006**, 100, 14-9	15
1825	Alteration of subcellular redox equilibrium and the consequent oxidative modification of nuclear factor kappaB are critical for anticancer cytotoxicity by emodin, a reactive oxygen species-producing agent. **2006**, 40, 2183-97	49
1824	Differential utilization of two ATP-generating pathways is regulated by p53. **2006**, 10, 4-6	37
1823	Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. **2006**, 10, 413-23	532
1822	Glucose metabolism and cancer. **2006**, 18, 598-608	441
1821	FSH signaling pathways in immature granulosa cells that regulate target gene expression: branching out from protein kinase A. **2006**, 18, 1351-9	277
1820	Biphasic electric current stimulates proliferation and induces VEGF production in osteoblasts. **2006**, 1763, 907-16	79

1819	Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. **2006**, 72, 19-31	106
1818	Molecular pathways in renal cell carcinoma--rationale for targeted treatment. **2006**, 33, 588-95	55
1817	Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications. **2006**, 33, 607-13	24
1816	Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. **2006**, 33, S1-7	104
1815	Motexafin gadolinium: a novel redox active drug for cancer therapy. **2006**, 16, 466-76	131
1814	ARDent about acetylation and deacetylation in hypoxia signalling. **2006**, 16, 616-21	33
1813	Hypoxia-inducible gene expression system using the erythropoietin enhancer and 3'-untranslated region for the VEGF gene therapy. **2006**, 115, 113-9	36
1812	Suppression of tumor growth by intratumoral injection of short hairpin RNA-expressing plasmid DNA targeting beta-catenin or hypoxia-inducible factor 1alpha. **2006**, 116, 90-5	22
1811	Sensing and responding to hypoxia via HIF in model invertebrates. **2006**, 52, 349-64	119
1810	Oxygen sensing in the body. **2006**, 91, 249-86	215
1809	Hypoxia-inducible transcription factor-1alpha promotes hypoxia-induced A549 apoptosis via a mechanism that involves the glycolysis pathway. **2006**, 6, 26	55
1808	Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. **2006**, 93, 1456-63	41
1807	Differential levels of tissue hypoxia in the developing chicken heart. **2006**, 235, 115-23	47
1806	Apoptosis in the developing mouse heart. **2006**, 235, 2592-602	35
1805	Ascorbate depletion mediates up-regulation of hypoxia-associated proteins by cell density and nickel. **2006**, 97, 1025-35	61
1804	Knockdown of hypoxia-inducible factor-1alpha by siRNA inhibits C2C12 myoblast differentiation. **2006**, 98, 642-9	34
1803	Hypoxia and DNA-damaging agent bleomycin both increase the cellular level of the protein 4E-BP. **2006**, 99, 126-32	13
1802	Disruption of the Arnt gene in endothelial cells causes hepatic vascular defects and partial embryonic lethality in mice. **2006**, 44, 550-60	39

1801	Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. **2006**, 118, 2609-16	62
1800	Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. **2006**, 119, 2750-9	101
1799	Pharmacologic transgene control systems for gene therapy. **2006**, 8, 535-56	83
1798	Clinicopathologic significance of hypoxia-inducible factor 1alpha overexpression in gastric carcinomas. **2006**, 94, 149-54	52
1797	Soluble nickel inhibits HIF-prolyl-hydroxylases creating persistent hypoxic signaling in A549 cells. **2006**, 45, 479-89	68
1796	Association between ulcerative growth and hypoxia inducible factor-1alpha polymorphisms in colorectal cancer patients. **2006**, 45, 833-40	58
1795	The positive regulation of p53 by the tumor suppressor VHL. **2006**, 5, 2054-6	38
1794	Translational control of gene expression during hypoxia. **2006**, 5, 749-55	116
1793	Radiation sensitivity of GL261 murine glioma model and enhanced radiation response by flavopiridol. **2006**, 5, 93-9	21
1792	Mammalian gene expression program resiliency: the roles of multiple coactivator mechanisms in hypoxia-responsive transcription. **2006**, 5, 142-6	39
1791	Effects of histone deacetylase inhibitors on HIF-1. **2006**, 5, 2430-5	64
1790	Mitogen-activated protein kinase signaling, oxygen sensors and hypoxic induction of neurogenesis. **2006**, 3, 50-5	16
1789	Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. **2006**, 129, 2426-35	107
1788	A novel low molecular weight inhibitor of dendritic cells and B cells blocks allergic inflammation. **2006**, 173, 599-606	38
1787	Vitamin C als Prodrug von H2O2: M□glichkeiten zur intraven□sen Hochdosistherapie bei Krebserkrankungen?. **2006**, 21, 120-124	
1786	Regulation of the chemokine receptor CXCR4 and metastasis by hypoxia-inducible factor in non small cell lung cancer cell lines. **2006**, 5, 1320-6	59
1785	Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. **2006**, 66, 6264-70	293
1784	CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. **2006**, 12, 6421-31	111

1783	Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. **2006**, 12, 6523-31	45
1782	Antiangiogenic therapy in human gastrointestinal malignancies. **2006**, 55, 1497-511	8
1781	Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. **2006**, 66, 11736-44	158
1780	Natural product-derived small molecule activators of hypoxia-inducible factor-1 (HIF-1). **2006**, 12, 2673-88	42
1779	Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: proposal of a unified hypothesis. **2006**, 24, 754-79	27
1778	Effects of geldanamycin on HIF-1alpha mediated angiogenesis and invasion in prostate cancer cells. **2006**, 9, 126-35	29
1777	Can we target the chemokine network for cancer therapeutics?. **2006**, 6, 659-70	11
1776	Chemokine-directed metastasis. **2006**, 13, 170-190	16
1775	ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. **2006**, 66, 3715-25	57
1774	EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. **2006**, 2, e116	150
1773	Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. **2006**, 66, 7983-90	113
1772	Casein kinase 2 inhibition decreases hypoxia-inducible factor-1 activity under hypoxia through elevated p53 protein level. **2006**, 119, 3351-62	49
1771	The regulation of trophoblast differentiation by oxygen in the first trimester of pregnancy. **2006**, 12, 137-44	139
1770	Baffled by bafilomycin: an anticancer agent that induces hypoxia-inducible factor-1alpha expression. **2006**, 70, 1841-3	9
1769	Hypoxia-inducible factor-1 in human breast and prostate cancer. **2006**, 13, 739-49	189
1768	von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms. **2006**, 66, 1553-60	64
1767	5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. **2006**, 26, 5336-47	365
1766	Inhibiting hypoxia-inducible factor 1 for cancer therapy. **2006**, 4, 601-5	137

1765	Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. **2006**, 66, 2937-45	127
1764	Pericellular proteases in angiogenesis and vasculogenesis. **2006**, 26, 716-28	307
1763	Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. **2006**, 24, 688-94	147
1762	Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. **2006**, 12, 4562-8	198
1761	Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. **2006**, 66, 3567-75	230
1760	Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. **2006**, 12, 6748-57	113
1759	Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention. **2006**, 5, 575-85	150
1758	Direct spectroscopic detection of a C-H-cleaving high-spin Fe(IV) complex in a prolyl-4-hydroxylase. **2006**, 103, 14738-43	269
1757	Cell-type-specific regulation of degradation of hypoxia-inducible factor 1 alpha: role of subcellular compartmentalization. **2006**, 26, 4628-41	49
1756	Respecting cancer drug transportability: a basis for successful lead selection. **2006**, 98, 1098-9	2
1755	MSF-A interacts with hypoxia-inducible factor-1alpha and augments hypoxia-inducible factor transcriptional activation to affect tumorigenicity and angiogenesis. **2006**, 66, 856-66	56
1754	HIF-1: hypoxia-inducible factor or dysoxia-inducible factor?. **2006**, 20, 828-32	71
1753	Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain. **2006**, 26, 5895-907	101
1752	Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1alpha in cancer: role of free radical formation. **2006**, 66, 770-4	95
1751	Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. **2006**, 66, 3639-48	140
1750	Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. **2006**, 281, 13612-13619	91
1749	Hypoxia-inducible factor 1 as a possible target for cancer chemoprevention. **2006**, 15, 2332-5	40
1748	Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. **2006**, 5, 1415-22	91

1747	Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. **2007**, 28, 529-36	124
1746	Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. **2006**, 4, 79-92	85
1745	Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. **2006**, 12, 473-7	111
1744	Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. **2006**, 12, 634-42	243
1743	Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. **2006**, 24, 727-35	244
1742	The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. **2006**, 66, 3688-98	215
1741	Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. **2006**, 66, 1561-9	70
1740	Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis. **2006**, 98, 984-95	65
1739	Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-alpha expression but decrease functional transcriptional activity, DNA binding, and degradation. **2006**, 12, 5384-94	43
1738	Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. **2006**, 66, 7216-24	91
1737	Low oxygen concentrations inhibit trophoblast cell invasion from early gestation placental explants via alterations in levels of the urokinase plasminogen activator system. **2006**, 74, 403-9	55
1736	The role of hypoxia inducible factor-1 in cell metabolism--a possible target in cancer therapy. **2006**, 10, 583-99	12
1735	Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. **2006**, 66, 1684-936	95
1734	Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. **2006**, 66, 6683-91	248
1733	Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness. **2006**, 12, 1080-7	76
1732	Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. **2006**, 5, 2193-202	51
1731	Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation. **2006**, 5, 2659-65	49
1730	The proangiogenic capacity of polymorphonuclear neutrophils delineated by microarray technique and by measurement of neovascularization in wounded skin of CD18-deficient mice. **2006**, 43, 1-11	25

1729	Inhibition of hypoxia-inducible factor-1alpha and endothelial progenitor cell differentiation by adenoviral transfer of small interfering RNA in vitro. **2006**, 43, 511-21	29
1728	Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. **2006**, 26, 2019-28	226
1727	Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. **2006**, 281, 15215-26	351
1726	Induction of the heat shock pathway during hypoxia requires regulation of heat shock factor by hypoxia-inducible factor-1. **2006**, 281, 38675-81	107
1725	Hypoxia-independent overexpression of hypoxia-inducible factor 1alpha as an early change in mouse hepatocarcinogenesis. **2006**, 66, 11263-70	88
1724	Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. **2006**, 12, 6351-8	75
1723	Calpain mediates a von Hippel-Lindau protein-independent destruction of hypoxia-inducible factor-1alpha. **2006**, 17, 1549-58	50
1722	The Met pathway: master switch and drug target in cancer progression. **2006**, 20, 1611-21	110
1721	Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme. **2006**, 6, 1313-22	20
1720	Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein. **2006**, 17, 1801-6	134
1719	The length of peptide substrates has a marked effect on hydroxylation by the hypoxia-inducible factor prolyl 4-hydroxylases. **2006**, 281, 28712-20	97
1718	Bafilomycin induces the p21-mediated growth inhibition of cancer cells under hypoxic conditions by expressing hypoxia-inducible factor-1alpha. **2006**, 70, 1856-65	59
1717	Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. **2006**, 103, 18154-9	610
1716	Clioquinol, a Cu(II)/Zn(II) chelator, inhibits both ubiquitination and asparagine hydroxylation of hypoxia-inducible factor-1alpha, leading to expression of vascular endothelial growth factor and erythropoietin in normoxic cells. **2006**, 281, 34056-63	51
1715	Targeting XBP-1 as a novel anti-cancer strategy. **2006**, 5, 756-9	105
1714	Meeting report: exploiting the tumor microenvironment for therapeutics. **2006**, 66, 4558-60	19
1713	Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. **2006**, 12, 5165-73	259
1712	Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer. **2006**, 66, 143-50	75

1711	Cell Motility in Cancer Invasion and Metastasis. **2006**,	5
1710	Proteomic analysis of colorectal cancer reveals alterations in metabolic pathways: mechanism of tumorigenesis. **2006**, 5, 1119-30	126
1709	A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. **2006**, 103, 654-9	263
1708	Genetics of mitochondrial electron transport chain in regulating oxygen sensing. **2007**, 435, 447-61	10
1707	Structural basis for depletion of heat shock protein 90 client proteins by deguelin. **2007**, 99, 949-61	126
1706	Beyond detection: novel applications for PET imaging to guide cancer therapy. **2007**, 48, 855-6	19
1705	Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. **2007**, 67, 4157-63	193
1704	Hepatitis C virus stabilizes hypoxia-inducible factor 1alpha and stimulates the synthesis of vascular endothelial growth factor. **2007**, 81, 10249-57	110
1703	Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. **2007**, 282, 4524-4532	379
1702	Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. **2007**, 67, 1735-43	56
1701	Hypoxia-inducible factor-1 mediates neuronal expression of the receptor for advanced glycation end products following hypoxia/ischemia. **2007**, 282, 36330-40	76
1700	Mucin 1 oncoprotein blocks hypoxia-inducible factor 1alpha activation in a survival response to hypoxia. **2007**, 282, 257-66	58
1699	Constitutive/hypoxic degradation of HIF-alpha proteins by the proteasome is independent of von Hippel Lindau protein ubiquitylation and the transactivation activity of the protein. **2007**, 282, 15498-505	61
1698	Interaction of hydroxylated collagen IV with the von hippel-lindau tumor suppressor. **2007**, 282, 13264-9	51
1697	Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. **2007**, 6, 732-41	84
1696	AKAP12 regulates human blood-retinal barrier formation by downregulation of hypoxia-inducible factor-1alpha. **2007**, 27, 4472-81	75
1695	Mitochondrial reactive oxygen species trigger hypoxia-inducible factor-dependent extension of the replicative life span during hypoxia. **2007**, 27, 5737-45	172
1694	Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. **2007**, 27, 7381-93	450

1693	Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. **2007**, 67, 6872-81	86
1692	Detection of reactive oxygen species via endogenous oxidative pentose phosphate cycle activity in response to oxygen concentration: implications for the mechanism of HIF-1alpha stabilization under moderate hypoxia. **2007**, 282, 36790-6	66
1691	Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumour xenografts. **2007**, 96, 1871-8	21
1690	The p53 codon 72 proline allele is endowed with enhanced cell-death inducing potential in cancer cells exposed to hypoxia. **2007**, 96, 1302-8	19
1689	The unfolded protein response and integrated stress response to anoxia. **2007**, 13, 2537-40	41
1688	Hypoxia and metastasis. **2007**, 13, 1947-9	80
1687	The peptidyl prolyl cis/trans isomerase FKBP38 determines hypoxia-inducible transcription factor prolyl-4-hydroxylase PHD2 protein stability. **2007**, 27, 3758-68	90
1686	Tumor hypoxia and targeted gene therapy. **2007**, 257, 181-212	8
1685	Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-Arginine Metabolism in Immune Modulation. **2007**, 369-399	
1684	Dead or alive: gene expression profiles of advanced atherosclerotic plaques from autopsy and surgery. **2007**, 30, 335-41	37
1683	Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells. **2007**, 67, 1725-34	73
1682	Activation of insulin-like growth factor signaling induces apoptotic cell death under prolonged hypoxia by enhancing endoplasmic reticulum stress response. **2007**, 67, 8095-103	35
1681	Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. **2007**, 292, C987-95	251
1680	Carbonic anhydrase inhibitors and the management of cancer. **2007**, 7, 865-78	46
1679	Expression of HIF-1alpha in injured arteries controls SDF-1alpha mediated neointima formation in apolipoprotein E deficient mice. **2007**, 27, 2540-7	78
1678	Reactive oxygen species regulate insulin-induced VEGF and HIF-1alpha expression through the activation of p70S6K1 in human prostate cancer cells. **2007**, 28, 28-37	82
1677	Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats. **2007**, 13, 3087-99	58
1676	Chemopreventive agents modulate the protein expression profile of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo[a]pyrene-induced lung tumors in A/J mice. **2008**, 29, 610-9	21

1675	Tribute to P. L. Lutz: putting life on 'pause'--molecular regulation of hypometabolism. **2007**, 210, 1700-14	200
1674	Inhibitor of DNA binding 1 activates vascular endothelial growth factor through enhancing the stability and activity of hypoxia-inducible factor-1alpha. **2007**, 5, 321-9	47
1673	Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. **2007**, 13, 1010-8	46
1672	Evidence for sustained renal hypoxia and transient hypoxia adaptation in experimental rhabdomyolysis-induced acute kidney injury. **2008**, 23, 1135-43	36
1671	Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. **2007**, 67, 3441-9	257
1670	SEPT9_V1 protein expression is associated with human cancer cell resistance to microtubule-disrupting agents. **2007**, 6, 1926-31	32
1669	Hypoxic suppression of the cell cycle gene CDC25A in tumor cells. **2007**, 6, 1919-26	50
1668	Multimodality optical imaging and 18F-FDG uptake in wild-type p53-containing and p53-null human colon tumor xenografts. **2007**, 6, 1649-53	12
1667	Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. **2007**, 6, 1393-402	52
1666	Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole. **2007**, 6, 70-5	33
1665	Energy sensing and regulation of gene expression in skeletal muscle. **2007**, 102, 529-40	63
1664	KCl depolarization increases HIF-1 transcriptional activity via the calcium-independent pathway in SGC7901 gastric cancer cells. **2007**, 28, 173-80	3
1663	Microarray analysis of p53-dependent gene expression in response to hypoxia and DNA damage. **2007**, 6, 1858-66	23
1662	Hypoxia inducible factor-2alpha in cancer. **2007**, 6, 919-26	153
1661	Effects of hypoxia on heterotypic macrophage interactions. **2007**, 6, 2620-4	6
1660	PDGFRbeta and HIF-1alpha inhibition with imatinib and radioimmunotherapy of experimental prostate cancer. **2007**, 6, 1763-72	13
1659	Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue. **2007**, 37, 812-9	47
1658	Estrogen-induced activation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor expression, and edema in the uterus are mediated by the phosphatidylinositol 3-kinase/Akt pathway. **2007**, 148, 2363-74	111

1657	HIF-1-regulated glucose metabolism: a key to apoptosis resistance?. **2007**, 6, 790-2	63
1656	Survival and invasiveness of astrocytomas promoted by erythropoietin. **2007**, 106, 338-50	28
1655	Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. **2007**, 6, 1900-7	51
1654	Differential regulation of hypoxia-inducible factor-1 through receptor tyrosine kinase transactivation in vascular smooth muscle cells. **2007**, 148, 4023-31	40
1653	Hypoxia and regulation of messenger RNA translation. **2007**, 435, 247-73	32
1652	Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1alpha in disease pathogenesis. **2007**, 176, 1108-19	140
1651	Identification of a new natural camptothecin analogue in targeted screening for HIF-1alpha inhibitors. **2007**, 73, 49-52	26
1650	A yeast two-hybrid system reconstituting substrate recognition of the von Hippel-Lindau tumor suppressor protein. **2007**, 35, e142	10
1649	Dual role of mitochondrial reactive oxygen species in hypoxia signaling: activation of nuclear factor-{kappa}B via c-SRC and oxidant-dependent cell death. **2007**, 67, 7368-77	178
1648	IRE1 signaling is essential for ischemia-induced vascular endothelial growth factor-A expression and contributes to angiogenesis and tumor growth in vivo. **2007**, 67, 6700-7	166
1647	RACK1 vs. HSP90: competition for HIF-1 alpha degradation vs. stabilization. **2007**, 6, 656-9	109
1646	Hypoxia-inducible factors Per/ARNT/Sim domains: structure and function. **2007**, 435, 3-24	17
1645	Up-regulation of tumor susceptibility gene 101 protein in ovarian carcinomas revealed by proteomics analyses. **2007**, 6, 294-304	28
1644	Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. **2007**, 72, 395-406	136
1643	Effect of hypoxia on 2-deoxyglucose uptake and cell cycle regulatory protein expression of mouse embryonic stem cells: involvement of Ca2+ /PKC, MAPKs and HIF-1alpha. **2007**, 19, 269-82	27
1642	Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. **2007**, 67, 563-72	289
1641	Cytotoxic metabolites from an Indonesian sponge Lendenfeldia sp. **2007**, 70, 1824-6	52
1640	Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. **2007**, 9, 1383-90	108

1639	An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor alpha. **2007**, 282, 30544-52	108
1638	1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. **2007**, 6, 1433-9	160
1637	The exon-junction-complex-component metastatic lymph node 51 functions in stress-granule assembly. **2007**, 120, 2774-84	56
1636	Why do tumors metastasize?. **2007**, 6, 141-4	12
1635	Hypoxic regulation of Id-1 and activation of the unfolded protein response are aberrant in neuroblastoma. **2007**, 282, 240-8	25
1634	Developmental regulation of hypoxia-inducible factor 1 and prolyl-hydroxylases in pulmonary vascular smooth muscle cells. **2007**, 104, 18789-94	31
1633	Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. **2007** , 104, 9445-50	134
1632	Hif-1alpha regulates differentiation of limb bud mesenchyme and joint development. **2007**, 177, 451-64	158
1631	Characterization of ankyrin repeat-containing proteins as substrates of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible transcription factor. **2007**, 435, 61-85	22
1630	MgcRacGAP interacts with HIF-1alpha and regulates its transcriptional activity. **2007**, 20, 995-1006	32
1629	Hypoxia up-regulates the angiogenic cytokine secretoneurin via an HIF-1alpha- and basic FGF-dependent pathway in muscle cells. **2007**, 21, 2906-17	56
1628	HIF gene expression in cancer therapy. **2007**, 435, 323-45	23
1627	Adenosine A2a receptor-mediated, normoxic induction of HIF-1 through PKC and PI-3K-dependent pathways in macrophages. **2007**, 82, 392-402	63
1626	HIF1alpha regulation of Sox9 is necessary to maintain differentiation of hypoxic prechondrogenic cells during early skeletogenesis. **2007**, 134, 3917-28	222
1625	Nicotine induces hypoxia-inducible factor-1alpha expression in human lung cancer cells via nicotinic acetylcholine receptor-mediated signaling pathways. **2007**, 13, 4686-94	119
1624	Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. **2007**, 6, 61-9	48
1623	Prolyl hydroxylase domain 2 protein suppresses hypoxia-induced endothelial cell proliferation. **2007**, 49, 178-84	32
1622	Thioredoxin 1 and thioredoxin 2 have opposed regulatory functions on hypoxia-inducible factor-1alpha. **2007**, 282, 7482-90	51

1621	From critters to cancers: bridging comparative and clinical research on oxygen sensing, HIF signaling, and adaptations towards hypoxia. **2007**, 47, 552-77	25
1620	A potential alpha-helix motif in the amino terminus of LANA encoded by Kaposi's sarcoma-associated herpesvirus is critical for nuclear accumulation of HIF-1alpha in normoxia. **2007**, 81, 10413-23	65
1619	The concurrent chemoradiation paradigm--general principles. **2007**, 4, 86-100	301
1618	An up-to-date anti-cancer treatment strategy focusing on HIF-1alpha suppression: its application for refractory ovarian cancer. **2007**, 40, 139-42	13
1617	Rakicidin A: a hypoxia-selective cytotoxin. **2007**, 30, 261-5	34
1616	Blueprint for the Response of Blood and Bone Marrow-Derived Stem Cells and Their Progeny to Hypoxia. **2007**, 61-84	1
1615	IOP1, a novel hydrogenase-like protein that modulates hypoxia-inducible factor-1alpha activity. **2007**, 401, 341-52	38
1614	Silencing hypoxia-inducible factor-1□nhibits cell migration and invasion under hypoxic environment in malignant gliomas. **2007**,	5
1613	Hypoxia-induced assembly of prolyl hydroxylase PHD3 into complexes: implications for its activity and susceptibility for degradation by the E3 ligase Siah2. **2007**, 401, 217-26	50
1612	The critical role of vascular endothelial growth factor in pulmonary vascular remodeling after lung injury. **2007**, 28, 4-14	50
1611	Development of a novel fluorescent imaging probe for tumor hypoxia by use of a fusion protein with oxygen-dependent degradation domain of HIF-1□**2007**,	1
1610	Modulation of vascular gene expression by hypoxia. **2007**, 18, 508-14	21
1609	ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1alpha accumulation. **2007**, 18, 435-45	7
1608	Targeting angiogenesis in head and neck cancer. **2007**, 7, 643-9	9
1607	Activation of hypoxia-inducible factor 1 in human T-cell leukaemia virus type 1-infected cell lines and primary adult T-cell leukaemia cells. **2007**, 406, 317-23	36
1606	Human telomere, oncogenic promoter and 5'-UTR G-quadruplexes: diverse higher order DNA and RNA targets for cancer therapeutics. **2007**, 35, 7429-55	737
1605	Fludarabine reduces survivability of HepG2 cells through VEGF under hypoxia. **2007**, 468, 100-6	2
1604	The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. **2007**, 43, 1392-8	163

1603	Hypoxia increases expression of selective facilitative glucose transporters (GLUT) and 2-deoxy-D-glucose uptake in human adipocytes. **2007**, 361, 468-73	106
1602	Comparison of hypoxia-inducible factor-1 alpha in hypoxia-sensitive and hypoxia-tolerant fish species. **2007**, 2, 177-86	32
1601	Hypoxia-inducible factors, stem cells, and cancer. **2007**, 129, 465-72	890
1600	AKT/PKB signaling: navigating downstream. **2007**, 129, 1261-74	4519
1599	RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. **2007**, 131, 309-23	243
1598	Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. **2007**, 131, 463-75	666
1597	Vascular endothelial growth factor: biology and therapeutic applications. **2007**, 39, 1349-57	129
1596	The effects of camptothecin on RNA polymerase II transcription: roles of DNA topoisomerase I. **2007**, 89, 482-9	38
1595	Mitochondria and reactive oxygen species in renal cancer. **2007**, 89, 1080-8	56
1594	Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy. **2007**, 252, 1-8	490
1593	Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. **2007**, 255, 107-16	74
1592	Inhibitory effects of nitric oxide on invasion of human cancer cells. **2007**, 257, 274-82	21
1591	Evidence of HIF-1 functional binding activity to caspase-3 promoter after photothrombotic cerebral ischemia. **2007**, 34, 40-7	38
1590	Regulation of HIF-1alpha stability through S-nitrosylation. **2007**, 26, 63-74	366
1589	p53 and NF-kappaB crosstalk: IKKalpha tips the balance. **2007**, 26, 158-9	84
1588	Can irradiated tumors take NO for an answer?. **2007**, 26, 157-8	0
1587	FOXO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2. **2007**, 28, 941-53	211
1586	Niche-to-niche migration of bone-marrow-derived cells. **2007**, 13, 72-81	190

1585	Targeting the mTOR signaling network in cancer. **2007**, 13, 433-42	281
1584	Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. **2007**, 74, 72-84	522
1583	A novel adenoviral vector-mediated neuronal selective gene expression in neonatal mouse brain in response to hypoxia. **2007**, 419, 23-7	6
1582	Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. **2007**, 38, 1310-20	92
1581	HIF-1 alpha expression is associated with an atheromatous inflammatory plaque phenotype and upregulated in activated macrophages. **2007**, 195, e69-75	92
1580	Hypoxia increases cytoplasmic expression of NDRG1, but is insufficient for its membrane localization in human hepatocellular carcinoma. **2007**, 581, 989-94	35
1579	Oxygen, a source of life and stress. **2007**, 581, 3582-91	262
1578	Wondonin, a novel compound, inhibits hypoxia-induced angiogenesis through hypoxia-inducible factor 1 alpha. **2007**, 581, 4977-82	11
1577	A role for CITED2, a CBP/p300 interacting protein, in colon cancer cell invasion. **2007**, 581, 5904-10	42
1576	Novel method for visualizing and modeling the spatial distribution of neural stem cells within intracranial glioma. **2007**, 37 Suppl 1, S18-26	28
1575	Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. **2007**, 83, 367-73	138
1574	Regulation of Cited2 expression provides a functional link between translational and transcriptional responses during hypoxia. **2007**, 83, 346-52	15
1573	Exploring the role of HIF-1 in early angiogenesis and response to radiotherapy. **2007**, 83, 249-55	34
1572	Hypoxia-inducible factor-1 facilitates cervical cancer progression in human papillomavirus type 16 transgenic mice. **2007**, 171, 667-81	24
1571	Human placental hypoxia-inducible factor-1alpha expression correlates with clinical outcomes in chronic hypoxia in vivo. **2007**, 170, 2171-9	86
1570	Mitochondrial membrane permeabilization in cell death. **2007**, 87, 99-163	2750
1569	Rational Drug Design of Small Molecule Anticancer Agents: Preclinical Discovery. **2007**,	1
1568	An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer. **2007**, 178, 677-82	48

1567	Breast tumour angiogenesis. **2007**, 9, 216	117
1566	Metastasis of Breast Cancer. **2007**,	4
1565	Antitumor activity, X-ray crystal structure, and DNA binding properties of thiocoraline A, a natural bisintercalating thiodepsipeptide. **2007**, 50, 3322-33	52
1564	(Aryloxyacetylamino)benzoic acid analogues: A new class of hypoxia-inducible factor-1 inhibitors. **2007**, 50, 1675-84	112
1563	A wrinkle in the unfolding of hypoxic response: HIF and ATF4. **2007**, 110, 3492-3493	2
1562	Hematopoietic cell transplantation: a lifelong commitment. **2007**, 110, 3493-3494	1
1561	Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice. **2007**, 67, 3483-91	128
1560	BNIP3 is an RB/E2F target gene required for hypoxia-induced autophagy. **2007**, 27, 6229-42	295
1559	Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. **2007**, 2, 561-71	111
1558	Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved. **2007**, 11, 1043-53	100
1557	Reducing a Biomarkers List via Mathematical Programming: Application to Gene Signatures to Detect Time-Dependent Hypoxia in Cancer. **2007**,	
1556	The flavonoid quercetin induces hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits cell proliferation by depleting intracellular iron. **2007**, 41, 342-56	37
1555	Targeting tumour-associated macrophages. **2007**, 11, 1219-29	52
1554	The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. **2007**, 21, 1037-49	270
1553	Molecular-targeted antitumor agents. 15. Neolamellarins from the marine sponge Dendrilla nigra inhibit hypoxia-inducible factor-1 activation and secreted vascular endothelial growth factor production in breast tumor cells. **2007**, 70, 1741-5	51
1552	Selected Molecular Mechanisms of Metal Toxicity and Carcinogenicity. **2007**, 79-100	8
1551	Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. **2007**, 11, 1055-69	24
1550	Hypoxia-selective antitumor agents: norsesterterpene peroxides from the marine sponge Diacarnus levii preferentially suppress the growth of tumor cells under hypoxic conditions. **2007**, 70, 130-3	22

1549	Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis. **2007**, 6, 220-6	124
1548	The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. **2007**, 13, 3109-14	220
1547	Total synthesis and absolute configuration of laurenditerpenol: a hypoxia inducible factor-1 activation inhibitor. **2007**, 50, 6299-302	23
1546	Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1. **2007**, 70, 1093-7	54
1545	Deubiquitinating enzymes as novel anticancer targets. **2007**, 3, 191-9	100
1544	Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. **2007**, 83, 398-405	76
1543	Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma. **2007** , 9, 237-41	19
1542	Cancer cell: using inflammation to invade the host. **2007**, 6, 29	39
1541	Differential effects of hypoxia on etoposide-induced apoptosis according to the cancer cell lines. **2007**, 6, 61	35
1540	Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. **2007**, 6, 63	48
1539	Transcriptional profiling of human cord blood CD133+ and cultured bone marrow mesenchymal stem cells in response to hypoxia. **2007**, 25, 1003-12	134
1538	The lethal phenotype of cancer: the molecular basis of death due to malignancy. **2007**, 57, 225-41	120
1537	Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. **2007**, 167, 127-45	145
1536	Chronic hypoxia as a mechanism for progressive renal fibrosis. **2007**, 4, 29-36	1
1535	Significance of the expression of phosphorylated-STAT3, -Akt, and -ERK1/2 in several tumors of the epidermis. **2007**, 48, 71-3	14
1534	Metabolic catastrophe as a means to cancer cell death. **2007**, 120, 379-83	177
1533	Central role of Muc5ac expression in mucous metaplasia and its regulation by conserved 5' elements. **2007**, 37, 273-90	134
1532	Hypoxia-inducible factor 1 inhibitors. **2007**, 435, 385-402	34

1531	Targeting tumors with hypoxia-activated cytotoxins. **2007**, 12, 3483-501	47
1530	Signaling mechanisms of endogenous angiogenesis inhibitors derived from type IV collagen. **2007**, 1, 217-26	16
1529	Targeting the molecular effects of a hypoxic tumor microenvironment. **2007**, 12, 4061-78	17
1528	Altered macrophage differentiation and immune dysfunction in tumor development. **2007**, 117, 1155-66	899
1527	Wireless communication. **2007**, 69-70	
1526	The Role of Glucose Metabolism and Glucose-Associated Signalling in Cancer. **2007**, 1, 1177391X0700100	8
1525	Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. **2007**, 117, 2713-22	300
1524	Flux analysis shows that hypoxia-inducible-factor-1-alpha minimally affects intracellular metabolism in tumor spheroids. **2007**, 96, 1167-82	29
1523	Genotype-phenotype correlations in von Hippel-Lindau disease. **2007**, 28, 143-9	174
1522	The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. **2007**, 120, 268-77	81
1521	HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. **2007**, 120, 1451-8	171
1520	Excessive superoxide anion generation plays a key role in carcinogenesis. **2007**, 120, 1378-80	49
1519	Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration. **2007**, 121, 276-83	109
1518	Increased HIF1 alpha in SDH and FH deficient tumors does not cause microsatellite instability. **2007**, 121, 1386-9	19
1517	Hypoxia upregulates carcinoembryonic antigen expression in cancer cells. **2007**, 121, 2443-50	24
1516	Prolyl-hydroxylase inhibition and HIF activation in osteoblasts promotes an adipocytic phenotype. **2007**, 100, 762-72	34
1515	Phenotypic expression of human hepatoma cells in culture. **2007**, 100, 1081-5	1
1514	Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. **2007**, 101, 937-49	411

1513	Microenvironmental influences in melanoma progression. **2007**, 101, 862-72	66
1512	Effects of prolyl hydroxylase inhibitors on adipogenesis and hypoxia inducible factor 1 alpha levels under normoxic conditions. **2007**, 101, 1545-57	29
1511	Acute L-glutamine deprivation compromises VEGF-a upregulation in A549/8 human carcinoma cells. **2007**, 212, 463-72	45
1510	Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. **2007**, 27, 317-52	351
1509	Correlation between tumor blood flow assessed by perfusion CT and effect of neoadjuvant therapy in advanced esophageal cancers. **2007**, 96, 220-9	35
1508	Synthesis and structure-activity relationships of 16-modified analogs of 2-methoxyestradiol. **2007**, 15, 7524-37	22
1507	Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1alpha inhibitors. **2007**, 17, 6305-10	27
1506	The hypoxic tumour microenvironment, patient selection and hypoxia-modifying treatments. **2007**, 19, 385-96	58
1505	The FTO (fat mass and obesity associated) gene codes for a novel member of the non-heme dioxygenase superfamily. **2007**, 8, 23	145
1504	Role of the ubiquitin proteasome system in renal cell carcinoma. **2007**, 8 Suppl 1, S4	16
1503	High levels of HIF-2alpha highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche. **2008**, 214, 482-8	88
1502	The homozygous P582S mutation in the oxygen-dependent degradation domain of HIF-1 alpha is associated with increased risk for prostate cancer. **2007**, 67, 8-13	42
1501	Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. **2007**, 67, 1354-61	45
1500	Dermcidin expression confers a survival advantage in prostate cancer cells subjected to oxidative stress or hypoxia. **2007**, 67, 1308-17	27
1499	Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancer. **2007**, 26, 132-41	55
1498	Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. **2007**, 26, 312-20	118
1497	Constitutively active CCK2 receptor splice variant increases Src-dependent HIF-1 alpha expression and tumor growth. **2007**, 26, 1013-9	29
1496	Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. **2007**, 26, 2027-38	127

1495	Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1. **2007**, 26, 3920-9		51
1494	Significance of HIF-1-active cells in angiogenesis and radioresistance. **2007**, 26, 7508-16		108
1493	HIF-2alpha specifically activates the VE-cadherin promoter independently of hypoxia and in synergy with Ets-1 through two essential ETS-binding sites. **2007**, 26, 7480-9		64
1492	Under-expression of VHL and over-expression of HDAC-1, HIF-1alpha, LL-37, and IAP-2 in affected skin biopsies of patients with psoriasis. **2007**, 46, 239-46		72
1491	Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. **2007**, 9, 210-7		380
1490	Non-heme dioxygenases: cellular sensors and regulators jelly rolled into one?. **2007**, 3, 144-53		186
1489	The tumour microenvironment as a target for chemoprevention. *Nature Reviews Cancer*, **2007**, 7, 139-47	31.3	625
1488	G-protein-coupled receptors and cancer. *Nature Reviews Cancer*, **2007**, 7, 79-94	31.3	970
1487	Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. *Nature Reviews Cancer*, **2007**, 7, 763-77	31.3	1887
1486	Models, mechanisms and clinical evidence for cancer dormancy. *Nature Reviews Cancer*, **2007**, 7, 834-46	31.3	1157
1485	Extracellular heat shock protein-90alpha: linking hypoxia to skin cell motility and wound healing. **2007**, 26, 1221-33		225
1484	Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. **2007**, 96, 95-103		88
1483	Target gene selectivity of hypoxia-inducible factor-alpha in renal cancer cells is conveyed by post-DNA-binding mechanisms. **2007**, 96, 1284-92		89
1482	Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells. **2007**, 97, 1099-105		23
1481	p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. **2007**, 446, 444-8		696
1480	Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. **2007**, 22, 1178-82		147
1479	Functional dissection of transformation by c-Src and v-Src. **2008**, 13, 1-12		34
1478	Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions. **2007**, 98, 1394-401		42

1477	Effects of decreased insulin-like growth factor-1 stimulation on hypoxia inducible factor 1-alpha protein synthesis and function during cutaneous repair in diabetic mice. **2007**, 15, 628-35	18
1476	Sustained expression of Hif-1alpha in the diabetic environment promotes angiogenesis and cutaneous wound repair. **2007**, 15, 636-45	132
1475	Therapeutic potential of H11 kinase for the ischemic heart. **2007**, 25, 14-29	26
1474	Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem cells and prolongs their lifespan. **2007**, 6, 745-57	393
1473	BRCA1 accumulates in the nucleus in response to hypoxia and TRAIL and enhances TRAIL-induced apoptosis in breast cancer cells. **2007**, 274, 5137-46	6
1472	Pyruvate reduces DNA damage during hypoxia and after reoxygenation in hepatocellular carcinoma cells. **2007**, 274, 5188-98	15
1471	Dual effect of echinomycin on hypoxia-inducible factor-1 activity under normoxic and hypoxic conditions. **2007**, 274, 5533-42	41
1470	Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell carcinoma. **2007**, 274, 6365-77	56
1469	Oxidative stress mediates CoCl(2)-induced prostate tumour cell adhesion: role of protein kinase C and p38 mitogen-activated protein kinase. **2007**, 101, 41-6	6
1468	Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review. **2007**, 32, 337-45	26
1467	Global gene expression profiling in human lung cells exposed to cobalt. **2007**, 8, 147	35
1466	Three autocrine feedback loops determine HIF1 alpha expression in chronic hypoxia. **2007**, 1773, 1511-25	26
1465	Harnessing the hypoxia-inducible factor in cancer and ischemic disease. **2007**, 73, 450-7	94
1464	Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. **2007**, 74, 191-201	56
1463	Up-regulation of HIF-1alpha expression induced by ginkgolides in hypoxic neurons. **2007**, 1166, 1-8	20
1462	Inflammation and cancer: breast cancer as a prototype. **2007**, 16 Suppl 2, S27-33	164
1461	HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. **2007**, 11, 335-47	616
1460	HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. **2007**, 11, 407-20	647

1459	HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. **2007**, 12, 108-13	574
1458	HIF-dependent antitumorigenic effect of antioxidants in vivo. **2007**, 12, 230-8	410
1457	An investigation of relationships between hypoxia-inducible factor-1 alpha gene polymorphisms and ovarian, cervical and endometrial cancers. **2007**, 31, 102-9	51
1456	Hypoxia signalling controls metabolic demand. **2007**, 19, 223-9	248
1455	PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. **2007**, 19, 2487-97	165
1454	Are postnatal hemangioblasts generated by dedifferentiation from committed hematopoietic stem cells?. **2007**, 35, 691-701	19
1453	Modulation of hypoxia-inducible factor-1 alpha in cultured primary cells by intracellular ascorbate. **2007**, 42, 765-72	88
1452	The role of ascorbate in the modulation of HIF-1alpha protein and HIF-dependent transcription by chromium(VI) and nickel(II). **2007**, 42, 1246-57	45
1451	Evaluation of HIF-1 inhibitors as anticancer agents. **2007**, 12, 853-9	312
1450	Bases cellulaires et moléculaires de l'hypertension artérielle pulmonaire. **2007**, 56, S93-S105	0
1449	Confluence-dependent resistance to doxorubicin in human MDA-MB-231 breast carcinoma cells requires hypoxia-inducible factor-1 activity. **2007**, 313, 867-77	45
1448	Survivin protein expression and hypoxia in advanced cervical carcinoma of patients treated by radiotherapy. **2007**, 104, 139-44	24
1447	Potential predictors of chemotherapy response in ovarian cancer--how do we define chemosensitivity?. **2007**, 104, 345-51	19
1446	Up-regulation and stabilization of HIF-1alpha in colorectal carcinomas. **2007**, 16 Suppl 1, S25-7	27
1445	Fetal growth plate: a developmental model of cellular adaptation to hypoxia. **2007**, 1117, 26-39	51
1444	Mammalian synthetic biology: engineering of sophisticated gene networks. **2007**, 130, 329-45	84
1443	Malignant astrocytic glioma: genetics, biology, and paths to treatment. **2007**, 21, 2683-710	1682
1442	Hypoxia-inducible factors: central regulators of the tumor phenotype. **2007**, 17, 71-7	367

1441	The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. **2007**, 14, 2600-7	83
1440	Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling. **2007**, 59, 717-21	18
1439	Triterpenoids and diarylheptanoids from Alnus hirsuta inhibit HIF-1 in AGS cells. **2007**, 30, 412-8	36
1438	Hypoxia-induced genetic instability--a calculated mechanism underlying tumor progression. **2007**, 85, 139-48	119
1437	Hypoxia and cancer. **2007**, 85, 1301-7	502
1436	Hypoxia inducible factor (HIF) function in innate immunity and infection. **2007**, 85, 1339-46	191
1435	The interaction of superoxide with nitric oxide destabilizes hypoxia-inducible factor-1alpha. **2007**, 64, 3295-305	11
1434	Hypoxia and breast cancer: prognostic and therapeutic implications. **2007**, 64, 3233-47	91
1433	Targeting the hypoxia inducible factor pathway with mitochondrial uncouplers. **2007**, 296, 35-44	10
1432	Promise and progress for functional and molecular imaging of response to targeted therapies. **2007**, 24, 1172-85	61
1431	HIF-1 mediates the Warburg effect in clear cell renal carcinoma. **2007**, 39, 231-4	224
1430	Actuality of Warburg's views in our understanding of renal cancer metabolism. **2007**, 39, 235-41	36
1429	MTA family of transcriptional metaregulators in mammary gland morphogenesis and breast cancer. **2007**, 12, 115-25	30
1428	Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. **2006**, 25, 621-33	78
1427	Metastasis and stem cell pathways. **2007**, 26, 261-71	49
1426	Hypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues. **2007**, 26, 273-9	76
1425	Hypoxia in cancer: significance and impact on clinical outcome. **2007**, 26, 225-39	1612
1424	Targeting hypoxia cell signaling for cancer therapy. **2007**, 26, 341-52	188

1423	Effects of hypoxia on tumor metabolism. **2007**, 26, 291-8	105
1422	Hypoxia-driven selection of the metastatic phenotype. **2007**, 26, 319-31	338
1421	Regulation of tumor pH and the role of carbonic anhydrase 9. **2007**, 26, 299-310	415
1420	Hypoxia: a key regulator of angiogenesis in cancer. **2007**, 26, 281-90	551
1419	The role of autocrine motility factor in tumor and tumor microenvironment. **2007**, 26, 725-35	57
1418	Role of phosphatidylinositol signaling pathway in the development of cross-resistance of tumor cells to hormonal cytostatics and hypoxia. **2007**, 143, 244-7	
1417	Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. **2007**, 455, 479-92	269
1416	Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification. **2007**, 9, 109-14	64
1415	Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. **2008**, 110, 465-75	122
1414	Imaging of tumor glucose utilization with positron emission tomography. **2008**, 27, 545-54	62
1413	Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents. **2008**, 27, 737-50	10
1412	Graded hypoxia modulates the invasive potential of HT1080 fibrosarcoma and MDA MB231 carcinoma cells. **2008**, 25, 253-64	18
1411	Regulation of breast cancer metastasis by IGF signaling. **2008**, 13, 431-41	25
1410	The magic of the hypoxia-signaling cascade. **2008**, 65, 1133-49	74
1409	Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervical cancer. **2008**, 184, 169-74	48
1408	Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters. **2008**, 184, 393-9	35
1407	Connective tissue growth factor (CTGF) and cancer progression. **2008**, 15, 675-85	105
1406	A dialogue between the hypoxia-inducible factor and the tumor microenvironment. **2008**, 1, 53-68	71

1405	Inhibitory effect of hypoxia inducible factor-1 antisense oligonucleotide on growth of human hepatocellular carcinoma cells. **2008**, 25, 88-92	8
1404	Circulating and imaging markers for angiogenesis. **2008**, 11, 321-35	38
1403	Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum. **2008**, 452, 535-44	39
1402	Experimental obstructive cholestasis: the wound-like inflammatory liver response. **2008**, 1, 6	44
1401	Deubiquitylating enzymes and disease. **2008**, 9 Suppl 1, S3	64
1400	The mTOR target 4E-BP1 contributes to differential protein expression during normoxia and hypoxia through changes in mRNA translation efficiency. **2008**, 8, 1019-28	39
1399	Potentiation of 2-methoxyestradiol-induced cytotoxicity by blocking endothelin A receptor in prostate cancer cells. **2008**, 68, 679-89	6
1398	HIF-1 alpha: a key survival factor for serum-deprived prostate cancer cells. **2008**, 68, 1405-15	26
1397	Increase in dopaminergic neurons from mouse embryonic stem cell-derived neural progenitor/stem cells is mediated by hypoxia inducible factor-1alpha. **2008**, 86, 2353-62	36
1396	STAT3: a critical transcription activator in angiogenesis. **2008**, 28, 185-200	224
1395	Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. **2008**, 52 Suppl 1, S103-27	139
1394	Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. **2008**, 47, 686-700	76
1393	Familial chronic myeloproliferative disorders: the state of the art. **2008**, 26, 131-8	28
1392	Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha. **2008**, 122, 5-14	63
1391	PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. **2008**, 123, 2430-7	75
1390	Hypoxia-inducible factor 1 and cancer pathogenesis. **2008**, 60, 591-7	128
1389	Ginkgolides protect PC12 cells against hypoxia-induced injury by p42/p44 MAPK pathway-dependent upregulation of HIF-1alpha expression and HIF-1DNA-binding activity. **2008**, 103, 564-75	28
1388	Does inhibition of degradation of hypoxia-inducible factor (HIF) alpha always lead to activation of HIF? Lessons learnt from the effect of proteasomal inhibition on HIF activity. **2008**, 104, 536-44	22

1387	AKT as locus of fragility in robust cancer system. **2008**, 104, 2071-7	15
1386	Egr-1 and serum response factor are involved in growth factors- and serum-mediated induction of E2-EPF UCP expression that regulates the VHL-HIF pathway. **2008**, 105, 1117-27	11
1385	Lysophosphatidic acid activates telomerase in ovarian cancer cells through hypoxia-inducible factor-1alpha and the PI3K pathway. **2008**, 105, 1194-201	26
1384	A23187, ionomycin and thapsigargin upregulate mRNA of HIF-1alpha via endoplasmic reticulum stress rather than a rise in intracellular calcium. **2008**, 215, 708-14	43
1383	Cancer stem cells in prostate adenocarcinoma: a target for new anticancer strategies. **2008**, 216, 571-5	7
1382	Can biomarkers play a role in the decision about treatment of the clinically negative neck in patients with head and neck cancer?. **2008**, 30, 525-38	34
1381	The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. **2008**, 66, 1-9	699
1380	Pancreatic cancer: from molecular signature to target therapy. **2008**, 68, 197-211	35
1379	Genetic causes of erythrocytosis and the oxygen-sensing pathway. **2008**, 22, 321-32	35
1378	Hypoxia-inducible factor-1 and nuclear factor-kappaB inhibitory meroterpene analogues of bakuchiol, a constituent of the seeds of Psoralea corylifolia. **2008**, 18, 2619-23	29
1377	Discovery of novel hydroxy-thiazoles as HIF-alpha prolyl hydroxylase inhibitors: SAR, synthesis, and modeling evaluation. **2008**, 18, 3925-8	38
1376	Origin of cancer stem cells: the role of self-renewal and differentiation. **2008**, 15, 407-14	48
1375	Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. **2008**, 19, 39-46	213
1374	Hypoxia causes downregulation of mismatch repair system and genomic instability in stem cells. **2008**, 26, 2052-62	70
1373	Molecular chaperone Hsp70 protects neuroblastoma SK-N-SH cells from hypoxic stress. **2008**, 2, 232-238	1
1372	Cancer micrometastasis and tumour dormancy. **2008**, 116, 754-70	133
1371	Imaging angiogenesis and the microenvironment. **2008**, 116, 695-715	124
1370	Overexpression of phosphorylated-ATF2 and STAT3 in cutaneous angiosarcoma and pyogenic granuloma. **2008**, 35, 722-30	26

1369	Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. **2008**, 222, 180-91		481
1368	Seed-based systematic discovery of specific transcription factor target genes. **2008**, 275, 3178-92		11
1367	CSB protein is (a direct target of HIF-1 and) a critical mediator of the hypoxic response. **2008**, 27, 2545-56		59
1366	Rapid degradation of hypoxia-inducible factor-1alpha by KRH102053, a new activator of prolyl hydroxylase 2. **2008**, 154, 114-25		39
1365	Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. **2008**, 15, 449-55		47
1364	Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2. **2008**, 27, 1004-12		69
1363	The ternary complex factor Net/Elk-3 participates in the transcriptional response to hypoxia and regulates HIF-1 alpha. **2008**, 27, 1333-41		30
1362	The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2alpha. **2008**, 27, 1501-10		109
1361	Hypoxia induced HIF-1 accumulation and VEGF expression in gastric epithelial mucosa cells: Involvement of ERK1/2 and PI3K/Akt. **2008**, 42, 403-412		8
1360	Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT. **2008**, 27, 7171-9		29
1359	Human mismatch repair gene, MLH1, is transcriptionally repressed by the hypoxia-inducible transcription factors, DEC1 and DEC2. **2008**, 27, 4200-9		76
1358	Reciprocal relationship between expression of hypoxia inducible factor 1alpha (HIF-1alpha) and the pro-apoptotic protein bid in ex vivo colorectal cancer. **2008**, 99, 459-63		11
1357	Inhibition of HIF-1alpha by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo. **2008**, 99, 1442-52		29
1356	A hypoxic twist in metastasis. **2008**, 10, 253-4		44
1355	Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. **2008**, 40, 170-80		383
1354	The interplay between MYC and HIF in cancer. *Nature Reviews Cancer*, **2008**, 8, 51-6	31.3	467
1353	Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. *Nature Reviews Cancer*, **2008**, 8, 425-37	31.3	781
1352	Modes of resistance to anti-angiogenic therapy. *Nature Reviews Cancer*, **2008**, 8, 592-603	31.3	2271

1351	Hypoxia, HIF1 and glucose metabolism in the solid tumour. *Nature Reviews Cancer*, **2008**, 8, 705-13	31.3	1188
1350	Hypoxia signalling through mTOR and the unfolded protein response in cancer. *Nature Reviews Cancer*, **2008**, 8, 851-64	31.3	690
1349	The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. *Nature Reviews Cancer*, **2008**, 8, 865-73	31.3	536
1348	The impact of O2 availability on human cancer. *Nature Reviews Cancer*, **2008**, 8, 967-75	31.3	983
1347	Carrot and stick: HIF-alpha engages c-Myc in hypoxic adaptation. **2008**, 15, 672-7		112
1346	Inhibition of tumor cell growth in the liver by RNA interference-mediated suppression of HIF-1alpha expression in tumor cells and hepatocytes. **2008**, 15, 572-82		23
1345	Metabolic and morphological differences between rapidly proliferating cancerous and normal breast epithelial cells. **2008**, 24, 334-41		44
1344	Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer. **2008**, 18, 499-505		38
1343	Interaction of caveolin-1, nitric oxide, and nitric oxide synthases in hypoxic human SK-N-MC neuroblastoma cells. **2008**, 107, 478-87		18
1342	Molecular mechanisms of carbonic anhydrase IX-mediated pH regulation under hypoxia. **2008**, 101 Suppl 4, 8-15		78
1341	Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. **2008**, 99, 1341-7		90
1340	Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. **2008**, 99, 1734-40		105
1339	TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. **2008**, 99, 2327-35		44
1338	Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family. **2008**, 141, 676-80		35
1337	Caenorhabditis elegans par2.1/mtssb-1 is essential for mitochondrial DNA replication and its defect causes comprehensive transcriptional alterations including a hypoxia response. **2008**, 314, 103-14		21
1336	The specific contribution of hypoxia-inducible factor-2alpha to hypoxic gene expression in vitro is limited and modulated by cell type-specific and exogenous factors. **2008**, 314, 2016-27		47
1335	Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence. **2008**, 108, 377-84		48
1334	ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo. **2008**, 8, 206		53

1333	Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression. **2008**, 8, 320	50
1332	Prognostic significance of Hypoxia-Inducible Factor 1 alpha(HIF-1 alpha) expression in serous ovarian cancer: an immunohistochemical study. **2008**, 8, 335	54
1331	Single nucleotide polymorphisms in the hypoxia-inducible factor-1alpha (HIF-1alpha) gene in human sporadic breast cancer. **2008**, 39, 338-45	40
1330	The mitochondrial thioredoxin system regulates nitric oxide-induced HIF-1alpha protein. **2008**, 44, 91-8	24
1329	Flavonoids induce HIF-1alpha but impair its nuclear accumulation and activity. **2008**, 44, 657-70	65
1328	VDUP1 mediates nuclear export of HIF1alpha via CRM1-dependent pathway. **2008**, 1783, 838-48	51
1327	Genetics and epigenetics of renal cell cancer. **2008**, 1785, 133-55	68
1326	The controversial place of vitamin C in cancer treatment. **2008**, 76, 1644-52	68
1325	Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. **2008**, 13, 193-205	365
1324	VHL inactivation: a new road to senescence. **2008**, 13, 295-7	7
1323	Q39, a novel synthetic Quinoxaline 1,4-Di-N-oxide compound with anti-cancer activity in hypoxia. **2008**, 581, 262-9	33
1322	A quassinoid 6alpha-tigloyloxychaparrinone inhibits hypoxia-inducible factor-1 pathway by inhibition of eukaryotic translation initiation factor 4E phosphorylation. **2008**, 592, 41-7	19
1321	Novel imaging approaches to head and neck cancer. **2008**, 35, 262-73	2
1320	Targeting angiogenesis in head and neck cancer. **2008**, 35, 274-85	66
1319	Macrophage polarization in tumour progression. **2008**, 18, 349-55	863
1318	The A3 adenosine receptor: an enigmatic player in cell biology. **2008**, 117, 123-40	177
1317	HIF-1 regulation: not so easy come, easy go. **2008**, 33, 526-34	246
1316	Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity?. **2008**, 100, 227-35	330

1315	Regulation of HIF: Prolyl Hydroxylases. **2008**, 15-32	25
1314	Determinants of VO2 max decline with aging: an integrated perspective. **2008**, 33, 130-40	89
1313	[Current strategies in the treatment of renal-cell cancer: targeted therapies]. **2008**, 130, 380-92	2
1312	Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity. **2008**, 7, 27	62
1311	Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade. **2008**, 134, 2036-48, 2048.e1-3	128
1310	Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. **2008**, 51, 1258-65	344
1309	The role of bevacizumab in breast cancer. **2008**, 6, 26-29	2
1308	A new weapon for attacking tumor blood vessels. **2008**, 358, 2066-7	34
1307	HIF and reactive oxygen species regulate oxidative phosphorylation in cancer. **2008**, 29, 1528-37	74
1306	Gene expression analysis of collembola in cadmium containing soil. **2008**, 42, 8152-7	56
1305	Neural stem cell tropism to glioma: critical role of tumor hypoxia. **2008**, 6, 1819-29	143
1304	Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. **2008**, 7, 1789-96	257
1303	Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas. **2008**, 39, 1483-94	29
1302	Cell death recognition model for the immune system. **2008**, 70, 585-96	13
1301	Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. **2008**, 30, 393-402	2112
1300	Abundance of aspargynyl-hydroxylase FIH is regulated by Siah-1 under normoxic conditions. **2008**, 433, 209-14	26
1299	Monocytes and dendritic cells in a hypoxic environment: Spotlights on chemotaxis and migration. **2008**, 213, 733-49	122
1298	Nitric oxide, apoptosis and macrophage polarization during tumor progression. **2008**, 19, 95-102	115

1297	Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. **2008**, 19, 205-16	160
1296	Expression and significance of hypoxemia-inducible factor-1alpha in osteosarcoma of the jaws. **2008**, 106, 254-7	18
1295	Targeting the mitochondria for cancer therapy: regulation of hypoxia-inducible factor by mitochondria. **2008**, 10, 635-40	28
1294	Genetic aspects of inflammation and cancer. **2008**, 410, 225-35	95
1293	Tumor angiogenesis. **2008**, 358, 2039-49	1788
1292	Hypoxic regulation of mRNA expression. **2008**, 7, 1916-24	59
1291	Nutrition-induced catch-up growth increases hypoxia inducible factor 1alpha RNA levels in the growth plate. **2008**, 42, 505-15	30
1290	Hypoxia in microscopic tumors. **2008**, 264, 172-80	51
1289	Transcriptional adaptation of neuroblastoma cells to hypoxia. **2008**, 366, 1054-60	21
1288	AMP-activated protein kinase is essential for survival in chronic hypoxia. **2008**, 370, 230-4	21
1287	Heterogeneity in binding and gene-expression regulation by HIF-2alpha. **2008**, 371, 251-5	5
1286	Hypoxia enhances CXCR4 expression favoring microglia migration via HIF-1alpha activation. **2008**, 371, 283-8	76
1285	Diameter of tumor blood vessels is a good parameter to estimate HIF-1-active regions in solid tumors. **2008**, 373, 533-8	14
1284	Stem cell factor induces HIF-1alpha at normoxia in hematopoietic cells. **2008**, 377, 98-103	59
1283	Rare variant of hypoxia-inducible factor-1alpha (HIF-1A) and breast cancer risk in Korean women. **2008**, 389, 167-70	40
1282	Regulation of gene expression by hypoxia: integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element. **2008**, 395, 6-13	106
1281	The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. **2008**, 7, 11-20	2786
1280	Multi-functional nanocarriers to overcome tumor drug resistance. **2008**, 34, 592-602	335

1279	Hungry for blood vessels: linking metabolism and angiogenesis. **2008**, 14, 313-4	11
1278	Fundamentals of molecular imaging: rationale and applications with relevance for radiation oncology. **2008**, 38, 119-28	17
1277	RNA-binding proteins HuR and PTB promote the translation of hypoxia-inducible factor 1alpha. **2008**, 28, 93-107	223
1276	Hypoxia inducible factor-1alpha inactivation unveils a link between tumor cell metabolism and hypoxia-induced cell death. **2008**, 173, 1186-201	35
1275	Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. **2008**, 173, 545-60	157
1274	Attenuation of p38 MAPK activity upon contact inhibition in fibroblasts. **2008**, 308, 65-73	4
1273	Tumor-microenvironment interactions: dangerous liaisons. **2008**, 100, 203-29	98
1272	BH3 mimetics reactivate autophagic cell death in anoxia-resistant malignant glioma cells. **2008**, 10, 873-85	22
1271	Increased expression of hypoxia-inducible factor-1 alpha in venous stenosis of arteriovenous polytetrafluoroethylene grafts in a chronic renal insufficiency porcine model. **2008**, 19, 260-5	30
1270	Mammalian target of rapamycin as a therapeutic target in oncology. **2008**, 12, 209-22	74
1269	Targeting transcription factors for therapeutic benefit. **2008**, 4, 909-19	39
1268	Roles of integrins in tumor angiogenesis and lymphangiogenesis. **2008**, 6, 155-63	73
1267	In situ calcium mapping in the mouse retina via time-of-flight secondary ion mass spectrometry: modulation of retinal angiogenesis by calcium ion in development and oxygen-induced retinopathy. **2008**, 86, 459-67	6
1266	Modern cancer drug discovery: integrating targets, technologies and treatments. **2008**, 3-38	3
1265	Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells. **2008**, 71, 396-402	53
1264	Molecular imaging of hypoxia. **2008**, 49 Suppl 2, 129S-48S	401
1263	Hypoxia and Angiogenesis in Glioblastomas. **2008**, 195-214	
1262	Tumor versus tumor-associated macrophages: how hot is the link?. **2008**, 7, 90-5	53

1261	Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. **2008**, 7, 1472-82	57
1260	Intronically encoded siRNAs improve dynamic range of mammalian gene regulation systems and toggle switch. **2008**, 36, e101	40
1259	Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. **2008**, 105, 16484-9	119
1258	Molecular Targeting in Hepatocellular Carcinoma. **2008**, 165-210	1
1257	Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene. **2008**, 16, 1227-34	36
1256	Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. **2008**, 14, 3589-97	99
1255	Angiogenesis. **2008**,	25
1254	Monoclonal antibody-based screening assay for factor inhibiting hypoxia-inducible factor inhibitors. **2008**, 13, 494-503	26
1253	Tocotrienol inhibits secretion of angiogenic factors from human colorectal adenocarcinoma cells by suppressing hypoxia-inducible factor-1alpha. **2008**, 138, 2136-42	60
1252	Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia. **2008**, 68, 4719-26	69
1251	Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. **2008**, 68, 9323-30	118
1250	Decreased ID2 promotes metastatic potentials of hepatocellular carcinoma by altering secretion of vascular endothelial growth factor. **2008**, 14, 1025-31	34
1249	Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. **2008**, 14, 2082-7	26
1248	Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. **2008**, 14, 7781-9	77
1247	A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. **2008**, 7, 3598-608	200
1246	Poly(ADP-ribose) polymerase 1 promotes tumor cell survival by coactivating hypoxia-inducible factor-1-dependent gene expression. **2008**, 6, 282-90	57
1245	Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. **2008**, 6, 1099-105	136
1244	Inhibition of VEGF blocks TGF-beta1 production through a PI3K/Akt signalling pathway. **2008**, 31, 523-31	67

1243	Synthesis and anticancer properties of water-soluble zinc ionophores. **2008**, 68, 5318-25	66
1242	Disruption of signaling through SEK1 and MKK7 yields differential responses in hypoxic colon cancer cells treated with oxaliplatin. **2008**, 74, 246-54	7
1241	Synergystic induction of HIF-1alpha transcriptional activity by hypoxia and lipopolysaccharide in macrophages. **2008**, 7, 232-41	50
1240	Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis. **2008**, 7, 1619-27	11
1239	EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. **2008**, 7, 2409-17	90
1238	Targeting apoptosis resistance in rhabdomyosarcoma. **2008**, 8, 536-44	14
1237	(2R)-[(4-Biphenylylsulfonyl)amino]-N-hydroxy-3-phenylpropionamide (BiPS), a matrix metalloprotease inhibitor, is a novel and potent activator of hypoxia-inducible factors. **2008**, 74, 282-8	9
1236	Cancer-associated carbonic anhydrases and their inhibition. **2008**, 14, 685-98	142
1235	Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha. **2008**, 416, 387-94	245
1234	HIF-1alpha mRNA gene expression levels in improved diagnosis of early stages of prostate cancer. **2008**, 13, 680-91	31
1233	The interplay between MYC and HIF in the Warburg effect. **2007**, 35-53	65
1232	Tumor cell metabolism imaging. **2008**, 49 Suppl 2, 43S-63S	236
1231	Prostate Cancer. **2008**,	3
1230	Hypoxia and the endocrine and signalling role of white adipose tissue. **2008**, 114, 267-76	105
1229	Inhibitors of tumor angiogenesis. **2008**, 351-381	
1228	Cancer-causing mutations in a novel transcription-dependent nuclear export motif of VHL abrogate oxygen-dependent degradation of hypoxia-inducible factor. **2008**, 28, 302-14	14
1227	Abnormal sympathoadrenal development and systemic hypotension in PHD3-/- mice. **2008**, 28, 3386-400	163
1226	Atypical CRM1-dependent nuclear export signal mediates regulation of hypoxia-inducible factor-1alpha by MAPK. **2008**, 283, 27620-27627	69

1225	Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. **2008**, 283, 20473-83	172
1224	Involvement of hypoxia-inducing factor-1alpha-dependent plasminogen activator inhibitor-1 up-regulation in Cyr61/CCN1-induced gastric cancer cell invasion. **2008**, 283, 15807-15	51
1223	Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. **2008**, 7, 1961-73	192
1222	Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition. **2008**, 68, 1872-80	63
1221	Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. **2008**, 105, 13544-9	132
1220	Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors. **2008**, 14, 6634-9	77
1219	Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. **2008**, 68, 5540-5	262
1218	Translational repression during chronic hypoxia is dependent on glucose levels. **2008**, 14, 771-81	14
1217	Review: Behaviour of endothelial cells faced with hypoxia. **2008**, 18, 295-299	3
1216	Hypoxia-inducible factor (HIF)-1 alpha directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF). **2008**, 29, 1853-61	109
1215	Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. **2008**, 29, 704-12	91
1214	Hypoxic regulation of metastasis via hypoxia-inducible factors. **2008**, 8, 60-7	108
1213	In vivo bioluminescence imaging monitoring of hypoxia-inducible factor 1alpha, a promoter that protects cells, in response to chemotherapy. **2008**, 191, 1779-84	28
1212	Role of hypoxia-inducible factor-1alpha in hypoxia-induced expressions of IL-8, MMP-1 and MMP-3 in rheumatoid fibroblast-like synoviocytes. **2008**, 47, 834-9	78
1211	The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates. **2008**, 29, 1077-82	35
1210	Principles of Molecular Oncology. **2008**,	1
1209	Hypoxia-inducible factor-1alpha obstructs a Wnt signaling pathway by inhibiting the hARD1-mediated activation of beta-catenin. **2008**, 68, 5177-84	77
1208	Oxygen regulation of arterial smooth muscle cell proliferation and survival. **2008**, 294, H839-52	13

1207	Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. **2008**, 29, 2267-78	245
1206	Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis. **2008**, 295, F1023-9	190
1205	The thioredoxin system: a key target in tumour and endothelial cells. **2008**, 81 Spec No 1, S57-68	68
1204	hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. **2008**, 14, 1340-8	555
1203	Chemosensitization by emodin, a plant-derived anti-cancer agent: mechanism of action. **2008**, 7, 476-8	12
1202	The biphasic role of the hypoxia-inducible factor prolyl-4-hydroxylase, PHD2, in modulating tumor-forming potential. **2008**, 6, 829-42	45
1201	Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. **2008**, 28, 7081-95	131
1200	Metallothionein induction by hypoxia involves cooperative interactions between metal-responsive transcription factor-1 and hypoxia-inducible transcription factor-1alpha. **2008**, 6, 483-90	63
1199	Regulation of hypoxia-inducible genes by ETS1 transcription factor. **2008**, 29, 1493-9	42
1198	Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha. **2008**, 7, 1974-84	64
1197	Yin-yang activities and vicious cycles in the tumor microenvironment. **2008**, 68, 9-13	81
1196	Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. **2008**, 68, 1003-11	290
1195	Hypoxic conditioning suppresses nitric oxide production upon myocardial reperfusion. **2008**, 233, 766-74	12
1194	Effects of Paclitaxel on human lung cancer cell lines in vitro and in vivo. **2008**, 518-523	
1193	Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. **2008**, 10, 767-77	162
1192	Hypoxia-mediated induction of the polyamine system provides opportunities for tumor growth inhibition by combined targeting of vascular endothelial growth factor and ornithine decarboxylase. **2008**, 68, 9291-301	35
1191	Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. **2008**, 7, 468-75	82
1190	Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab. **2008**, 7, 1207-17	58

1189	The ubiquitin ligase Siah2 regulates tumorigenesis and metastasis by HIF-dependent and -independent pathways. **2008**, 105, 16713-8	81
1188	Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. **2008**, 105, 13568-73	540
1187	Transcriptional Regulation of SDHa flavoprotein by nuclear respiratory factor-1 prevents pseudo-hypoxia in aerobic cardiac cells. **2008**, 283, 10967-77	32
1186	A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers. **2008**, 7, 1598-603	51
1185	Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells. **2008**, 7, 1817-26	59
1184	Modulation of matrix metalloproteinase secretion by adenosine A3 receptor in preeclamptic villous explants. **2008**, 15, 939-49	13
1183	Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-Gluco-RGD autoradiography. **2008**, 49, 597-605	37
1182	A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer. **2008**, 68, 1144-53	42
1181	Visualization of hypoxia-inducible factor-1 transcriptional activation in C6 glioma using luciferase and sodium iodide symporter genes. **2008**, 49, 1489-97	19
1180	Chemosensitization of cancer by nitric oxide. **2008**, 14, 1113-23	76
1179	A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. **2008**, 358, 162-8	247
1178	Physiological Targeting to Improve Anticancer Drug Selectivity. **2008**, 61, 647	21
1177	Molecular targeting agents in renal cell carcinoma: present strategies and future perspectives. **2008**, 14, 1058-77	6
1176	Hypoxic regulation of miR-210: shrinking targets expand HIF-1's influence. **2008**, 7, 265-7	40
1175	Adventitial transplantation of blood outgrowth endothelial cells in porcine haemodialysis grafts alleviates hypoxia and decreases neointimal proliferation through a matrix metalloproteinase-9-mediated pathway--a pilot study. **2009**, 24, 85-96	27
1174	Molecular imaging of metastatic potential. **2008**, 49 Suppl 2, 96S-112S	50
1173	Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma. **2008**, 61, 658-64	66
1172	Involvement of estrogen-related receptors in transcriptional response to hypoxia and growth of solid tumors. **2008**, 105, 7821-6	101

1171	Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. **2008**, 68, 8635-42	115
1170	Expanded adipose tissue: 'out of breath' and inflamed. **2008**, 100, 236-7	1
1169	Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines. **2008**,	4
1168	Accumulation of hypoxia-inducible factor-1 alpha protein and its role in the differentiation of myeloid leukemic cells induced by all-trans retinoic acid. **2008**, 93, 1480-7	25
1167	Targeting vessels to treat hepatocellular carcinoma. **2008**, 114, 467-77	6
1166	Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. **2008**, 111, 3229-35	211
1165	The effect of hypoxic microenvironment on matrix metalloproteinase expression in xenografts of human oral squamous cell carcinoma. **2008**,	1
1164	HIF-1-regulated glucose metabolism in the control of apoptosis signaling. **2008**, 3, 303-308	2
1163	Predicting response to clinical radiotherapy: past, present, and future directions. **2008**, 15, 151-6	29
1162	Zebularine-induced reduction in VEGF secretion by HIF-1□degradation in oral squamous cell carcinoma. **2008**,	0
1161	mTOR pathway and mTOR inhibitors as agents for cancer therapy. **2008**, 8, 647-65	86
1160	Carbon monoxide ameliorates renal cold ischemia-reperfusion injury with an upregulation of vascular endothelial growth factor by activation of hypoxia-inducible factor. **2008**, 85, 1833-40	64
1159	Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. **2008**, 36, e1-9	131
1158	Posttranscription regulation of prostate cancer growth. **2008**, 14, 46-53	13
1157	G-protein coupled chemoattractant receptors and cancer. **2008**, 13, 3352-63	32
1156	Pathophysiology of placentation abnormalities in pregnancy-induced hypertension. **2008**, 4, 1301-13	53
1155	Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. **2008**, 118, 217-28	142
1154	Targeting Cancer Cells by an Oxidant-Based Therapy. **2008**, 1, 80-92	24

1153	Prognostic significance of HIF-2alpha expression on tumor infiltrating macrophages in patients with uterine cervical cancer undergoing radiotherapy. **2008**, 55, 78-86	33
1152	Heat shock transcription factor 1 preserves cardiac angiogenesis and adaptation during pressure overload. **2008**,	
1151	Oxygen and Cell Fate Decisions. **2008**, 2, 43-51	25
1150	Oxidative stress in neurodegeneration and available means of protection. **2008**, 13, 3288-311	84
1149	Molecular Imaging of Hypoxia-Inducible Factor 1 and von Hippel-Lindau Interaction in Mice. **2008**, 7, 7290.2008.00017	5
1148	System Recovery. **2009**, 185-222	
1147	. **2009**,	7
1146	Synthesis of Neolamellarin A, an Inhibitor of Hypoxia-Inducible Factor-1. **2009**, 4, 1934578X0900400	2
1145	Multiple roles and therapeutic implications of Akt signaling in cancer. **2009**, 2, 135-50	14
1144	An algorithm for identifying novel targets of transcription factor families: application to hypoxia-inducible factor 1 targets. **2009**, 7, 75-89	7
1143	The Fathers of Italian Histology. **2009**, 51, 1	4
1142	Genetics, cellular biology and tumor microenvironment of melanoma. **2009**, 14, 918-28	10
1141	Green tea and prostate cancer: from bench to clinic. **2009**, 1, 13-25	42
1140	Regulation of Oxygen Delivery by Red Cells and Red Cell Substitutes. 29-53	
1139	Gefitinib circumvents hypoxia-induced drug resistance by the modulation of HIF-1 **2009**,	
1138	Hypoxia-inducible factor-1alpha expression predicts the response to 5-fluorouracil-based adjuvant chemotherapy in advanced gastric cancer. **2009**, 22, 693-9	11
1137	Imaging and Targeting of the Hypoxia-inducible Factor 1-active Microenvironment. **2009**, 22, 93-100	7
1136	[Molecular mechanisms of tissue fibrosis]. **2009**, 32, 160-7	8

1135	Associations between hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms and risk of developing breast cancer. **2009**, 56, 441-7	25
1134	HIF-1 modulates dietary restriction-mediated lifespan extension via IRE-1 in Caenorhabditis elegans. **2009**, 5, e1000486	190
1133	Real-time imaging of HIF-1alpha stabilization and degradation. **2009**, 4, e5077	83
1132	Avicin D: a protein reactive plant isoprenoid dephosphorylates Stat 3 by regulating both kinase and phosphatase activities. **2009**, 4, e5578	23
1131	Modulating temporal and spatial oxygenation over adherent cellular cultures. **2009**, 4, e6891	63
1130	The Warburg effect is genetically determined in inherited pheochromocytomas. **2009**, 4, e7094	179
1129	Hypoxia induced CCR7 expression via HIF-1alpha and HIF-2alpha correlates with migration and invasion in lung cancer cells. **2009**, 8, 322-30	55
1128	HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. **2009**, 106, 14391-6	156
1127	Hypoxia drives prostate tumour progression and impairs the effectiveness of therapy, but can also promote cell death and serve as a therapeutic target. **2009**, 13, 219-25	23
1126	Cellular Respiration and Carcinogenesis. **2009**,	
1125	Chemically induced pheochromocytomas in rats: mechanisms and relevance for human risk assessment. **2009**, 39, 695-718	44
1124	A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. **2009**, 29, 5729-41	117
1123	Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis. **2009**, 106, 21300-5	164
1122	Expression and correlation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and microvessel density in experimental rat hepatocarcinogenesis. **2009**, 37, 417-25	28
1121	Targeting the hypoxia-inducible factor (HIF) pathway in cancer. **2009**, 11, e26	151
1120	Effects of nickel on cyclin expression, cell cycle progression and cell proliferation in human pulmonary cells. **2009**, 18, 1720-9	39
1119	Methylalpinumisoflavone inhibits hypoxia-inducible factor-1 (HIF-1) activation by simultaneously targeting multiple pathways. **2009**, 284, 5859-68	52
1118	Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. **2009**, 106, 4260-5	316

1117	Cockayne syndrome B protein (CSB): linking p53, HIF-1 and p300 to robustness, lifespan, cancer and cell fate decisions. **2009**, 8, 693-6	27
1116	Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events. **2009**, 106, 14004-9	54
1115	mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. **2009**, 9, 231-41	57
1114	Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. **2009**, 69, 1836-43	49
1113	Human cancers converge at the HIF-2alpha oncogenic axis. **2009**, 106, 21306-11	103
1112	The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. **2009**, 182, 3510-21	141
1111	Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene. **2009**, 182, 1270-7	42
1110	Epidermal growth factor-activated aryl hydrocarbon receptor nuclear translocator/HIF-1{beta} signal pathway up-regulates cyclooxygenase-2 gene expression associated with squamous cell carcinoma. **2009**, 284, 9908-16	22
1109	Hypoxia-induced expression of carbonic anhydrase 9 is dependent on the unfolded protein response. **2009**, 284, 24204-12	44
1108	BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}. **2009**, 284, 10004-12	121
1107	Polyphyllin D exerts potent anti-tumour effects on Lewis cancer cells under hypoxic conditions. **2009**, 37, 631-40	23
1106	Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. **2009** , 29, 4467-83	578
1105	Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer. **2009**, 101, 1769-81	123
1104	Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. **2009**, 106, 17910-5	365
1103	Hitting HIF1 in cancer. **2009**, 2, 1461-1461	
1102	Regulation of glucose metabolism-related genes and VEGF by HIF-1alpha and HIF-1beta, but not HIF-2alpha, in gastric cancer. **2009**, 41, 51-8	29
1101	G3139, an anti-Bcl-2 antisense oligomer that binds heparin-binding growth factors and collagen I, alters in vitro endothelial cell growth and tubular morphogenesis. **2009**, 15, 2797-807	17
1100	Chronic hypoxia activates the Akt and beta-catenin pathways in human macrophages. **2009**, 29, 1664-70	34

1099	Ethnic variability of HIF-1alpha polymorphisms. **2009**, 5, 273-7	6
1098	HIF at a glance. **2009**, 122, 1055-7	175
1097	The antihypoxia-adenosinergic pathogenesis as a result of collateral damage by overactive immune cells. **2009**, 86, 545-8	10
1096	Kinome siRNA screen identifies SMG-1 as a negative regulator of hypoxia-inducible factor-1alpha in hypoxia. **2009**, 284, 16752-16758	22
1095	Cellular hypoxia and adipose tissue dysfunction in obesity. **2009**, 68, 370-7	190
1094	Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. **2009**, 8, 2329-38	50
1093	Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. **2009**, 30, 1848-56	84
1092	Control of ovulation in mice by progesterone receptor-regulated gene networks. **2009**, 15, 821-8	56
1091	The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths. **2009**, 284, 20299-310	218
1090	Hypoxia-inducible factor-1alpha suppresses squamous carcinogenic progression and epithelial-mesenchymal transition. **2009**, 69, 2638-46	56
1089	Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. **2009**, 69, 5082-90	72
1088	Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells. **2009**, 7, 393-401	89
1087	Inhibition of prolyl hydroxylase domain proteins promotes therapeutic revascularization. **2009**, 120, 50-9	68
1086	Effect of siRNA targeting HIF-1alpha combined L-ascorbate on biological behavior of hypoxic MiaPaCa2 cells. **2009**, 8, 235-40	4
1085	Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. **2009**, 27, 227-34	98
1084	Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. **2009**, 8, 1596-603	38
1083	p62 degradation by autophagy: another way for cancer cells to survive under hypoxia. **2009**, 5, 410-2	39
1082	Activation of a unique p53-dependent DNA damage response. **2009**, 8, 1630-2	12

1081	The hypoxic response and aging. **2009**, 8, 2324	29
1080	Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads. **2009**, 8, 4040-3	20
1079	In situ modulation of oxidative stress: a novel and efficient strategy to kill cancer cells. **2009**, 16, 1821-30	57
1078	Nitric oxide: cancer target or anticancer agent?. **2009**, 9, 214-36	45
1077	Assessing metabolic stress and autophagy status in epithelial tumors. **2009**, 453, 53-81	29
1076	Subcellular dynamics of the VHL tumor suppressor: on the move for HIF degradation. **2009**, 5, 85-95	4
1075	HIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides. **2009**, 9, 881-7	26
1074	Effects of lipoxin A(4) on CoCl(2)-induced angiogenesis and its possible mechanisms in human umbilical vein endothelial cells. **2009**, 84, 17-23	20
1073	Role of oxygen in cancer: looking beyond hypoxia. **2009**, 9, 517-25	16
1072	Role of the phosphatidylinositol-3-kinase and extracellular regulated kinase pathways in the induction of hypoxia-inducible factor (HIF)-1 activity and the HIF-1 target vascular endothelial growth factor in ovarian granulosa cells in response to follicle-stimulating hormone. **2009**, 150, 915-28	91
1071	Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target. **2009**, 5, 509-22	22
1070	Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?. **2009**, 5, 871-88	3
1069	HIF-1alpha and HIF-2alpha are differentially regulated in vivo in neuroblastoma: high HIF-1alpha correlates negatively to advanced clinical stage and tumor vascularization. **2009**, 15, 7130-6	61
1068	DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity. **2009**, 69, 3884-91	69
1067	Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. **2009**, 8, 1867-77	148
1066	Sphingosine-1-phosphate: a novel nonhypoxic activator of hypoxia-inducible factor-1 in vascular cells. **2009**, 29, 902-8	49
1065	Hypoxia inducible factor 1 as a therapeutic target in ischemic stroke. **2009**, 16, 4593-600	111
1064	Angiogenese und Tumorhypoxie beim Mammakarzinom: Fakten, Fragen und therapeutische M□lichkeiten. **2009**, 69, 549-558	1

1063	Hypoxia-induced alveolar epithelial-mesenchymal transition requires mitochondrial ROS and hypoxia-inducible factor 1. **2009**, 297, L1120-30	156
1062	Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. **2009**, 15, 3433-41	72
1061	Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. **2009**, 69, 1624-32	104
1060	Hypoxia-inducible factor-2alpha mRNA expression in human renal cell carcinoma. **2009**, 48, 909-14	11
1059	Inhibition of prolyl hydroxylase domain-containing protein suppressed lipopolysaccharide-induced TNF-alpha expression. **2009**, 29, 2132-7	53
1058	Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. **2009**, 50, 36-44	117
1057	Identification of a novel small molecule HIF-1alpha translation inhibitor. **2009**, 15, 6128-36	84
1056	Kruppel-like factor 2 inhibits hypoxia-inducible factor 1alpha expression and function in the endothelium. **2009**, 284, 20522-30	65
1055	Key role for activin B in cellular transformation after loss of the von Hippel-Lindau tumor suppressor. **2009**, 29, 1707-18	20
1054	The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. **2009**, 8, 947-58	74
1053	Enhanced interferon-gamma gene expression in T Cells and reduced ovalbumin-dependent lung eosinophilia in hypoxia-inducible factor-1-alpha-deficient mice. **2009**, 149, 98-102	34
1052	Drug discovery for overcoming chronic kidney disease (CKD): prolyl-hydroxylase inhibitors to activate hypoxia-inducible factor (HIF) as a novel therapeutic approach in CKD. **2009**, 109, 24-31	32
1051	Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment. **2009**, 8, 1148-56	50
1050	Mechanism of cancer cell adaptation to metabolic stress: proteomics identification of a novel thyroid hormone-mediated gastric carcinogenic signaling pathway. **2009**, 8, 70-85	59
1049	Radiotherapy decreases vascular density and causes hypoxia with macrophage aggregation in TRAMP-C1 prostate tumors. **2009**, 15, 1721-9	101
1048	Where did they come from? The origin of endogenous gamma-H2AX foci in tumor cells. **2009**, 8, 2324	8
1047	Identification of chemical compounds that induce HIF-1alpha activity. **2009**, 112, 153-63	47
1046	Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. **2009**, 29, 2570-81	1008

1045	Characterization of a robust enzymatic assay for inhibitors of 2-oxoglutarate-dependent hydroxylases. **2009**, 14, 627-35	12
1044	An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. **2009**, 15, 3462-71	95
1043	Blood flow-metabolism mismatch: good for the tumor, bad for the patient. **2009**, 15, 5294-6	38
1042	Hypoxia regulates insulin receptor substrate-2 expression to promote breast carcinoma cell survival and invasion. **2009**, 69, 8894-901	33
1041	Participation of the lipoprotein receptor LRP1 in hypoxia-HSP90alpha autocrine signaling to promote keratinocyte migration. **2009**, 122, 1495-8	57
1040	Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. **2009**, 69, 4708-15	78
1039	Angiogenesis as a therapeutic target in malignant gliomas. **2009**, 14, 621-36	87
1038	Emerging role of Notch signaling in epidermal differentiation and skin cancer. **2009**, 8, 1986-93	62
1037	Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. **2009** , 69, 2669-76	80
1036	The association between hypoxia inducible factor-1alpha gene polymorphisms and increased susceptibility to oral cancer. **2009**, 45, e222-6	45
1035	Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. **2009**, 121, 29-40	526
1034	Regulation of cancer cell metabolism by hypoxia-inducible factor 1. **2009**, 19, 12-6	357
1033	Cancer stem cells, hypoxia and metastasis. **2009**, 19, 106-11	186
1032	Therapeutic targets in malignant glioblastoma microenvironment. **2009**, 19, 163-70	55
1031	An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer. **2009**, 146, 241-9	13
1030	Maternal diabetes alters transcriptional programs in the developing embryo. **2009**, 10, 274	83
1029	The l1-l2 regularization framework unmasks the hypoxia signature hidden in the transcriptome of a set of heterogeneous neuroblastoma cell lines. **2009**, 10, 474	23
1028	Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. **2009**, 9, 270	44

1027	No evidence for promoter region methylation of the succinate dehydrogenase and fumarate hydratase tumour suppressor genes in breast cancer. **2009**, 2, 194	11
1026	Hypoxia regulates inflammatory gene expression in endothelial cells. **2009**, 315, 733-47	26
1025	HIF-1alpha induces MXI1 by alternate promoter usage in human neuroblastoma cells. **2009**, 315, 1924-36	20
1024	Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. **2009**, 86, 174-9	268
1023	[Tumor hypoxia: the role of HIF]. **2009**, 33, 941-51	16
1022	E2F1 represses beta-catenin/TCF activity by direct up-regulation of Siah1. **2009**, 13, 1719-1727	20
1021	RNA-binding proteins implicated in the hypoxic response. **2009**, 13, 2759-69	63
1020	Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth. **2009**, 1793, 368-77	38
1019	Identification of DH IC-2 as a HIF-1 independent protein involved in the adaptive response to hypoxia in tumor cells: A putative role in metastasis. **2009**, 1793, 1676-90	3
1018	Tumor cell energy metabolism and its common features with yeast metabolism. **2009**, 1796, 252-65	69
1017	Metastasis mechanisms. **2009**, 1796, 293-308	230
1016	Dioxin-induced toxicity on vascular remodeling of the placenta. **2009**, 77, 660-9	30
1015	Transcriptional activation of hypoxia-inducible factor-1alpha by HDAC4 and HDAC5 involves differential recruitment of p300 and FIH-1. **2009**, 583, 55-60	43
1014	Increase in mitochondrial biogenesis, oxidative stress, and glycolysis in murine lymphomas. **2009**, 46, 387-96	44
1013	Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. **2009**, 16, 413-24	102
1012	The redox state of glutathione regulates the hypoxic induction of HIF-1. **2009**, 606, 45-9	41
1011	Synthetic Gene Networks. 489-528	
1010	Transcriptional upregulation of HSP70-2 by HIF-1 in cancer cells in response to hypoxia. **2009**, 124, 298-305	45

1009	NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. **2009**, 124, 223-32	36
1008	Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. **2009**, 125, 367-73	216
1007	Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis. **2010**, 126, 2090-101	54
1006	HIF-1alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy. **2010**, 127, 1158-71	30
1005	MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. **2010**, 127, 1081-95	155
1004	Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. **2009**, 115, 2346-54	22
1003	Altered hypoxia-inducible factor-1 alpha expression levels correlate with coronary vessel anomalies. **2009**, 238, 2688-700	34
1002	Role of hypoxia in the hallmarks of human cancer. **2009**, 107, 1053-62	330
1001	The Ape-1/Ref-1 redox antagonist E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: therapeutic implications in tumor angiogenesis. **2009**, 219, 209-18	62
1000	Oxygen-independent degradation of HIF-alpha via bioengineered VHL tumour suppressor complex. **2009**, 1, 66-78	15
999	Increase in gene dosage is a mechanism of HIF-1alpha constitutive expression in head and neck squamous cell carcinomas. **2009**, 48, 441-54	16
998	The relation between hypoxia-inducible factor (HIF)-1alpha expression with p53 expression and outcome in surgically treated supraglottic laryngeal cancer. **2009**, 99, 373-8	15
997	Human inflammatory synovial fibroblasts induce enhanced myeloid cell recruitment and angiogenesis through a hypoxia-inducible transcription factor 1alpha/vascular endothelial growth factor-mediated pathway in immunodeficient mice. **2009**, 60, 2926-34	78
996	Effect of intermittent hypoxic training on HIF gene expression in human skeletal muscle and leukocytes. **2009**, 105, 515-24	24
995	Effects of acute hypoxia tests on blood markers in high-level endurance athletes. **2009**, 106, 713-20	23
994	An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway. **2009** , 455, 261-70	16
993	Cancer's craving for sugar: an opportunity for clinical exploitation. **2009**, 135, 867-77	46
992	Effects of HIF-1alpha on human gastric cancer cell apoptosis at different CO(2) pressures. **2009**, 9, 139-47	7

991	The expression of HIF-1α and VEGF as well as their correlation with angiogenesis in esophageal squamous cell carcinomas. **2009**, 8, 199-202	1
990	Backbone resonance assignment of a proteolysis-resistant fragment in the oxygen-dependent degradation domain of the hypoxia inducible factor 1alpha. **2009**, 27, 493-6	5
989	Association of the hypoxia inducible factor-1alpha gene polymorphisms with gastric cancer in Tibetans. **2009**, 47, 625-34	30
988	Combined analysis of hypoxia-inducible factor 1 alpha and metallothionein indicates an aggressive subtype of colorectal carcinoma. **2009**, 24, 1287-96	19
987	Structure-based virtual screening approach to the discovery of novel inhibitors of factor-inhibiting HIF-1: identification of new chelating groups for the active-site ferrous ion. **2009**, 17, 7769-74	4
986	Dual role of HIF-1alpha in delivering a survival or death signal in hypoxia exposed human K562 erythroleukemia cells. **2009**, 33, 49-56	4
985	Inhibition of PKHD1 may cause S-phase entry via mTOR signaling pathway. **2009**, 33, 926-33	6
984	The tumor microenvironment and metastatic disease. **2009**, 26, 19-34	232
983	Three-dimensional context regulation of metastasis. **2009**, 26, 35-49	245
982	Marine Natural Products as Inhibitors of Hypoxic Signaling in Tumors. **2009**, 8, 415-429	31
981	Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells. **2009**, 27, 89-98	10
980	Regression of Dalton's lymphoma in vivo via decline in lactate dehydrogenase and induction of apoptosis by a ruthenium(II)-complex containing 4-carboxy N-ethylbenzamide as ligand. **2009**, 27, 503-16	28
979	HIF-1α siRNA leads to apoptosis of pancreatic cancer cells under hypoxic conditions. **2009**, 6, 10-15	1
978	Expression of hypoxia-inducible factor-1alpha in liver tumors after transcatheter arterial embolization in an animal model. **2009**, 29, 776-81	7
977	Effect of small interference RNA targeting HIF-1alpha mediated by rAAV combined L: -ascorbate on pancreatic tumors in athymic mice. **2009**, 15, 109-14	13
976	Pharmacophore-based 3D-QSAR of HIF-1 inhibitors. **2009**, 32, 317-23	8
975	In Vivo Therapeutic Silencing of Hypoxia-Inducible Factor 1 Alpha (HIF-1α) Using Single-Walled Carbon Nanotubes Noncovalently Coated with siRNA. **2009**, 2, 279-291	94
974	Role of hypoxia-inducible factor-1alpha in angiogenic-osteogenic coupling. **2009**, 87, 583-90	125

973	Endothelial oxygen sensors regulate tumor vessel abnormalization by instructing phalanx endothelial cells. **2009**, 87, 561-9	29
972	Reactive oxygen species-dependent signaling regulates cancer. **2009**, 66, 3663-73	206
971	Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing. **2009**, 66, 3539-54	182
970	Proteomics-based identification of two novel direct targets of hypoxia-inducible factor-1 and their potential roles in migration/invasion of cancer cells. **2009**, 9, 3901-12	56
969	Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. **2009**, 218, 7-29	270
968	A HIF-1alpha-dependent autocrine feedback loop promotes survival of serum-deprived prostate cancer cells. **2009**, 69, 263-75	16
967	Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer. **2010**, 70, 162-9	36
966	Potent antitumor activity of double-regulated oncolytic adenovirus-mediated ST13 for colorectal cancer. **2009**, 100, 678-83	22
965	Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia. **2009**, 100, 1366-73	165
964	SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. **2009**, 266, 19-42	211
963	SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation. **2009**, 28, 2748-62	145
962	Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model. **2009**, 16, 195-205	30
961	Regulation of endocytosis via the oxygen-sensing pathway. **2009**, 15, 319-24	158
960	Oxygen sensor boosts growth factor signaling. **2009**, 15, 246-7	21
959	Intolerant of glucose and gasping for oxygen. **2009**, 15, 247-9	8
958	When integrins fail to integrate. **2009**, 15, 249-50	7
957	Molecular targets for cancer chemoprevention. **2009**, 8, 213-25	113
956	Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. **2009**, 8, 139-52	269

955	Generating specificity and diversity in the transcriptional response to hypoxia. **2009**, 10, 821-32	270
954	Hypoxia-activated autophagy accelerates degradation of SQSTM1/p62. **2009**, 28, 334-44	118
953	Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. **2009**, 28, 313-24	133
952	VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo. **2009**, 28, 1694-705	32
951	Reactivating HIF prolyl hydroxylases under hypoxia results in metabolic catastrophe and cell death. **2009**, 28, 4009-21	84
950	Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. **2009**, 28, 3949-59	527
949	The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIM(EL). **2009**, 28, 1864-74	25
948	HIF-1alpha determines the metastatic potential of gastric cancer cells. **2009**, 100, 772-81	74
947	Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer. **2009**, 100, 874-80	86
946	Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. **2010**, 39, 313-7	41
945	Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells. **2009**, 46, 415-21	60
944	Concordant overexpression of phosphorylated ATF2 and STAT3 in extramammary Paget's disease. **2009**, 36, 402-8	11
943	Impact of cyclic hypoxia on HIF-1alpha regulation in endothelial cells--new insights for anti-tumor treatments. **2009**, 276, 509-18	35
942	Hypoxia-inducible factor-1alpha blocks differentiation of malignant gliomas. **2009**, 276, 7291-304	30
941	Cellular oxygen sensing, signalling and how to survive translational arrest in hypoxia. **2009**, 195, 205-30	42
940	AMP-activated protein kinase and cancer. **2009**, 196, 55-63	134
939	HIF-1alpha protein expression is associated with the environmental inflammatory reaction in Barrett's metaplasia. **2009**, 22, 694-9	12
938	Expression of vascular endothelial growth factor and hypoxia inducible factor-1alpha in cervical neoplasia. **2009**, 1171, 105-10	20

937	Role of hypoxia-inducible factors in epigenetic regulation via histone demethylases. **2009**, 1177, 185-97	86
936	Regulation of vascularization by hypoxia-inducible factor 1. **2009**, 1177, 2-8	42
935	Expression of KIT receptor tyrosine kinase in endothelial cells of juvenile brain tumors. **2010**, 20, 763-70	12
934	Development of targeted angiogenic medicine. **2009**, 7, 21-33	68
933	Induction of trefoil factor (TFF)1, TFF2 and TFF3 by hypoxia is mediated by hypoxia inducible factor-1: implications for gastric mucosal healing. **2009**, 156, 262-72	57
932	Vitamin C: update on physiology and pharmacology. **2009**, 157, 1097-110	279
931	Analysis of HIF-1 inhibition by manassantin A and analogues with modified tetrahydrofuran configurations. **2009**, 19, 3783-6	23
930	Gene regulation in response to graded hypoxia: the non-redundant roles of the oxygen sensors PHD and FIH in the HIF pathway. **2009**, 259, 304-16	35
929	Concomitant chemo-radiotherapy in clinical trials: to promote step by step rational development. **2009**, 70, 206-15	4
928	Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives. **2009**, 70, 93-102	52
927	On the path to seeking novel radiosensitizers. **2009**, 73, 988-96	33
926	Immunohistochemical detection of changes in tumor hypoxia. **2009**, 73, 1177-86	48
925	Usefulness of HIF-1 imaging for determining optimal timing of combining bevacizumab and radiotherapy. **2009**, 75, 463-7	19
924	1-[4-(N-Benzylamino)phenyl]-3-phenylurea derivatives as a new class of hypoxia-inducible factor-1alpha inhibitors. **2009**, 19, 3166-9	22
923	IFATS collection: Adipose stromal cells adopt a proangiogenic phenotype under the influence of hypoxia. **2009**, 27, 266-74	119
922	Chemokines in Lung Cancer Metastasis. **2009**, 155-172	
921	Expression of the cellular oxygen sensor PHD2 (EGLN-1) predicts radiation sensitivity in squamous cell cancer of the head and neck. **2009**, 85, 900-8	11
920	Metabolic transformation in cancer. **2009**, 30, 1269-80	174

919	The HIF-1-active microenvironment: an environmental target for cancer therapy. **2009**, 61, 623-32	52
918	Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer. **2009**, 61, 572-88	28
917	Regulation of osteogenesis-angiogenesis coupling by HIFs and VEGF. **2009**, 24, 1347-53	261
916	The role of vascular endothelial growth factor genetic variability in cancer. **2009**, 15, 5297-302	66
915	Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. **2009**, 172, 653-65	175
914	The Caulerpa pigment caulerpin inhibits HIF-1 activation and mitochondrial respiration. **2009**, 72, 2104-9	42
913	Nonrenal regulation of EPO synthesis. **2009**, 75, 682-8	56
912	Nucleophilic addition of organozinc reagents to 2-sulfonyl cyclic ethers: stereoselective synthesis of manassantins A and B. **2009**, 11, 89-92	38
911	Cellular signal transduction of the hypoxia response. **2009**, 146, 757-65	64
910	PI3K/PTEN signaling in angiogenesis and tumorigenesis. **2009**, 102, 19-65	377
909	Grape seed extract inhibits VEGF expression via reducing HIF-1alpha protein expression. **2009**, 30, 636-44	39
908	Pharmaceutical Perspectives of Cancer Therapeutics. **2009**,	11
907	Erythropoietin: An Historical Overview of Physiology, Molecular Biology and Gene Regulation. **2009** , 1-18	
906	Regulation of angiogenesis by oxygen and metabolism. **2009**, 16, 167-79	293
905	Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor. **2009**, 45, 857-65	59
904	Effect of HIF-1 modulation on the response of two- and three-dimensional cultures of human colon cancer cells to 5-fluorouracil. **2009**, 45, 890-8	33
903	Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1alpha involvement in CYP3A4 repression. **2009**, 45, 2882-92	40
902	The role of angiogenesis in solid tumours: an overview. **2009**, 20, 663-71	103

901	Revisiting the seed and soil in cancer metastasis. **2009**, 41, 1452-62	93
900	Mitochondrial reticulum network dynamics in relation to oxidative stress, redox regulation, and hypoxia. **2009**, 41, 1790-804	73
899	Hypoxia and HIF-1alpha expression in the epiphyseal cartilage following ischemic injury to the immature femoral head. **2009**, 45, 280-8	40
898	Cinnamon extract suppresses tumor progression by modulating angiogenesis and the effector function of CD8+ T cells. **2009**, 278, 174-182	69
897	Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. **2009**, 280, 233-41	312
896	Upregulated expression of periostin by hypoxia in non-small-cell lung cancer cells promotes cell survival via the Akt/PKB pathway. **2009**, 281, 213-9	81
895	PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. **2009**, 282, 109-15	47
894	Iron metabolism in the eye: a review. **2009**, 88, 204-15	30
893	Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. **2009**, 136, 839-851	642
892	Endothelial cells form a phalanx to block tumor metastasis. **2009**, 136, 810-2	27
891	Oxygen sensors at the crossroad of metabolism. **2009**, 9, 11-22	216
890	Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. **2009**, 9, 152-64	284
889	Estrogen and hypoxia regulate estrogen receptor alpha in a synergistic manner. **2009**, 378, 842-6	21
888	Hypoxia enhances MUC1 expression in a lung adenocarcinoma cell line. **2009**, 379, 1060-5	27
887	Comparative proteome analysis using amine-reactive isobaric tagging reagents coupled with 2D LC/MS/MS in 3T3-L1 adipocytes following hypoxia or normoxia. **2009**, 383, 135-40	14
886	A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway. **2009**, 385, 16-21	50
885	STAT1 represses hypoxia-inducible factor-1-mediated transcription. **2009**, 387, 806-10	22
884	TNFalpha induces HIF-1alpha expression through activation of IKKbeta. **2009**, 389, 640-4	22

883	Silibinin inhibits expression of HIF-1alpha through suppression of protein translation in prostate cancer cells. **2009**, 390, 71-6	36
882	FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression. **2009**, 390, 1001-6	33
881	Hammerhead ribozyme targeting human hypoxia inducible factor-1alpha gene effectively attenuates HeLa xenograft tumors. **2009**, 72 Suppl 1, S8-S16; discussion S16	3
880	Commentary. **2009**, 72, S16	
879	Potential vascular actions of 2-methoxyestradiol. **2009**, 20, 374-9	42
878	Clinical implications of hypoxia inducible factor in renal cell carcinoma. **2009**, 27, 238-45	47
877	In vivo characterization of a reporter gene system for imaging hypoxia-induced gene expression. **2009**, 36, 821-31	14
876	T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. **2009**, 30, 102-8	150
875	Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. **2009**, 16, 1119-30	80
874	Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour model. **2009**, 77, 96-103	74
873	Adenovirus-mediated brain-derived neurotrophic factor expression regulated by hypoxia response element protects brain from injury of transient middle cerebral artery occlusion in mice. **2009**, 465, 220-5	57
872	Regulatory role of HIF-1alpha in the pathogenesis of age-related macular degeneration (AMD). **2009**, 8, 349-58	109
871	Adenosine receptors and cancer. **2009**, 399-441	102
870	A Drosophila model for congenital heart disease. **2009**, 6, 47-54	3
869	Hypoxia-HIF-1alpha-C/EBPalpha/Runx1 signaling in leukemic cell differentiation. **2009**, 16, 297-303	17
868	Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. **2009**, 11, 99-133	99
867	Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. **2009**, 24 Suppl 1, 1-39	153
866	Micro-environmental mechanical stress controls tumor spheroid size and morphology by suppressing proliferation and inducing apoptosis in cancer cells. **2009**, 4, e4632	298

865	Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. **2009**, 8, 1	90
864	Expression and function of hypoxia inducible factor-1 alpha in human melanoma under non-hypoxic conditions. **2009**, 8, 104	56
863	Identification of small molecule compounds that inhibit the HIF-1 signaling pathway. **2009**, 8, 117	22
862	CLU "in and out": looking for a link. **2009**, 105, 93-113	23
861	The dose of growth factors influences the synergistic effect of vascular endothelial growth factor on bone morphogenetic protein 4-induced ectopic bone formation. **2009**, 15, 2123-33	46
860	CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. **2009**, 58, 1391-8	114
859	Direct inhibition of hypoxia-inducible transcription factor complex with designed dimeric epidithiodiketopiperazine. **2009**, 131, 18078-88	68
858	Cyclooxygenase-2 in cancer and angiogenesis. **2009**, 60, 242-53	60
857	Mitochondrial regulation of cell survival and death during low-oxygen conditions. **2009**, 11, 2673-83	40
856	Preferential binding of HIF-1 to transcriptionally active loci determines cell-type specific response to hypoxia. **2009**, 10, R113	103
855	A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. **2009**, 11, 1064-73	59
854	Solid tumours arising from differently pre-oxygenated cells: comparable growth rates despite dissimilar tissue oxygenation. **2009**, 85, 981-8	1
853	An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. **2009**, 37, 4587-602	328
852	Deficient carbonic anhydrase 9 expression in UPR-impaired cells is associated with reduced survival in an acidic microenvironment. **2009**, 92, 437-42	16
851	Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. **2009**, 92, 423-8	173
850	Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. **2009**, 92, 329-33	383
849	Expression and functional regulation of myoglobin in epithelial cancers. **2009**, 175, 201-6	57
848	Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. **2009**, 8, 3223-33	98

847	Hypoxia, melanocytes and melanoma - survival and tumor development in the permissive microenvironment of the skin. **2009**, 22, 166-74	89
846	Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer. **2009**, 11, 196-206	48
845	Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophore. **2009**, 20, 493-502	5
844	Paraganglioma of the head and neck: long-term local control with radiotherapy. **2009**, 32, 304-7	50
843	Evodiamine represses hypoxia-induced inflammatory proteins expression and hypoxia-inducible factor 1alpha accumulation in RAW264.7. **2009**, 32, 263-9	45
842	Dynamic contrast-enhanced magnetic resonance imaging as a predictor of clinical outcome in canine spontaneous soft tissue sarcomas treated with thermoradiotherapy. **2009**, 15, 4993-5001	28
841	Signaling by hypoxia-inducible factors is critical for ovulation in mice. **2009**, 150, 3392-400	87
840	ABC Proteins and Oncology: Expression, Detection, and Implication of ABC Proteins in Solid Tumors. 143-176	1
839	PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma. **2009**, 8, 1389-401	38
838	Chemotactic cytokines, obesity and type 2 diabetes: in vivo and in vitro evidence for a possible causal correlation?. **2009**, 68, 378-84	49
837	Endothelial progenitor cell homing: prominent role of the IGF2-IGF2R-PLCbeta2 axis. **2009**, 113, 233-43	120
836	Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. **2009**, 113, 5568-74	112
835	SNS-032 prevents hypoxia-mediated glioblastoma cell invasion by inhibiting hypoxia inducible factor-1alpha expression. **2009**, 34, 1051-60	11
834	Imaging probe for tumor malignancy. **2009**,	
833	Upregulation of hypoxia-inducible factor-1alpha mRNA and its clinical significance in non-small cell lung cancer. **2009**, 4, 284-90	36
832	In vitro effects of hypoxia-inducible factor 1alpha on the biological characteristics of the SiHa uterine cervix cancer cell line. **2009**, 19, 898-904	5
831	MUC1 oncoprotein promotes autophagy in a survival response to glucose deprivation. **2009**, 34, 1691-9	39
830	Aging and diabetes impair the neovascular potential of adipose-derived stromal cells. **2009**, 123, 475-485	76

829	Recent Advances in the Signal Transduction Targeting of Colorectal Cancer: The Paradigm of Translational Medicine. **2009**, 4, 6-21	
828	Regulation of autophagy through multiple independent hypoxic signaling pathways. **2009**, 9, 417-24	91
827	Hypoxic tumor microenvironment and cancer cell differentiation. **2009**, 9, 425-34	128
826	The basic science of vascular biology: implications for the practicing surgeon. **2010**, 126, 1528-1538	36
825	Hypoxia Inducible Factor-1 in Cancer Immune Suppression. **2010**, 6, 260-271	8
824	Tumour reactions to hypoxia. **2010**, 10, 381-6	33
823	Vascular disrupting agents (VDAs) in anticancer therapy. **2010**, 5, 178-85	19
822	Recent advances in structural studies of the carbonic anhydrase family: the crystal structure of human CA IX and CA XIII. **2010**, 16, 3246-54	27
821	Double immunohistochemical staining method for HIF-1alpha and its regulators PHD2 and PHD3 in formalin-fixed paraffin-embedded tissues. **2010**, 18, 375-81	7
820	Moscatilin repressed lipopolysaccharide-induced HIF-1alpha accumulation and NF-kappaB activation in murine RAW264.7 cells. **2010**, 33, 70-5	22
819	Endothelial cell energy metabolism, proliferation, and apoptosis in pulmonary hypertension. **2011**, 1, 357-72	60
818	Activated STAT3 regulates hypoxia-induced angiogenesis and cell migration in human glioblastoma. **2010**, 67, 1386-95; discussion 1395	50
817	Integration of anti-vascular endothelial growth factor therapies with cytotoxic chemotherapy in the treatment of colorectal cancer. **2010**, 16, 220-5	4
816	Role of intermittent hypoxia in the treatment of bronchial asthma and chronic obstructive pulmonary disease. **2010**, 10, 206-13	16
815	Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. **2010**, 5, 940-9	39
814	Rodent-specific hypoxia response elements enhance PAI-1 expression through HIF-1 or HIF-2 in mouse hepatoma cells. **2010**, 37, 1627-38	15
813	Oxygen: Stress and adaptation in cold-hardy insects. 141-165	32
812	Cycling hypoxia increases U87 glioma cell radioresistance via ROS induced higher and long-term HIF-1 signal transduction activity. **2010**, 24, 1629-36	79

811	Thymosin β4 expression correlates with lymph node metastasis through hypoxia inducible factor-β induction in breast cancer. **2010**, 25,	1
810	Low-dose radiation augments vasculogenesis signaling through HIF-1-dependent and -independent SDF-1 induction. **2010**, 116, 3669-76	56
809	Macrophages give Gas(6) to cancer. **2010**, 115, 2122-3	7
808	Porcupine expression is associated with the expression of S100P and other cancer-related molecules in non-small cell lung carcinoma. **2010**, 36, 1015-21	12
807	Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer. **2010**,	
806	Effect of hypoxia-inducible factor 1-β on Survivin in colorectal cancer. **2010**, 3, 409-15	17
805	Current advancement in radiation therapy for uterine cervical cancer. **2010**, 51, 1-8	34
804	The suppression of hypoxia-inducible factor and vascular endothelial growth factor by siRNA does not affect the radiation sensitivity of multicellular tumor spheroids. **2010**, 51, 47-55	10
803	Role of the RNA-Binding Protein HuR in Apoptosis and Apoptosome Function. **2010**, 203-220	2
802	xCT modulation in gliomas: relevance to energy metabolism and tumor microenvironment normalization. **2010**, 192, 309-13	32
801	Molecular interactions in cancer cell metastasis. **2010**, 112, 3-25	218
800	The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. **2010**, 330, 1340-4	894
799	Correlation of hypoxia-inducible factor 1alpha with angiogenesis in liver tumors after transcatheter arterial embolization in an animal model. **2010**, 33, 806-12	46
798	Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha. **2010**, 66, 899-911	57
797	Role of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma. **2010**, 88, 817-27	31
796	Impaired retinal vascular development in anencephalic human fetus. **2010**, 134, 277-84	10
795	Hypoxia stimulates lactate release and modulates monocarboxylate transporter (MCT1, MCT2, and MCT4) expression in human adipocytes. **2010**, 459, 509-18	107
794	Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX. **2010**, 457, 53-61	67

793	Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha. **2010**, 136, 447-56	50
792	Expression of hypoxia-inducible factor-1 alpha (HIF-1alpha) in patients with the gallbladder carcinoma. **2010**, 15, 59-64	26
791	Stroma : partenaire actif mais sous-estimé de la tumorigenèse, « quand le dialogue remplace le monologue ». **2010**, 12, 303-321	2
790	Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. **2010**, 45, 794-807	50
789	Molecular imaging of inflammation and intraplaque vasa vasorum: a step forward to identification of vulnerable plaques?. **2010**, 17, 897-912	50
788	Perspectives in drug development for metastatic renal cell cancer. **2010**, 5, 139-56	9
787	Genome-wide identification and annotation of HIF-1 binding sites in two cell lines using massively parallel sequencing. **2010**, 4, 35-48	30
786	Von Hippel-Lindau syndrome: molecular mechanisms of the disease. **2010**, 12, 160-5	14
785	New developments in targeted therapy for soft tissue sarcoma. **2010**, 12, 261-5	11
784	Cardiac microvascular endothelial cells express and release nerve growth factor but not fibroblast growth factor-2. **2010**, 46, 469-76	9
783	No evidence for DNA methylation of von Hippel-Lindau ubiquitin ligase complex genes in breast cancer. **2010**, 124, 853-6	2
782	The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. **2010**, 20, 427-34	281
781	Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole. **2010**, 10, 143	39
780	Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: effects of preoperative chemotherapy. **2010**, 10, 320	27
779	The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A. **2010**, 8, 19	15
778	Blood cell gene expression associated with cellular stress defense is modulated by antioxidant-rich food in a randomised controlled clinical trial of male smokers. **2010**, 8, 54	58
777	The VHL-dependent regulation of microRNAs in renal cancer. **2010**, 8, 64	141
776	Hypoxia and mitochondrial oxidative metabolism. **2010**, 1797, 1171-7	348

775	Activation of the sonic hedgehog signaling controls human pulmonary arterial smooth muscle cell proliferation in response to hypoxia. **2010**, 1803, 1359-67	44
774	Dissecting the transcriptional functions of human DNA topoisomerase I by selective inhibitors: implications for physiological and therapeutic modulation of enzyme activity. **2010**, 1806, 240-50	26
773	Synchronised phosphorylation of BNIP3, Bcl-2 and Bcl-xL in response to microtubule-active drugs is JNK-independent and requires a mitotic kinase. **2010**, 79, 1562-72	15
772	Flavonoids inhibit hypoxia-induced vascular endothelial growth factor expression by a HIF-1 independent mechanism. **2010**, 79, 1600-9	53
771	Apoptosis and cancer stem cells: Implications for apoptosis targeted therapy. **2010**, 80, 423-30	62
770	The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. **2010**, 80, 455-62	62
769	LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line. **2010**, 80, 982-9	90
768	Modulation of cell sensitivity to antitumor agents by targeting survival pathways. **2010**, 80, 1459-65	16
767	Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. **2010**, 18, 23-38	161
766	Consequences of IkappaB alpha hydroxylation by the factor inhibiting HIF (FIH). **2010**, 584, 4725-30	17
765	HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. **2010**, 48, 1626-35	102
764	Retention of prolyl hydroxylase PHD2 in the cytoplasm prevents PHD2-induced anchorage-independent carcinoma cell growth. **2010**, 316, 1169-78	10
763	Liprin-4 is a new hypoxia-inducible target gene required for maintenance of cell-cell contacts. **2010**, 316, 2883-92	10
762	MFTZ-1 reduces constitutive and inducible HIF-1 accumulation and VEGF secretion independent of its topoisomerase II inhibition. **2010**, 14, 2281-91	14
761	Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. **2010**, 14, 771-94	422
760	Oxygen-mediated endocytosis in cancer. **2010**, 14, 496-503	30
759	The role of HIF prolyl hydroxylases in tumour growth. **2010**, 14, 758-70	70
758	Antiangiogenesis agents in the treatment of soft tissue sarcomas. **2010**, 116, 1177-83	20

757	Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells. **2010**, 126, 90-103	63
756	VEGF-A expression in osteoclasts is regulated by NF-kappaB induction of HIF-1alpha. **2010**, 110, 343-51	40
755	The transcriptional response of normal and rheumatoid arthritis synovial fibroblasts to hypoxia. **2010**, 62, 3584-94	44
754	Hypoxia inducible factor-1alpha gene polymorphism G1790A and its interaction with tobacco and alcohol consumptions increase susceptibility to hepatocellular carcinoma. **2010**, 102, 163-9	42
753	Cobalt chloride, a chemical inducer of hypoxia-inducible factor-1 in U251 human glioblastoma cell line. **2010**, 14, 197-201	31
752	Anti-HIF-1alpha antibody-conjugated pluronic triblock copolymers encapsulated with Paclitaxel for tumor targeting therapy. **2010**, 31, 2302-12	95
751	Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1alpha inhibitors. **2010**, 20, 1453-6	53
750	MKP-1 Modulates Mitochondrial Transcription Factors, Oxidative Phosphorylation, and Glycolysis. **2020**, 4, 245-258	5
749	Role of Carbon Monoxide in Neurovascular Repair Processing. **2018**, 26, 93-100	20
748	The Role of a Neurovascular Signaling Pathway Involving Hypoxia-Inducible Factor and Notch in the Function of the Central Nervous System. **2020**, 28, 45-57	9
747	Tumour Regression via Integrative Regulation of Neurological, Inflammatory, and Hypoxic Tumour Microenvironment. **2020**, 28, 119-130	5
746	Anticancer effect of Andrographis paniculata by suppression of tumor altered hypoxia signaling cascade in mouse melanoma cells. **2019**, 6, 117	5
745	Antitumor Effects of Ethanol Extracts from in H Tumor-bearing Mice. **2017**, 13, 571-575	2
744	Neurovascular patterning cues and implications for central and peripheral neurological disease. **2017**, 8, 208	4
743	Prognostic Significance of Glycolytic Metabolic Change Related to HIF-1 in Oral Squamous Cell Carcinomas. **2010**, 44, 360	1
742	bHLH-Orange Transcription Factors in Development and Cancer. **2007**, 2, 107-20	31
741	A model System for Validation of PET Radiopharmaceuticals: Focusing on Tumor Microenvironment. **2013**, 02, 19-29	5
740	Cancer: Tumor Iron Metabolism, Mitochondrial Dysfunction and Tumor Immunosuppression; A Tight Partnership Was Warburg Correct? **2012**, 03, 278-311	19

739	Suppression of NF-B/p65 Inhibits the Proliferation in Oral Squamous Cancer Cells. **2013**, 04, 891-897	5
738	Thymoquinone Suppresses Cellular Proliferation, Inhibits VEGF Production and Obstructs Tumor Progression and Invasion in the Rat Model of DMH-Induced Colon Carcinogenesis. **2013**, 04, 7-17	18
737	Tumor progression-dependent angiogenesis in gastric cancer and its potential application. **2019**, 11, 686-704	21
736	Surgery for colorectal liver metastases: The evolution of determining prognosis. **2013**, 5, 207-21	58
735	Synthesis and Biological Evaluation of 2-Aminoisonicotinic Acid Analogues as HIF-1 Inhibitors. **2010**, 31, 3826-3829	5
734	Design of Human FIH-1 Inhibitors through Virtual Screening. **2010**, 31, 1407-1410	2
733	Responses of developmental and physiological traits to manipulated incubation conditions in broiler embryos at hypoxic high altitude. **2018**, 61, 337-349	1
732	CITED2 and the modulation of the hypoxic response in cancer. **2020**, 11, 260-274	3
731	Hypoxia and cytokines regulate carbonic anhydrase 9 expression in hepatocellular carcinoma cells in vitro. **2012**, 3, 82-91	15
730	Inhibition of N-Myc down regulated gene 1 in in vitro cultured human glioblastoma cells. **2012**, 3, 104-10	1
729	Positron emission tomography to assess hypoxia and perfusion in lung cancer. **2014**, 5, 824-44	8
728	ERG is a novel and reliable marker for endothelial cells in central nervous system tumors. **2015**, 34, 117-27	11
727	The novel peptide F29 facilitates the DNA-binding ability of hypoxia-inducible factor-1alpha. **2009**, 42, 737-42	3
726	Mitochondrial superoxide anion (O(2)(-)) inducible "mev-1" animal models for aging research. **2011**, 44, 298-305	28
725	Human selenium binding protein-1 (hSP56) is a negative regulator of HIF-1 and suppresses the malignant characteristics of prostate cancer cells. **2014**, 47, 411-6	13
724	Suppression of Akt-HIF-1 signaling axis by diacetyl atractylodiol inhibits hypoxia-induced angiogenesis. **2016**, 49, 508-13	9
723	Mitochondrial DNA somatic mutation in cancer. **2014**, 30, 235-42	6
722	A new twist in neuroendocrine tumor research: Pacak-Zhuang syndrome, HIF-2 as the major player in its pathogenesis and future therapeutic options. **2014**, 158, 175-80	9

721	Hypoxia-induced chemoresistance in cancer cells: The role of not only HIF-1. **2015**, 159, 166-77	70
720	Dysregulated pH in Tumor Microenvironment Checkmates Cancer Therapy. **2013**, 3, 149-62	105
719	Targeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines. **2014**, 4, 55-67	68
718	Overexpression of KAI1 Protein in Diabetic Skin Tissues. **2014**, 41, 248-52	4
717	Comparative study of antioxidants as cancer preventives through inhibition of HIF-1 alpha activity. **2009**, 4, 233-6	16
716	Oxygen as a regulator of serine dehydratase (SerDH) gene expression. **2007**, 23, 391-397	1
715	Importance of the physicochemical properties of fluorescent dyes for obtaining target-specific in vivo images by membrane-permeable macromolecular imaging probes. **2013**, 2, 2	1
714	MicroRNA expression profile analysis reveals diagnostic biomarker for human prostate cancer. **2012**, 13, 3313-7	18
713	Expression of endogenous hypoxia markers in vulvar squamous cell carcinoma. **2012**, 13, 3675-80	7
712	Application of stem cells in targeted therapy of breast cancer: a systematic review. **2013**, 14, 2789-800	14
711	Hypoxia-inducible factor 1 alpha (HIF-1 as a prognostic indicator in patients with gastric tumors: a meta-analysis. **2013**, 14, 4195-8	19
710	Concomitant EGFR inhibitors combined with radiation for treatment of non-small cell lung carcinoma. **2013**, 14, 4485-94	11
709	Genetic variations in the HIF1A gene modulate response to adjuvant chemotherapy after surgery in patients with colorectal cancer. **2014**, 15, 4637-42	5
708	Expression of hypoxia-inducible factor prolyl hydroxylase 3 HIFPH3 in human non-small cell lung cancer (NSCLC) and its correlation with prognosis. **2014**, 15, 5819-23	4
707	Upregulation of HIF-1 by hypoxia protect neuroblastoma cells from apoptosis by promoting survivin expression. **2014**, 15, 8251-7	12
706	No association of hypoxia inducible factor-1 gene polymorphisms with breast cancer in North-West Indians. **2014**, 15, 9973-8	9
705	HIF-1 regulates IL-1 and IL-17 in sarcoidosis. **2019**, 8,	27
704	Dichotomous role of the human mitochondrial Na/Ca2/Li exchanger NCLX in colorectal cancer growth and metastasis. **2020**, 9,	16

703	Cell cycle progression in glioblastoma cells is unaffected by pathophysiological levels of hypoxia. **2016**, 4, e1755	14
702	Chemical composition and the potential for proteomic transformation in cancer, hypoxia, and hyperosmotic stress. **2017**, 5, e3421	8
701	Endothelial cell-initiated extravasation of cancer cells visualized in zebrafish. **2014**, 2, e688	18
700	Delphinidin Suppresses Angiogenesis via the Inhibition of HIF-1□and STAT3 Expressions in PC3M Cells. **2016**, 48, 66-71	1
699	Dormancy in the Tumor Microenvironment. **2021**, 1329, 35-49	1
698	Application of Cluster Analysis of Time Evolution for Magnetic Resonance Imaging -Derived Oxygen Extraction Fraction Mapping: A Promising Strategy for the Genetic Profile Prediction and Grading of Glioma. **2021**, 15, 736891	0
697	Establishment of a novel ferroptosis-related lncRNA pair prognostic model in colon adenocarcinoma. **2021**, 13, 23072-23095	6
696	MicroRNAs: Important Players in Breast Cancer Angiogenesis and Therapeutic Targets. **2021**, 8, 764025	2
695	Mechanisms and triggers of adaptation to hypoxia. **2021**, 19, 269-280	
694	Metabolic Reprogramming in COVID-19. **2021**, 22,	5
693	Hypoxia effects on cancer stem cell phenotype in colorectal cancer: a mini-review. **2021**, 48, 7527-7535	0
692	Research Progress on Circular RNA in Glioma. **2021**, 11, 705059	1
691	Anticancer Mechanisms of Bioactive Compounds from Solanaceae: An Update. **2021**, 13,	2
690	Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets. **2021**, 13,	6
689	The Role of General Anesthetic Drug Selection in Cancer Outcome. **2021**, 2021, 2563093	2
688	Regulation of Tumor Metabolism and Extracellular Acidosis by the TIMP-10-CD63 Axis in Breast Carcinoma. **2021**, 10,	0
687	Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers. **2021**, 57,	0
686	Simple oligonucleotide-based multiplexing of single-cell chromatin accessibility. **2021**, 81, 4319-4332.e10	1

685	Pharmacological inhibition of Mint3 attenuates tumour growth, metastasis, and endotoxic shock. **2021**, 4, 1165	1
684	SETD7 regulates chondrocyte differentiation and glycolysis via the Hippo signaling pathway and HIF-1 **2021**, 48,	2
683	Microenvironmental Reactive Oxygen Species in Colorectal Cancer: Involved Processes and Therapeutic Opportunities. **2021**, 13,	3
682	Long Non-coding RNA DANCR in Cancer: Roles, Mechanisms, and Implications. **2021**, 9, 753706	3
681	USP29 coordinates MYC and HIF1 stabilization to promote tumor metabolism and progression. **2021**, 40, 6417-6429	5
680	Lactate in the tumour microenvironment: From immune modulation to therapy. **2021**, 73, 103627	11
679	Overview of molecular target-based drugs. **2006**, 21, 18-23	2
678	Can Post-Transcription Modifiers Change the Course of Prostate Cancer?. **2006**, 179-194	
677	Interactions entre les cellules tumorales et le microenvironnement tissulaire : « Quand le dialogue remplace le monologue ». **2007**, 97-123	
676	Angiogenesis-Targeted Redox-Based Therapeutics. **2007**, 155-164	
675	Survivin. **2007**, 209-218	
674	Targeting Angiogenesis with Oral Agents. **2007**, 253-268	
673	Deubiquitinating Enzymes, Cell Proliferation, and Cancer. 212-231	
672	The Cellular Microenvironment and Metastases. **2008**, 33-47	
671	Therapeutic Strategies that Target the HIF System. **2008**, 359-373	
670	Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. **2008**, 317-365	
669	Hypoxic Regulation of Angiogenesis by HIF-1. **2008**, 169-179	
668	Imaging and Targeting Tumors by Fusion Proteins with ODD Domain of HIF-1 **2008**, 9, 13-19	

667 Differentiation of the invasive cytotrophoblast lineage in normal pregnancy and in preeclampsia. **2008**, 454-465

666 Hypoxic Response and Associated Diseases. 1

665 Functional Role of a Conserved Sequence Motif in the Oxygen-dependent Degradation Domain of Hypoxia-inducible Factor 1 in the Recognition of p53. **2008**, 6, 72-76

664 Cellular Respiration and Tumor Suppressor Genes. **2009**, 131-144

663 HIF-1 Regulation of Chemokine Receptor Expression. **2009**, 47-61

662 Tumor Microvasculature and Microenvironment: Therapeutic Targets for Inhibition of Tumor Angiogenesis and Metastasis. **2009**, 1-47

661 The Regulation of the IGF-1/mTOR Pathway by the p53 Tumor Suppressor Gene Functions. **2009**, 37-48

660 Modulation of Protein Stability: Targeting the VHL Pathway. **2009**, 45-63

659 Medical Applications of Biointerface. **2009**, 30, 236-247

658 RAS Oncogenes and Tumor-Vascular Interface. **2010**, 133-165 1

657 von Hippel-Lindau Tumor Suppressor, Hypoxia-Inducible Factor-1, and Tumor Vascularization. **2010**, 119-132

656 Anti-Vascular Endothelial Growth Factor Monoclonal Antibodies. **2010**, 465-491

655 Expression of Notch 1,HIF-1 in human renal carcinoma and its relation with clinical tumor staging. **2009**, 29, 970-971

654 Establishment of a Stable Cell Line Expressing Green Fluorescence Protein-fused Hypoxia Inducible Factor-1 for Assessment of Carcinogenicity of Chemical Toxicants. **2009**, 25, 189-193

653 Role of Inducible Nitric Oxide Synthase (iNOS) in Regulation of Nitric Oxide (NO) Production and Stabilization of HIF-1 Potential Role of Se-Methylselenocysteine (MSC), an Antioxidant Multi-targeted Small Molecule. **2010**, 479-488

652 Role of Nitric Oxide for Modulation of Cancer Therapy Resistance. **2010**, 265-282

651 Angiogenesis and Lymphangiogenesis in Colon Cancer Metastasis. **2010**, 243-287 1

650 Radiotherapy and Chemotherapy. **2010**, 82-94

649 Prognostic Significance of iNOS in Human Melanoma. **2010**, 293-307

648 The Role of Hypoxia-Induced Factors. **2010**, 107-123

647 Prognostic Significance of iNOS in Hepatocellular Carcinoma. **2010**, 309-328

646 Hypoxia and the DNA Damage Response. 207-228

645 HIF-1 Inhibitors for Cancer Therapy. 377-400

644 Establishing the Tumor Microenvironment. 7-33

643 Head and Neck Cancer and the PI3K/Akt/mTOR Signaling Network: Novel Molecular Targeted Therapies. **2011**, 407-429 1

642 Regulation of Oxygen Homeostasis by Prolyl Hydroxylase Domains. **2011**, 419-436

641 Novel Therapeutic Approaches Against Oxidative Stress and Hypoxia, Targeting Intracellular Sensor Molecules for Oxygen and Oxidative Stress. **2011**, 633-656

640 Oxygen-Sensitive Transcription Factors and Hypoxia-Mediated Pulmonary Hypertension. **2011**, 713-723

639 Influence of the Embryonic Microenvironment on Tumor Progression. **2011**, 223-242

638 Principes de la chimioradiothérapie concomitante. **2011**, 17-22

637 Hypoxia in Head and Neck Cancers: Clinical Relevance and Treatment. **2011**, 169-178

636 Impact of Tumor Hypoxia, Src, and Met Signaling in the Dissemination of Tumor Cells. **2011**, 171-194

635 Patients with Recurrent High-Grade Glioma: Therapy with Combination of Bevacizumab and Irinotecan. **2011**, 289-299

634 Encyclopedia of Cancer. **2011**, 1792-1795

633 Molecular Mechanisms of Hemodialysis Graft Failure. **2011**, 77-91

632 Encyclopedia of Cancer. **2011**, 1796-1797

631 Chronic Hypoxia Emerging as One of the Driving Forces behind Gene Expression and Prognosis of Hepatocellular Carcinoma. **2011**, 2011, 1-10

630 IGF-1 Cellular Action and its Relationship to Cancer: Evidence from in Vitro and in Vivo Studies. **2012**, 105-146 1

629 Transcriptional Stress by Camptothecin: Mechanisms and Implications for the Drug Antitumor Activity. **2012**, 309-324

628 Natural Products as Inhibitors of Hypoxia-Inducible Factor-1. **2011**, 187-264

627 Neuroblastoma: Role of Hypoxia and Hypoxia Inducible Factors in Tumor Progression. **2012**, 137-149

626 Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and Therapeutic Perspectives. **2012**, 319-334

625 STAT3 and Src Signaling in Melanoma. **2012**, 89-105

624 Antisense Oligonucleotides in the Treatment of Malignant Gliomas. **2012**, 215-246

623 Gene Expression Profile, Androgen Independence and Prostate Cancer. **2012**, 03, 637-644

622 Hypoxia Imaging of Tumor and Spatiotemporal Analysis during Oxygen Inhalation. **2012**, 132, 1602-1607

621 Stereotactic radiosurgery: radiobiology and physics aspects of treatment. **2012**, 253-267

620 Anticancer Effects of Intermittent Hypoxia in Acute Myeloid Leukemia. **2012**, 229-238

619 Transcriptional Regulation of Human Telomerase. 105-134

618 Tocotrienols, Inflammation, and Cancer. **2012**, 209-224

617 Antiangiogenic Effects of Tocotrienol. **2012**, 79-88

616 Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and Therapeutic Perspectives. **2013**, 315-333 1

615 DNA-PK, a Pharmacological Target in Cancer Chemotherapy and Radiotherapy?. **2013**, 25-44

614 Die Rolle der Hypoxie und Hyperthermie in der Chemotherapie. **2013**, 55-64

613 Targeting HIF-1α and HIF-2α to Overcome Treatment Resistance Mediated by Oncogenic KRAS in Colorectal Cancer. **2013**, 04, 1132-1139

612 Targeting the Stem Cell Plasticity of Tumor Cells. **2013**, 441-448

611 Targeting Tumor Angiogenesis. **2013**, 221-231

610 Counteracting Hypoxia in Radio-Resistant Metastatic Lesions. **2013**, 255-269

609 CK2: A Global Regulator of Cell Survival. 239-266 1

608 Oxidative Stress and Angiogenesis in Tumor Progression. **2013**, 394-425

607 Tumor Angiogenesis Regulators in Breast Cancer. **2013**, 387-410

606 Molecular Imaging of Inflammation and Intraplaque Vasa Vasorum. **2014**, 299-316

605 Current Clinical Imaging of Hypoxia with PET and Future Perspectives. **2014**, 241-268

604 Essentials of Angiogenesis. **2014**, 1-34 1

603 Reciprocal Crosstalk Between Angiogenesis and Metabolism. **2014**, 219-233

602 Pathophysiology of HCC. **2014**, 15-32

601 Development of Combination Therapy with Targeted Agents. **2015**, 349-375

600 Encyclopedia of Cancer. **2015**, 1-3

599 Expression Profiling as Biomarkers in Colorectal Serrated Carcinoma. **2015**, 631-657

598 Biomarkers for Renal Cell Carcinoma. **2015**, 59-82

597 Targeting Cancer Stem Cells and the Tumor Microenvironment. **2015**, 445-476

596 Encyclopedia of Cancer. **2015**, 1-4

595	Encyclopedia of Signaling Molecules. **2016**, 1-9	
594	Therapeutic Strategies, the Concept of Normalization and the Role of VEGF Inhibition. **2016**, 51-60	
593	Mechanisms of Tumor Angiogenesis. **2016**, 1-29	
592	Epigenetic Tumor Response to Hypoxia: An Epimutation Pattern and a Method of Multi Targeted Epigenetic Therapy (MTET). **2016**, 07, 254-269	1
591	mTOR Pathway in Renal Cell Carcinoma. **2016**, 417-428	
590	The Role of Hypoxia and Hyperthermia in Chemotherapy. **2016**, 61-71	
589	Angiogenesis: Basics of Vascular Biology. **2016**, 1-29	0
588	Hypoxia in Head and Neck Cancers: Clinical Relevance and Treatment. **2016**, 229-242	
587	Application of HaloTag Technology to in Vivo Molecular Imaging Using Protein Probes Labeled by Metallic Radionuclides. **2016**, 65, 247-255	
586	Disturbances of Lipid Metabolism in a Cancer Cell and How This Knowledge Increases Its Role in Clinical Oncology. **2016**, 761-789	
585	Zoledronic Acid Inhibits Angiogenesis Through Promoting HIF-1 Protein Degradation in Human Umbilical Vein Endothelial Cells. **2016**, 6, 745-753	1
584	Glycemic Index and Eye Health. **2016**, 219-271	
583	Role of STAT3 in Colorectal Cancer Development. **2017**, 269-298	2
582	Hypoxia-Inducible Factor (HIF)-1 and Its Regulation in Pancreatic Cancer. **2017**, 371-378	1
581	Overview of Transcription Factors in Esophagus Cancer. **2017**, 33-44	
580	Encyclopedia of Cancer. **2017**, 2187-2190	
579	Locally Advanced Non-small Cell Lung Cancer and Targeted Therapy. **2017**, 155-165	
578	A Potential Role of Hypoxia-Inducible Factor-1 (HIF-1) in Esophageal Cancer. **2017**, 91-100	

577 Encyclopedia of Cancer. **2017**, 2190-2192

576 The Tumor Microenvironment in Cutaneous Melanoma: Friend or Foe. **2017**, 481-506

575 Role of STAT3 in Liver Cancer. **2017**, 479-493

574 Chemical composition and the potential for proteomic transformation in cancer, hypoxia, and hyperosmotic stress.

573 Daam2 Driven Degradation of VHL Promotes Gliomagenesis.

572 Topotecan Decreases the Expression of Programmed Death-Ligand 1 in Glioblastoma Cell Lines; Implications for Immunotherapy. 1

571 Meme Kanseri H□crelerinde Zamana Ba□□HIF-2□□adesi De□□minin Analizi. 1

570 The Clinical Impact of Hypoxia in Head and Neck Squamous Cell Carcinoma. **2018**, 397-438

569 Multi-target analysis of neoplasms for the evaluation of tumor progression: stochastic approach of biologic processes. **2018**, 5, 14-62

568 Encyclopedia of Signaling Molecules. **2018**, 2489-2498

567 Using Concurrent or Sequential Chemotherapy and Biomolecules. **2018**, 265-290

566 Pre/post-surgical investigation of some angiogenic factors due to cancer and obesity. 97-102

565 Cancerous phenotypes associated with hypoxia-inducible factors are not influenced by the volatile anesthetic isoflurane in renal cell carcinoma.

564 Metabolic deregulation in prostate cancer. 0

563 Identification of substrates for the conserved prolyl hydroxylase Ofd1 using quantitative proteomics in fission yeast. 0

562 Molecular Docking and Drug-Likeness for the Identification of Inhibitory Action of Acetogenins from Annona muricata as Potential Anticancer against Hypoxia Inducible Factor 1 Alpha. **2018**, 11, 1301-1307

561 On the optimal design of metabolic RNA labeling experiments.

560 Lactate dehydrogenase and maternal and perinatal outcome in preeclamptic women. **2019**, 7, 163

559	Metabolic Adaptations in Diabetes Mellitus and Cancer. **2019**, 53-69	
558	Stromal Cell-Derived Factor 1 (SDF-1) Signaling and Tissue Homeostasis. **2019**, 47-59	
557	Anti-angiogenics and Radiation Therapy. **2019**, 349-358	
556	Computational staining of pathology images to study tumor microenvironment in lung cancer.	
555	The role of tumor-derived exosomes in tumor angiogenesis and tumor progression. **2019**, 32, 193-202	5
554	Exploring Mechanisms of Glucose Uptake Regulation and Dilution Resistance in Growing Cancer Cells.	0
553	A sound strategy for homology modeling-based affinity maturation of a HIF-1? single-domain intrabody.	
552	Hypothetical structure for energy transformation Evolution of cellular structures for energy transformation.	
551	Conditional Antisense Oligonucleotides Triggered by miRNA. **2021**, 16, 2255-2267	1
550	Vascular endothelial growth factor (VEGF) and hypoxia inducible factor-1 alpha (HIF-1?) in lacrimal gland Adenoid cystic carcinoma: Correlation with clinical outcome. **2021**, 56, 151846	0
549	Chemoprotective and chemosensitizing effects of apigenin on cancer therapy. **2021**, 21, 574	2
548	Modulating hypoxia inducible factor-1 by nanomaterials for effective cancer therapy. **2021**, e1766	0
547	Targeting Hypoxia: Revival of Old Remedies. **2021**, 11,	2
546	Current Understandings and Clinical Translation of Nanomedicines for Breast Cancer Therapy. **2021**, 180, 114034	5
545	Effects of an Environmentally Relevant Mixture of Organophosphate Esters Derived From House Dust on Endochondral Ossification in Murine Limb Bud Cultures. **2021**, 180, 62-75	1
544	Gene Expression Signatures of a Preclinical Mouse Model during Colorectal Cancer Progression under Low-Dose Metronomic Chemotherapy. **2020**, 13,	2
543	HIF-1? as a Potential Therapeutic Target for Tuberculosis Treatment. **2021**, 41-59	
542	Digitoxin promotes apoptosis and inhibits proliferation and migration by reducing HIF-1? and STAT3 in KRAS mutant human colon cancer cells. **2021**, 351, 109729	1

541	Angiogenesis: A Therapeutic Target for Cancer. **2020**, 165-183	2
540	Signaling Pathways Involved in Kidney and Urinary Tract Physiology and Pathology. **2020**, 163-193	
539	Reprogramming of Cancer Cell Metabolism: Warburg and Reverse Warburg Hypothesis. **2020**, 15-26	
538	The Influence of Bcl-3 Expression on Cell Migration and Chemosensitivity of Gastric Cancer Cells via Regulating Hypoxia-Induced Protective Autophagy. **2020**, 20, 95-105	1
537	Role of Selected Transcription Factors in Pancreatic and Colorectal Cancer Growth and Metastasis. **2020**, 193-207	
536	Generation and characterization of human emryonic stem cells with increased expression of HIF-2α **2020**, XV,	
535	Clinical and prognostic association of oncogene cadherin 11 in gastric cancer. **2020**, 19, 4011-4023	0
534	Hypoxia-inducible factor-1α regulates Lipin1 differently in pre-adipocytes and mature adipocytes. **2020**, 22, 559-565	1
533	In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors. **2020**, 20, 295-305	1
532	Self-Remedied Nanomedicine for Surmounting the Achilles' Heel of Photodynamic Tumor Therapy.. **2021**, 4, 8023-8032	2
531	PDGFRβ Modulates Aerobic Glycolysis in Osteosarcoma HOS Cells via the PI3K/AKT/mTOR/c-Myc Pathway. **2021**,	1
530	Target-Based Radiosensitization Strategies: Concepts and Companion Animal Model Outlook. **2021**, 11, 768692	2
529	Preconditioning of Hypoxic Culture Increases The Therapeutic Potential of Adipose Derived Mesenchymal Stem Cells. **2021**, 9, 505-515	
528	Molecular insights of metastasis and cancer progression derived using 3D cancer spheroid co-culture in vitro platform. **2021**, 168, 103511	2
527	Dynamic nano-assemblies based on two-dimensional inorganic nanoparticles: Construction and preclinical demonstration. **2021**, 180, 114031	6
526	HIF1 and ID1 Interplay Confers Adaptive Survival to HIF1β nhibition. **2021**, 9, 724059	
525	Matrix metalloproteinase-1 expression is regulated by HIF-1-dependent and epigenetic mechanisms and serves a tumor-suppressive role in gastric cancer progression. **2021**, 59,	0
524	Tumor-intrinsic FABP5 is a novel driver for colon cancer cell growth via the HIF-1 signaling pathway. **2021**, 258-259, 151-156	2

523	The Key Role of the WNT/Catenin Pathway in Metabolic Reprogramming in Cancers under Normoxic Conditions. **2021**, 13,	4
522	The lymphocyte in inflammatory angiogenesis. **2008**, 45-57	
521	Signalling Pathways Leading to Furin Expression in Cancer. **2006**, 27-45	1
520	The Maturation of Vessels A Limitation to Forced Neovascularization?. **2007**, 139-158	
519	Combinations of Hypoxia-Targeting Compounds and Radiation-Activated Prodrugs with Ionizing Radiation. **2006**, 67-91	
518	Regulation of Erythropoietin Expression in the Nervous System: The Hypoxia Inducible Factor. **2006**, 49-67	
517	Modeling Cancer as A Complex Adaptive System: Genetic Instability and Evolution. **2006**, 537-556	
516	Role of Genetic Susceptibility in Environmental Exposure Induced Diseases. **2007**, 103-123	
515	Novel Therapeutic Strategies For Posterior Segment Neovascularization. **2008**, 445-526	
514	Hypoxia Inducible Factor-1 and VEGF Induction. **2008**, 169-185	
513	Selfish Business. **2008**, 65-74	
512	Gastric Cancer: Overexpression of Hypoxia-Inducible Factor 1 as a Prognostic Factor. **2008**, 171-180	
511	The Role of Tumor Hypoxia in Head and Neck Cancer Radiotherapy. **2005**, 145-163	1
510	Targeted Therapies in Head and Neck Cancer. **2005**, 239-261	
509	The Cycle Between Angiogenesis, Perfusion, and Hypoxia in Tumors. **2006**, 3-19	1
508	Tumor Oxygenation and Treatment Response. **2006**, 43-66	
507	The Cycle Between Angiogenesis, Perfusion, and Hypoxia in Tumors. **2008**, 27-47	
506	Angiogenesis Inhibitors for the Treatment of Lung Cancer. **2008**, 409-426	0

505	Hypoxia-Inducible Factor 1 in the Angiogenesis of Prostate Cancer. **2008**, 209-221	
504	Antiangiogenic Therapies in Renal Cell Carcinoma. **2008**, 449-456	
503	Biological Therapies for Metastatic Breast Cancer: Antiangiogenesis. **2006**, 671-704	
502	SF3B1 promotes tumor malignancy through splicing-independent activation of HIF1	0
501	A Glucose-Triptolide Conjugate Selectively Targets Cancer Cells under Hypoxia. **2020**, 23, 101536	4
500	Tumor-Induced Metabolism and T Cells Located in Tumor Environment. **2020**, 20, 741-756	1
499	The role of glucose metabolism and glucose-associated signalling in cancer. **2008**, 1, 64-82	30
498	Targeted genes and interacting proteins of hypoxia inducible factor-1. **2012**, 3, 165-78	130
497	Regulation of Aerobic Glycolysis by microRNAs in Cancer. **2011**, 3, 125-134	47
496	The diverse and complex roles of radiation on cancer treatment: therapeutic target and genome maintenance. **2012**, 2, 372-82	6
495	Age-related macular degeneration: beyond anti-angiogenesis. **2014**, 20, 46-55	24
494	Hypoxia promotes the proliferation of cervical carcinoma cells through stimulating the secretion of IL-8. **2014**, 7, 575-83	16
493	Molecular imaging of hypoxia-inducible factor 1 alpha and von Hippel-Lindau interaction in mice. **2008**, 7, 139-46	4
492	Immunohistochemical expression of CD117 and vascular endothelial growth factor in retinoblastoma: possible targets of new therapies. **2014**, 7, 5725-37	13
491	Genetic association between the HIF-1P582S polymorphism and cervical cancer risk: a meta analysis. **2014**, 7, 6085-90	2
490	Down-regulation of hypoxia-inducible factor-1 suppresses malignant biological behavior of triple-negative breast cancer cells. **2014**, 7, 3933-40	7
489	Melatonin combined with exercise cannot alleviate cerebral injury in a rat model of focal cerebral ischemia/reperfusion injury. **2012**, 7, 993-9	4
488	Minocycline attenuates hypoxia-inducible factor-1expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies. **2015**, 5, 575-88	16

487	The association between the rs11549465 polymorphism in the hif-1α gene and cancer risk: a meta-analysis. **2015**, 8, 1561-74	9
486	Effect of simvastatin on mitochondrial enzyme activities, ghrelin, hypoxia-inducible factor 1α in hepatic tissue during early phase of sepsis. **2015**, 8, 3640-50	7
485	Hispidulin prevents hypoxia-induced epithelial-mesenchymal transition in human colon carcinoma cells. **2015**, 5, 1047-61	14
484	Preventing effects of joint contracture by high molecular weight hyaluronan injections in a rat immobilized knee model. **2015**, 8, 3426-40	8
483	T-cell lymphoma with von Hippel-Lindau disease: a rare case report and review of literature. **2015**, 8, 5837-43	
482	Distribution and inhibition effect of Seleno-L-Methionine on 4T1 mouse mammary carcinoma. **2015**, 7, 76-86	4
481	A preclinical study on the combination therapy of everolimus and transarterial chemoembolization in hepatocellular carcinoma. **2015**, 5, 2376-86	4
480	Bortezomib enhances the radiosensitivity of hypoxic cervical cancer cells by inhibiting HIF-1α expression. **2015**, 8, 9032-41	12
479	The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression. **2015**, 35, 5249-61	8
478	Chemokine CCL17 induced by hypoxia promotes the proliferation of cervical cancer cell. **2015**, 5, 3072-84	11
477	HIF-1α regulates Cx40-dependent vasodilatation following hemorrhagic shock in rats. **2017**, 9, 1277-1286	3
476	GC7 blocks epithelial-mesenchymal transition and reverses hypoxia-induced chemotherapy resistance in hepatocellular carcinoma cells. **2017**, 9, 2608-2617	10
475	Design, Synthesis and Biological Evaluation of Novel HIF1α Inhibitors. **2015**, 35, 3849-59	17
474	[The relationship of GLUT1 and lung cancer and its PET imaging]. **2010**, 13, 165-7	
473	The molecular mechanism and clinical significance of LDHA in HER2-mediated progression of gastric cancer. **2018**, 10, 2055-2067	12
472	Examining correlations of oxygen sensitive MRI (BOLD/TOLD) with [F]FMISO PET in rat prostate tumors. **2019**, 9, 156-167	5
471	eIF3a mediates HIF1α-dependent glycolytic metabolism in hepatocellular carcinoma cells through translational regulation. **2019**, 9, 1079-1090	6
470	PGK1-mediated cancer progression and drug resistance. **2019**, 9, 2280-2302	31

469	Co-expression of HIF-1 and TLR3 is associated with poor prognosis in oral squamous cell carcinoma. **2020**, 13, 65-72	3
468	Current statuses of molecular targeted and immune checkpoint therapies in hepatocellular carcinoma. **2020**, 10, 1522-1533	4
467	[Effect of Fei-Liu-Ping ointment combined with cyclophosphamide on lung cancer cell proliferation and acidic microenvironment]. **2020**, 52, 247-253	
466	Epithelial-mesenchymal transition and metastatic ability of CD133 colorectal cancer stem-like cells under hypoxia. **2021**, 21, 19	
465	Non-coding RNAs: emerging regulators of glucose metabolism in hepatocellular carcinoma. **2020**, 10, 4066-4084	1
464	Potential Role of Glucose Transporter-1 Expression in Gastric Cancer: A Meta-Analysis and Systematic Review. **2020**, 49, 2044-2053	
463	BMP4 augments the survival of hepatocellular carcinoma (HCC) cells under hypoxia and hypoglycemia conditions by promoting the glycolysis pathway. **2021**, 11, 793-811	2
462	Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy. **2021**, 9,	0
461	A reciprocal feedback loop between HIF-1□and HPIP controls phenotypic plasticity in breast cancer cells. **2021**, 526, 12-28	1
460	Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles. **2021**, 13,	6
459	Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results. **2021**, 13,	3
458	SLC7A5 is linked to increased expression of genes related to proliferation and hypoxia in estrogen-receptor-positive breast cancer. **2022**, 47,	0
457	Intraoperative Fractions of Inspiratory Oxygen Are Associated With Recurrence-Free Survival After Elective Cancer Surgery.. **2021**, 8, 761786	
456	A paradoxical role for sestrin 2 protein in tumor suppression and tumorigenesis. **2021**, 21, 606	1
455	How cancer cells remodel lipid metabolism: strategies targeting transcription factors. **2021**, 20, 163	5
454	Molekulare Pr□iktion f□ die Radio(chemo)therapie von Kopf-Hals-Plattenepithelkarzinomen. 1	
453	A Role for Fructose Metabolism in Development of Sheep and Pig Conceptuses. **2022**, 1354, 49-62	1
452	Targeting the Tumor Microenvironment: A Literature Review of the Novel Anti-Tumor Mechanism of Statins. **2021**, 11, 761107	5

451	The role of immune cells in pulmonary hypertension: Focusing on macrophages. **2021**, 83, 153-153	2
450	Hypoxia and Its Influence on Radiotherapy Response of HPV-Positive and HPV-Negative Head and Neck Cancer. **2021**, 13,	5
449	Aqueous angiopoietin-like levels correlate with optical coherence tomography angiography metrics in diabetic macular edema.. **2021**, 14, 1888-1894	
448	Fumarate is a terminal electron acceptor in the mammalian electron transport chain. **2021**, 374, 1227-1237	13
447	Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas.. **2021**, 12, 790661	1
446	Hypoxia Induced Stress Responses in Cancer and Cancer-Stem Cells. **2021**, 1-15	
445	Vitexin Inhibits Gastric Cancer Growth and Metastasis through HMGB1-mediated Inactivation of the PI3K/AKT/mTOR/HIF-1 Signaling Pathway.. **2021**, 21, 439-456	3
444	Downregulation of the Long Non-Coding RNA MALAT1 in Tenofovir-Treated Pregnant Women with Hepatitis B Virus Infection Promotes Immune Recovery of Natural Killer Cells Via the has-miR-155-5p/HIF-1 Axis.	
443	Hypoxia induction of SH2D3A triggers malignant progression of lung cancer.. **2022**, 58, 102630	
442	Targeted Anti-Cancer Provascular Therapy Using Ultrasound, Microbubbles, and Nitrite to Increase Radiotherapy Efficacy.. **2022**,	0
441	Context-dependent transcriptional regulations of YAP/TAZ in stem cell and differentiation.. **2022**, 13, 10	3
440	Capsaicin inhibits HIF-1 accumulation through suppression of mitochondrial respiration in lung cancer cells. **2021**, 146, 112500	2
439	Proteolysis of a histone acetyl reader, ATAD2, induces chemoresistance of cancer cells under severe hypoxia by inhibiting cell cycle progression in S phase.. **2021**, 528, 76-76	0
438	Thioredoxin and aging: What have we learned from the survival studies?. **2020**, 2, 126-133	0
437	Potential Role of Glucose Transporter-1 Expression in Gastric Cancer: A Meta-Analysis and Systematic Review. **2020**, 49, 2044-2053	
436	Epithelial-mesenchymal transition and metastatic ability of CD133+ colorectal cancer stem-like cells under hypoxia. **2020**, 21, 1-1	1
435	Monitoring and Modulating mtDNA G-Quadruplex Dynamics Reveal Its Close Relationship to Cell Glycolysis. **2021**,	8
434	Improving therapeutic resistance: beginning with targeting the tumor microenvironment. **2021**, 1-25	0

433	Molecular Mechanisms of Glucose Uptake Regulation in Thyroid Cancer.	0
432	Kinetically Orthogonal Probe for Simultaneous Measurement of HS and Nitroreductase: A Refined Method to Predict the Invasiveness of Tumor Cells.. **2022**,	1
431	DNA Origami-Anthraquinone Hybrid Nanostructures for In Vivo Quantitative Monitoring of the Progression of Tumor Hypoxia Affected by Chemotherapy.. **2022**,	0
430	SIPA1 Enhances Aerobic Glycolysis Through HIF-2α Pathway to Promote Breast Cancer Metastasis.. **2021**, 9, 779169	0
429	Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol.. **2022**,	0
428	Hypoxia-Induced Stress Responses in Cancer and Cancer Stem Cells. **2022**, 1829-1843	
427	Interaction among noncoding RNAs, DNA damage reactions, and genomic instability in the hypoxic tumor: is it therapeutically exploitable practice?. **2022**,	1
426	Selected molecular mechanisms of metal toxicity and carcinogenicity. **2022**, 253-278	
425	Hypoxia-inducible factor (HIF)-1α induced regulation of lung injury in pulmonary aspiration is mediated through NF-kB.. **2022**, 4, 309-328	0
424	ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer.. **2022**, 41, 15	8
423	The functional role of Pescadillo ribosomal biogenesis factor 1 in cancer.. **2022**, 13, 268-277	1
422	Molecular Mechanism of HIF-1α and CD31 Promoting Metastasis and Invasion of Advanced Hepatocellular Carcinoma. **2022**, 12, 236-245	
421	Tumor-Acidity and Bioorthogonal Chemistry-Mediated On-Site Size Transformation Clustered Nanosystem to Overcome Hypoxic Resistance and Enhance Chemoimmunotherapy.. **2022**,	11
420	Campylobacter jejuni induces differentiation of human neutrophils to the CD16hi/CD62Llo subtype which possess cancer promoting activities.	
419	microRNA-671-5p reduces tumorigenicity of ovarian cancer via suppressing HDAC5 and HIF-1α expression.. **2022**, 355, 109780	0
418	An ApoA-I Mimic Peptide of 4F Promotes SDF-1α Expression in Endothelial Cells Through PI3K/Akt/ERK/HIF-1α Signaling Pathway.. **2021**, 12, 760908	2
417	Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality?. **2021**, 11, 778761	1
416	Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy.. **2021**, 11, 786089	0

415	Quenching Epigenetic Drug Resistance Using Anti-hypoxic Microparticles in Glioblastoma Patient-derived Chips.. **2021**, e2102226	2
414	DNA demethylase ALKBH1 promotes adipogenic differentiation via regulation of HIF-1 signaling.. **2021**, 101499	2
413	Kaempferol increases intracellular ATP content in CC myotubes under hypoxic conditions by suppressing the HIF-1α stabilization and/or by enhancing the mitochondrial complex IV activity.. **2022**, 108949	1
412	Photomedicine based on heme-derived compounds.. **2022**, 114134	3
411	Hypoxia inducible factor 1α inhibitor PX-478 reduces atherosclerosis in mice.. **2022**, 344, 20-30	2
410	A tiered approach to investigate the inhalation toxicity of cobalt substances. Tier 2a: Grouping cobalt compounds based on their capacity to stabilize HIF-1α in human alveolar epithelial cells in vitro.. **2022**, 130, 105121	8
409	Zinc-enriched nanosystem for dual glycolysis regulation and photothermal therapy to synergistically inhibit primary melanoma and lung metastasis. **2022**, 435, 134781	2
408	Shed syndecan-2 enhances colon cancer progression by increasing cooperative angiogenesis in the tumor microenvironment.. **2022**,	1
407	Osthole Exerts Inhibitory Effects on Hypoxic Colon Cancer Cells via EIF2[Formula: see text] Phosphorylation-mediated Apoptosis and Regulation of HIF-1[Formula: see text].. **2022**, 1-17	0
406	Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy. **2021**, 9, e002755	0
405	Interplay Among Metabolism, Epigenetic Modifications, and Gene Expression in Cancer.. **2021**, 9, 793428	6
404	Silencing of HOXB9 suppresses cellular proliferation, angiogenesis, migration and invasion of prostate cancer cells. **2020**, 45,	3
403	Sensitization of breast cancer to Herceptin by redox active nanoparticles. **2021**, 11, 4884-4899	
402	Emerging Metabolic Regulation of Redox Status in Cancer Stem Cells Progression and Metastasis. **2022**, 1-16	
401	Neuronal STAT3/HIF-1β/PTRF axis-mediated bioenergetic disturbance exacerbates cerebral ischemia-reperfusion injury via PLA2G4A.. **2022**, 12, 3196-3216	0
400	Targeting KCTD1 as a Potential Novel Therapy Ameliorates Hepatocellular Carcinoma Progression via the HIF-1α/VEGF Pathway.	
399	Three-Dimensional Growth of Prostate Cancer Cells Exposed to Simulated Microgravity.. **2022**, 10, 841017	4
398	Ropivacaine Inhibits Lung Cancer Cell Malignancy Through Downregulation of Cellular Signaling Including HIF-1α. **2021**, 12, 806954	

397	Does Normobaric Hypoxic Resistance Training Confer Benefit over Normoxic Training in Athletes? A Narrative Review. 1	0
396	TAMpepK Suppresses Metastasis through the Elimination of M2-Like Tumor-Associated Macrophages in Triple-Negative Breast Cancer.. **2022**, 23,	0
395	Role of mitochondrial reactive oxygen species in homeostasis regulation.. **2022**, 27, 45-52	11
394	Oxygen Self-Supply Engineering-Ferritin for the Relief of Hypoxia in Tumors and the Enhancement of Photodynamic Therapy Efficacy.. **2022**, e2200116	16
393	iASPP is essential for HIF-1α stabilization to promote angiogenesis and glycolysis via attenuating VHL-mediated protein degradation.. **2022**,	0
392	Blockage of citrate export prevents TCA cycle fragmentation via Irg1 inactivation.. **2022**, 38, 110391	1
391	Tissue miRNA Combinations for the Differential Diagnosis of Adrenocortical Carcinoma and Adenoma Established by Artificial Intelligence.. **2022**, 14,	0
390	Molecular Mechanisms and Clinical Challenges of Glioma Invasion.. **2022**, 12,	1
389	Tumor Dormancy: Biologic and Therapeutic Implications.. **2022**, 13, 8-19	2
388	The evolutionarily conserved arginyltransferase 1 mediates a pVHL-independent oxygen-sensing pathway in mammalian cells.. **2022**,	2
387	Targeting stearoyl-CoA desaturase in solid tumors.. **2022**,	1
386	Quercetin Inhibits Glioblastoma Growth and Prolongs Survival Rate through Inhibiting Glycolytic Metabolism.. **2022**,	1
385	Lipid metabolic reprogramming by hypoxia-inducible factor-1 in the hypoxic tumour microenvironment.. **2022**, 1	0
384	Precise tumor immune rewiring via synthetic CRISPRa circuits gated by concurrent gain/loss of transcription factors.. **2022**, 13, 1454	0
383	Regulatory miRNAs in Cardiovascular and Alzheimer's Disease: A Focus on Copper.. **2022**, 23,	1
382	Adenosine-A2A Receptor Pathway in Cancer Immunotherapy.. **2022**, 13, 837230	5
381	Extracellular ATP promotes breast cancer chemoresistance via HIF-1α signaling.. **2022**, 13, 199	0
380	Pan-cancer Bioinformatics Analysis of the Double-edged Role of Hypoxia-inducible Factor 1α (HIF-1α) in Human Cancer.. **2022**, 2, 263-278	

379	Regulation of Glucose, Fatty Acid and Amino Acid Metabolism by Ubiquitination and SUMOylation for Cancer Progression.. **2022**, 10, 849625	0
378	A comprehensive single-cell expression atlas of human AML leukemia-initiating cells unravels the contribution of HIF pathway and its therapeutic potential.	
377	Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.. **2022**,	2
376	Adipose tissue: a neglected organ in the response to severe trauma?. **2022**, 79, 207	3
375	Hypoxia and Hypoxia-Inducible Factors in Lymphedema.. **2022**, 13, 851057	1
374	Glycogen synthase kinase GSK3β promotes tumorigenesis by activating HIF1/VEGFA signaling pathway in NSCLC tumor.. **2022**, 20, 32	0
373	A novel AMPK activator shows therapeutic potential in hepatocellular carcinoma by suppressing HIF1α-mediated aerobic glycolysis.. **2022**,	1
372	Ginsengenin derivatives synthesized from 20(R)-panaxotriol: Synthesis, characterization, and antitumor activity targeting HIF-1 pathway. **2022**,	0
371	Hypoxia and HIF-1 Trigger Marek's Disease Virus Reactivation in Lymphoma-Derived Latently Infected T Lymphocytes.. **2021**, JVI0142721	1
370	Hypoxia Enhances HIF1 Transcription Activity by Upregulating KDM4A and Mediating H3K9me3, Thus Inducing Ferroptosis Resistance in Cervical Cancer Cells.. **2022**, 2022, 1608806	3
369	Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer.. **2022**, 20, 41	0
368	Comparing the Secretomes of Chemorefractory and Chemoresistant Ovarian Cancer Cell Populations.. **2022**, 14,	2
367	IP-Se-06, a Selenylated Imidazo[1,2-]pyridine, Modulates Intracellular Redox State and Causes Akt/mTOR/HIF-1 and MAPK Signaling Inhibition, Promoting Antiproliferative Effect and Apoptosis in Glioblastoma Cells.. **2022**, 2022, 3710449	0
366	Targeting HIF-1α abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues.. **2022**,	6
365	Naphthalimide-Based Azo-Functionalized Supramolecular Vesicle in Hypoxia-Responsive Drug Delivery.. **2022**,	1
364	Tie2 Receptor in Tumor-Infiltrating Macrophages Is Dispensable for Tumor Angiogenesis and Tumor Relapse after Chemotherapy.. **2022**, 82, 1353-1364	1
363	Correlations between DWI, IVIM, and HIF-1α expression based on MRI and pathology in a murine model of rhabdomyosarcoma.. **2022**,	0
362	Gas regulation of complex II reversal via electron shunting to fumarate in the mammalian ETC.. **2022**,	0

361	NLGP regulates RGS5-TGF axis to promote pericyte-dependent vascular normalization during restricted tumor growth.. **2022**, 36, e22268	0
360	Aptamer-drug conjugates: New probes for imaging and targeted therapy. **2022**, 10, 100126	0
359	Hypoxic preconditioning improves the survival and pro-angiogenic capacity of transplanted human umbilical cord mesenchymal stem cells via HIF-1 signaling in a rat model of bronchopulmonary dysplasia.. **2022**, 605, 111-118	0
358	Downregulation of the long non-coding RNA MALAT1 in tenofovir-treated pregnant women with hepatitis B virus infection promotes immune recovery of natural killer cells via the has-miR-155-5p/HIF-1 axis.. **2022**, 107, 108701	0
357	MoS/LaF for enhanced photothermal therapy performance of poorly-differentiated hepatoma.. **2022**, 214, 112462	1
356	Regulation of epithelial-to-mesenchymal transition in hypoxia by the HIF-1 network.. **2021**,	1
355	HIF-1 n cerebral ischemia (Review). **2022**, 25,	3
354	Apigenin Induces Autophagy and Cell Death by Targeting EZH2 under Hypoxia Conditions in Gastric Cancer Cells.. **2021**, 22,	2
353	The Expression of Glutaminases and their Association with Clinicopathological Parameters in the Head and Neck Cancers.. **2021**,	0
352	HIF-1 switches the functionality of TGF- signaling via changing the partners of smads to drive glucose metabolic reprogramming in non-small cell lung cancer.. **2021**, 40, 398	1
351	Trident cold atmospheric plasma blocks three cancer survival pathways to overcome therapy resistance.. **2021**, 118,	1
350	A novel targeted multifunctional nanoplatform for visual chemo-hyperthermia synergy therapy on metastatic lymph nodes via lymphatic delivery.. **2021**, 19, 432	2
349	Ionophore Ability of Carnosine and Its Trehalose Conjugate Assists Copper Signal in Triggering Brain-Derived Neurotrophic Factor and Vascular Endothelial Growth Factor Activation In Vitro.. **2021**, 22,	1
348	Diagnostic and Therapeutic Values of Angiogenic Factors in Endometrial Cancer.. **2021**, 12,	0
347	Siah1 in cancer and nervous system diseases (Review).. **2022**, 47,	2
346	Differentially Expressed Genes Correlated with Fibrosis in a Rat Model of Chronic Partial Bladder Outlet Obstruction. **2021**, 9, 2219	
345	Homeostatic Regulation of Glucocorticoid Receptor Activity by Hypoxia-Inducible Factor 1: From Physiology to Clinic.. **2021**, 10,	0
344	Understanding p300-transcription factor interactions using sequence variation and hybridization.	

343	Impact of cancer metabolism on therapy resistance - Clinical implications.. **2021**, 100797	3
342	HIF-Dependent CKB Expression Promotes Breast Cancer Metastasis, Whereas Cyclocreatine Therapy Impairs Cellular Invasion and Improves Chemotherapy Efficacy.. **2021**, 14,	1
341	Canagliflozin Modulates Hypoxia-Induced Metastasis, Angiogenesis and Glycolysis by Decreasing HIF-1α Protein Synthesis via AKT/mTOR Pathway.. **2021**, 22,	3
340	HIF-1 Is Associated with Resistance to Hypoxia-Induced Apoptosis in Ameloblastoma.. **2021**, 2021, 3060375	3
339	HIF-1α s a Rational Target for Future Ovarian Cancer Therapies.. **2021**, 11, 785111	1
338	Biological Functions and Regulatory Mechanisms of Hypoxia-Inducible Factor-1α n Ischemic Stroke.. **2021**, 12, 801985	5
337	Induction of lncRNA NORAD accounts for hypoxia-induced chemoresistance and vasculogenic mimicry in colorectal cancer by sponging the miR-495-3p/ hypoxia-inducible factor-1α (HIF-1α). **2022**, 13, 950-962	0
336	Understanding p300-transcription factor interactions using sequence variation and hybridization.	0
335	Uncovering a Hub Signaling Pathway of Antimicrobial-Antifungal-Anticancer Peptides' Axis on Short Cationic Peptides via Network Pharmacology Study.. **2022**, 23,	0
334	Identification of a 5-Nutrient Stress-Sensitive Gene Signature to Predict Survival for Colorectal Cancer.. **2022**, 2022, 2587120	
333	Role of the IL-6/Jak/Stat Pathway in Tumor Angiogenesis: Influence of Estrogen Status.	1
332	Introducing the brain erythropoietin circle to explain adaptive brain hardware upgrade and improved performance.. **2022**,	0
331	Boron Chemicals in Drug Discovery and Development: Synthesis and Medicinal Perspective.. **2022**, 27,	16
330	Ultrasensitive Hypoxia Sensing at the Single-Molecule Level via Super-Resolution Quantum Dot-Linked Immunosandwich Assay.. **2022**,	1
329	The highly effective therapy of ovarian cancer by Bismuth-doped oxygen-deficient BaTiO3 with enhanced sono-piezocatalytic effects. **2022**, 442, 136380	3
328	Image_1.pdf. **2020**,	
327	Image_1.TIF. **2019**,	
326	Image_2.TIF. **2019**,	

325 Image_3.TIF. **2019**,

324 Image_4.TIF. **2019**,

323 Image_5.TIF. **2019**,

322 Table_1.DOCX. **2019**,

321 Table_2.DOCX. **2019**,

320 Table_3.DOCX. **2019**,

319 Table_4.DOCX. **2019**,

318 Table_5.DOCX. **2019**,

317 Table_6.DOCX. **2019**,

316 Table_7.DOCX. **2019**,

315 Data_Sheet_1.zip. **2019**,

314 Data_Sheet_2.pdf. **2019**,

313 Image_1.TIF. **2019**,

312 Image_2.TIF. **2019**,

311 Image_1.tif. **2019**,

310 Image_2.tif. **2019**,

309 Table_1.docx. **2019**,

308 Data_Sheet_1.pdf. **2020**,

307 Image_1.TIF. **2020**,

306 Image_2.TIF. **2020**,

305 Image_3.TIF. **2020**,

304 Image_4.TIF. **2020**,

303 Image_5.TIF. **2020**,

302 Image_6.TIF. **2020**,

301 Image_7.TIF. **2020**,

300 Image_8.TIF. **2020**,

299 Image_9.TIF. **2020**,

298 Data_Sheet_1.pdf. **2020**,

297 Video_1.MOV. **2020**,

296 Video_2.MOV. **2020**,

295 Video_3.MOV. **2020**,

294 Video_4.MOV. **2020**,

293 Video_5.MOV. **2020**,

292 Table_1.DOCX. **2019**,

291 Data_Sheet_1.ZIP. **2019**,

290 Video_1.MP4. **2019**,

289	Anti-hypoxic Effect of Polysaccharide Extract of Brown Seaweed in Tongue Squamous Cell Carcinoma.. **2022**, 9, 854780	
288	The roles of E3 ligases in Hepatocellular carcinoma.. **2022**, 12, 1179-1214	
287	Royal Jelly Extract Accelerates Keratinocyte Proliferation, and Upregulates Laminin <i></i>3 and Integrin <i></i>1 mRNA Expression, via Akt/mTOR/HIF-1<i></i> Pathway. **2022**, 12, 83-94	0
286	mTOR regulates aerobic glycolysis through NEAT1 and nuclear paraspeckle-mediated mechanism in hepatocellular carcinoma.. **2022**, 12, 3518-3533	0
285	Development and Validation of a Novel Hypoxia Score for Predicting Prognosis and Immune Microenvironment in Rectal Cancer.. **2022**, 9, 881554	
284	PHD3 inhibits cell proliferation through hydroxylation of PAX2 at proline 9. **2022**, 50, 1-8	
283	Inhibition of HIF prolyl hydroxylase modulates platelet function.. **2022**,	0
282	The Synergistic Cooperation between TGF-β and Hypoxia in Cancer and Fibrosis. **2022**, 12, 635	0
281	Oxygen Desaturation Is Associated With Fibrocyte Activation via Epidermal Growth Factor Receptor/Hypoxia-Inducible Factor-1α Axis in Chronic Obstructive Pulmonary Disease. **2022**, 13,	0
280	Synthesis and Anticancer Screening of Some Novel Pd-Catalysed 3-methyl Indole based Analogues on Mia PaCa-2 Cell Line. **2022**, 133211	1
279	The Mechanism of Long Non-coding RNA in Cancer Radioresistance/Radiosensitivity: A Systematic Review. **2022**, 13,	2
278	Targeting HIF-1α Function in Cancer through the Chaperone Action of NQO1: Implications of Genetic Diversity of NQO1. **2022**, 12, 747	1
277	Regulating Acidosis and Relieving Hypoxia by Platelet Membrane-Coated Nanoparticle for Enhancing Tumor Chemotherapy. **2022**, 10,	1
276	A potent PGK1 antagonist reveals PGK1 regulates the production of IL-1β and IL-6. **2022**,	0
275	Targeting the Immuno-Oncology Metabolism in Cancer. **2022**, 117-152	
274	Immuno-onco-metabolism and Therapeutic Resistance. **2022**, 45-89	3
273	Accounting Conformational Dynamics into Structural Modeling Reflected by Cryo-EM with Deep Learning.. **2022**,	
272	A Novel Predictive Model for Adrenocortical Carcinoma Based on Hypoxia- and Ferroptosis-Related Gene Expression. **2022**, 9,	0

271	Hypoxia-Responsive Luminescent CEST MRI Agent for and Tumor Detection and Imaging.. **2022**,	0
270	Manganese Dioxide-Based Nanocarrier Delivers Paclitaxel to Enhance Chemotherapy against Orthotopic Glioma through Hypoxia Relief.. **2022**, e2101531	1
269	Carotenoid transporter CD36 expression depends on hypoxia-inducible factor-1 in mouse soleus muscles. **2022**,	
268	An Extensive Review on Preclinical and Clinical Trials of Oncolytic Viruses Therapy for Pancreatic Cancer. **2022**, 12,	0
267	From Tissue Physoxia to Cancer Hypoxia, Cost-Effective Methods to Study Tissue-Specific O2 Levels in Cellular Biology. **2022**, 23, 5633	1
266	Crosstalk of Epigenetic and Metabolic Signaling Underpinning Glioblastoma Pathogenesis. **2022**, 14, 2655	2
265	Hypoxia, a key factor in the immune microenvironment. **2022**, 151, 113068	1
264	Tirapazamine-loaded CalliSpheres microspheres enhance synergy between tirapazamine and embolization against liver cancer in an animal model. **2022**, 151, 113123	0
263	Dual Stimuli Responsive Nanoparticle Conjugates for Hypoxia Targeted Drug Delivery.	
262	Action Sites and Clinical Application of HIF-1 Inhibitors. **2022**, 27, 3426	2
261	Paeoniflorin alleviates the progression of retinal vein occlusion via inhibiting hypoxia inducible factor-1 /vascular endothelial growth factor/STAT3 pathway. **2022**, 13, 13622-13631	0
260	UBE2C triggers HIF -1 glycolytic flux in head and neck squamous cell carcinoma.	2
259	Tumour Angiogenesis in Breast Cancer.	
258	Methanol fixed feeder layers altered the pluripotency and metabolism of bovine pluripotent stem cells. **2022**, 12,	0
257	Neuroinflammation in Vascular Cognitive Impairment and Dementia: Current Evidence, Advances, and Prospects. **2022**, 23, 6224	2
256	Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. **2022**, 15,	6
255	Naked mole-rat and Damaraland mole-rat exhibit lower respiration in mitochondria, cellular and organismal levels. **2022**, 148582	0
254	High-Dose Vitamin C for Cancer Therapy. **2022**, 15, 711	3

253	Identification of Differentially Expressed Genes and miRNAs for Ulcerative Colitis Using Bioinformatics Analysis. 13,	1
252	Hypoxia-driven metabolic heterogeneity and immune evasive behaviour of gastrointestinal cancers: Elements of a recipe for disaster. **2022**, 156, 155917	
251	ARNT Inhibits H5N1 Influenza A Virus Replication by Interacting with the PA Protein. **2022**, 14, 1347	
250	Histone Demethylase JMJD2D: A Novel Player in Colorectal and Hepatocellular Cancers. **2022**, 14, 2841	
249	Interleukin-17 governs hypoxic adaptation of injured epithelium.	1
248	Ginsenoside Rh3 Inhibits Lung Cancer Metastasis by Targeting Extracellular Signal-Regulated Kinase: A Network Pharmacology Study. **2022**, 15, 758	0
247	A mitochondrion-targeting two-photon photosensitizer with aggregation-induced emission characteristics for hypoxia-tolerant photodynamic therapy. **2022**, 137604	1
246	The multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation.	1
245	EV-Mediated Chemoresistance in the Tumor Microenvironment: Is NF-B a Player?. 12,	
244	Novel Drugs with High Efficacy against Tumor Angiogenesis. **2022**, 23, 6934	1
243	A Novel Hypoxia-inducible Factor 1 Inhibitor KC7F2 Attenuates Oxygen-induced Retinal Neovascularization. **2022**, 63, 13	0
242	Functional genomics screening identifies aspartyl-tRNA synthetase as a novel prognostic marker and a therapeutic target for gastric cancers.	0
241	Self-Sustained Regulation or Self-Perpetuating Dysregulation: ROS-dependent HIF-YAP-Notch Signaling as a Double-Edged Sword on Stem Cell Physiology and Tumorigenesis. 10,	0
240	Celastrol inhibits pathologic neovascularization in oxygen-induced retinopathy by targeting the miR-17-5p/HIF-1 /VEGF pathway. 1-18	0
239	Effect of chronic intermittent hypoxia-induced HIF-1 /ATAD2 expression on lung cancer stemness. **2022**, 27,	1
238	Cascade Reaction of Mn 2+ -Catechol Triggered by H 2 O 2 to Integrate Firm Tumor Vessel Embolization and Hypoxic Response Relief. 2200544	
237	Pharmacological Activation of the HIF Pathway Exerts Distinct Proliferative Effects in MDA-MB-231 and MCF7 cells**. **2022**, 7,	
236	HIF-1 mediated augmentation of miRNA-18b-5p facilitates proliferation and metastasis in osteosarcoma through attenuation PHF2. **2022**, 12,	0

235	The Epigenetic Regulation of Nonhistone Proteins by SETD7: New Targets in Cancer. 13,	0
234	Applications of resveratrol in the treatment of gastrointestinal cancer. **2022**, 153, 113274	1
233	PLIN2 promotes HCC cells proliferation by inhibiting the degradation of HIF1**2022**, 418, 113244	1
232	Regulatory perspectives of nanomaterials for theranostic application. **2022**, 373-384	
231	Biomimetically constructing a hypoxia-activated programmable phototheranostics at the molecular level.	0
230	Degradable polyprodrugs: design and therapeutic efficiency.	3
229	Protective Effect of Cardiomyocyte-Specific Prolyl-4-Hydroxylase 2 Inhibition on Ischemic Injury in a Mouse MI Model. **2022**, 235, 240-254	0
228	Contribution of Fatty Acid Oxidation to the Pathogenesis of Pulmonary Hypertension.	0
227	Research Progress of DUB Enzyme in Hepatocellular Carcinoma. 12,	0
226	Curcumenol Targeting YWHAG Inhibits the Pentose Phosphate Pathway and Enhances Antitumor Effects of Cisplatin. **2022**, 2022, 1-12	0
225	Hypoxia signaling in human health and diseases: implications and prospects for therapeutics. **2022**, 7,	4
224	Mitochondrial oxidative phosphorylation became functional under aglycemic hypoxia conditions in A549 cells.	0
223	Effects of glycolysis and polyamine predation on intestinal epithelial barrier in colorectal cancer. 12,	0
222	Orexin-A Reverse Bone Mass Loss Induced by Chronic Intermittent Hypoxia Through OX1R-Nrf2/HIF-1Pathway. Volume 16, 2145-2160	1
221	Cancer-Associated Fibroblasts in the Hypoxic Tumor Microenvironment. **2022**, 14, 3321	0
220	The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia. 13,	1
219	Recent Advances on the Role of ATGL in Cancer. 12,	0
218	The role of microglia immunometabolism in neurodegeneration: Focus on molecular determinants and metabolic intermediates of metabolic reprogramming. **2022**, 153, 113412	1

217	Organophosphate flame retardant TDCPP: A risk factor for renal cancer?. **2022**, 305, 135485	0
216	Dual active nanozyme-loaded MXene enables hyperthermia-enhanced tumor nanocatalytic therapy. **2022**, 449, 137847	4
215	Expression of Erythropoietin and Erythropoietin Receptor in Non‐Small Cell Lung Carcinomas. **2005**, 11, 993-999	16
214	Identification of a Novel Small-Molecule Inhibitor of the Hypoxia-Inducible Factor 1 Pathway. **2005**, 65, 605-612	27
213	Role of glycine and glycine receptors in vascular endothelium: a new perspective for the management of the post-ischemic injury-. **2022**, 20,	0
212	Pull the plug: Anti-angiogenesis potential of natural products in gastrointestinal cancer therapy.	0
211	Postoperative Long-Term Outcomes and Independent Risk Factors of Non-Small-Cell Lung Cancer Patients With Propofol versus Sevoflurane Anesthesia: A Retrospective Cohort Study. 13,	1
210	Hypoxia-mediated stabilization of HIF1A in prostatic intraepithelial neoplasia promotes cell plasticity and malignant progression. **2022**, 8,	0
209	Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms. 13,	0
208	Hypoxia and Alpha-Synuclein: Inextricable Link Underlying the Pathologic Progression of Parkinson's Disease. 14,	1
207	Campylobacter jejuni induces differentiation of human neutrophils to the CD16 hi /CD62L lo subtype.	0
206	Spatial meta-transcriptomics reveal associations of intratumor bacteria burden with lung cancer cells showing a distinct oncogenic signature. **2022**, 10, e004698	0
205	The Thioredoxin-1 Inhibitor 1-Methylpropyl 2-Imidazolyl Disulfide (PX-12) Decreases Vascular Permeability in Tumor Xenografts Monitored by Dynamic Contrast Enhanced Magnetic Resonance Imaging. **2005**, 11, 529-536	11
204	Molecular Pathways and Genomic Landscape of Glioblastoma Stem Cells: Opportunities for Targeted Therapy. **2022**, 14, 3743	1
203	Hypoxia: molecular pathophysiological mechanisms in human diseases.	2
202	Hypoxia mimetics restore bone biomineralisation in hyperglycaemic environments. **2022**, 12,	
201	Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer. **2022**, 23, 8844	1
200	Association of hypoxia inducible factor 1-Alpha gene polymorphisms with multiple disease risks: A comprehensive meta-analysis. **2022**, 17, e0273042	

199	Relationship between metabolic reprogramming and drug resistance in breast cancer. 12,	1
198	Cell-Type Dependent Regulation of the Electrogenic Na+/HCO3− Cotransporter 1 (NBCe1) by Hypoxia and Acidosis in Glioblastoma. **2022**, 23, 8975	
197	Acriflavine, an Acridine Derivative for Biomedical Application: Current State of the Art.	0
196	Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments. **2022**, 13,	1
195	Oxidative stress: An essential factor in the process of arteriovenous fistula failure. 9,	1
194	Non-coding RNAs in lung cancer: emerging regulators of angiogenesis. **2022**, 20,	2
193	Curcumin Sensitises Cancerous Kidney Cells to TRAIL Induced Apoptosis via Let-7C Mediated Deregulation of Cell Cycle Proteins and Cellular Metabolism. **2022**, 23, 9569	0
192	FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A.	0
191	The Hypoxia-Adenosine Link during Myocardial Ischemia−Reperfusion Injury. **2022**, 10, 1939	0
190	A narrative review of circulating tumor cells clusters: A key morphology of cancer cells in circulation promote hematogenous metastasis. 12,	1
189	SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. **2022**, 40, 111266	
188	Uropathogenic Escherichia coli subverts mitochondrial metabolism to enable intracellular bacterial pathogenesis in urinary tract infection. **2022**, 7, 1348-1360	2
187	Von Hippel−Lindau (VHL) disease and VHL-associated tumors in Indian subjects: VHL gene testing in a resource constraint setting. **2022**, 23,	
186	RING-finger E3 ligases regulatory network in PI3K/AKT-mediated glucose metabolism. **2022**, 8,	0
185	Inhibition of hypoxia-inducible factor 1 by acriflavine renders glioblastoma sensitive for photodynamic therapy. **2022**, 234, 112537	
184	Vitamin C-induced competitive binding of HIF-1α and p53 to ubiquitin E3 ligase CBL contributes to anti-breast cancer progression through p53 deacetylation. **2022**, 168, 113321	0
183	Injectable hyaluronan/MnO2 nanocomposite hydrogel constructed by metal-hydrazide coordinated crosslink mineralization for relieving tumor hypoxia and combined phototherapy. **2022**, 628, 79-94	0
182	Evaluation of the potential of ultrasound-mediated drug delivery for the treatment of ovarian cancer through preclinical studies. 12,	0

181	Precise gliomas therapy: Hypoxia-activated prodrugs sensitized by nano-photosensitizers. **2022**, 289, 121770	0
180	Engineered biomimetic nanoreactor for synergistic photodynamic-chemotherapy against hypoxic tumor. **2022**, 351, 151-163	1
179	Emerging Metabolic Regulation of Redox Status in Cancer Stem Cells Progression and Metastasis. **2022**, 2281-2295	0
178	Platinum nanoplatforms: classic catalysts claiming a prominent role in cancer therapy. **2022**, 51, 7662-7681	2
177	Molecular Characterisation of Coding Regions of HIF-1a Gene in Vechur Cattle by Cdna Sequencing.	0
176	Signaling Metabolite Succinylacetone Activates HIF-1□and Promotes Angiogenesis in <i>GSTZ1</i>-Deficient Hepatocellular Carcinoma.	0
175	Dynamic fluorescence probing glycolysis suppression process in the cancer cells treated with Trichostatin A.	0
174	CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment. **2022**, 11,	1
173	Overcoming the Impact of Hypoxia in Driving Radiotherapy Resistance in Head and Neck Squamous Cell Carcinoma. **2022**, 14, 4130	0
172	S100A9 Derived from Chemoembolization-Induced Hypoxia Governs Mitochondrial Function in Hepatocellular Carcinoma Progression. 2202206	0
171	Integrated System Pharmacology Approaches to Elucidate Multi-Target Mechanism of Solanum surattense against Hepatocellular Carcinoma. **2022**, 27, 6220	1
170	Caveolin-1 suppresses hippocampal neuron apoptosis via the regulation of HIF1□n hypoxia in naked mole-rats.	0
169	The Role of Hypoxia-Inducible Factor Isoforms in Breast Cancer and Perspectives on Their Inhibition in Therapy. **2022**, 14, 4518	1
168	Hypoxia-induced long non-coding RNA plasmacytoma variant translocation 1 upregulation aggravates pulmonary arterial smooth muscle cell proliferation by regulating autophagy via miR-186/Srf/Ctgf and miR-26b/Ctgf signaling pathways. **2022**,	0
167	Twist alters the breast tumor microenvironment via choline kinase to facilitate an aggressive phenotype.	0
166	The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies. **2022**, 21,	1
165	Drivers of Radioresistance in Prostate Cancer. **2022**, 11, 5637	1
164	Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies. **2022**, 14, 4568	2

163	Pulmonary Thrombosis Promotes Tumorigenesis via Myeloid Hypoxia-Inducible Factors. **2022**, 12, 1354	0
162	Pharmacological features, health benefits and clinical implications of honokiol. 1-23	1
161	Conducive target range of breast cancer: Hypoxic tumor microenvironment. 12,	0
160	Recent progress of biocompatible carbon dots in hypoxia-related fields. 088532822211253	0
159	Modeling preclinical cancer studies under physioxia to enhance clinical translation.	2
158	Human Umbilical Vein Endothelial Cells Survive on the Ischemic TCA Cycle under Lethal Ischemic Conditions. **2022**, 21, 2385-2396	0
157	Identification of a functional circRNA-miRNA-mRNA regulatory network in infantile hemangioma by bioinformatics analysis. **2022**, 101, e30791	0
156	Fluorinated Hyaluronic Acid Encapsulated Perfluorocarbon Nanoparticles as Tumor-Targeted Oxygen Carriers to Enhance Radiotherapy.	1
155	Cutting edge: interleukin-17a prompts HIF1Ɑ for wound healing. **2022**,	0
154	Activation of Piezo1 contributes to matrix stiffness-induced angiogenesis in hepatocellular carcinoma.	1
153	Regulation of Lipid Metabolism Under Stress and Its Role in Cancer. **2022**, 81-113	0
152	Antibody therapeutics for epithelial ovarian cancer.	0
151	Neurological Applications of Belzutifan in von Hippel Lindau Disease.	0
150	Hypoxia-Inducible Factor-1Ɑ in Rods Is Neuroprotective Following Retinal Detachment. **2022**, 63, 7	0
149	PX478-loaded silk fibroin nanoparticles reverse multidrug resistance by inhibiting the hypoxia-inducible factor. **2022**,	1
148	Novel Implications of Nanoparticle-Enhanced Radiotherapy and Brachytherapy: Z-Effect and Tumor Hypoxia. **2022**, 12, 943	1
147	Differential Expression of HIF1A, EPAS1, and VEGF Genes in Benign and Malignant Ovarian Neoplasia. **2022**, 14, 4899	0
146	Monoamine Oxidase Inhibitors Prevent Glucose-Dependent Energy Production, Proliferation and Migration of Bladder Carcinoma Cells. **2022**, 23, 11747	0

145	Zinc Finger Proteins: Functions and Mechanisms in Colon Cancer. **2022**, 14, 5242	0
144	Metabolic features of innate lymphoid cells. **2022**, 219,	0
143	BANCR positively regulates the HIF-1/VEGF-C/VEGFR-3 pathway in a hypoxic microenvironment to promote lymphangiogenesis in pancreatic cancer cells. **2022**, 24,	0
142	Extracellular vesicles from gastric epithelial GES-1 cells infected with Helicobacter pylori promote changes in recipient cells associated with malignancy. 12,	0
141	Obstructive sleep apnea is related to melanoma aggressiveness through paraspeckle protein-1 upregulation. 2200707	1
140	ESM1/VEGF/ERK signaling axis augments cell proliferation and tumor angiogenesis in human cervical squamous cell carcinoma.	0
139	The Clinical and Molecular Features in the VHL Renal Cancers; Close or Distant Relatives with Sporadic Clear Cell Renal Cell Carcinoma?. **2022**, 14, 5352	0
138	The Rate of Cisplatin Dosing Affects the Resistance and Metastatic Potential of Triple Negative Breast Cancer Cells, Independent of Hypoxia. **2022**, 14, 2184	0
137	VHL syndrome without clear family history: A rare case report and literature review of Chinese patients. 13,	0
136	Genetically Encoded Whole Cell Biosensor for Drug Discovery of HIF-1 Interaction Inhibitors. **2022**, 11, 3182-3189	0
135	Nanocatalase-Based Oxygen-Generating Nanocarriers for Active Oxygen Delivery to Relieve Hypoxia in Pancreatic Cancer.	1
134	Methyltransferase SMYD3 impairs hypoxia tolerance by augmenting hypoxia signaling independent of its enzymatic activity. **2022**, 102633	0
133	Tumor Angiogenesis. 1-30	0
132	Disruption of HIF1A translational control attenuates the HIF-dependent hypoxic response and solid tumour formation in vivo.	0
131	Targeting lactate-related cell cycle activities for cancer therapy. **2022**, 86, 1231-1243	1
130	SOCS5 knockdown suppresses metastasis of hepatocellular carcinoma by ameliorating HIF-1dependent mitochondrial damage. **2022**, 13,	0
129	Integrated approach to elucidate metal-implant related adverse outcome pathways. **2022**, 136, 105277	0
128	Regulation of pleiotropic physiological roles of nitric oxide signaling. **2023**, 101, 110496	1

127	CD8+ T cell metabolic changes in breast cancer. **2023**, 1869, 166565	0
126	The malignant phenotype. **2006**, 116,	0
125	Investigation of the effects of isoeugenol-based phenolic compounds on migration and proliferation of HT29 colon cancer cells at cellular and molecular level. **2023**, 130, 106230	0
124	Tumorigenesis Mechanisms Found in Hereditary Renal Cell Carcinoma: A Review. **2022**, 13, 2122	0
123	EGFR-dependent aerotaxis is a common trait of breast tumour cells. **2022**, 41,	0
122	Single-cell RNA sequencing reveals cellular and molecular reprograming landscape of gliomas and lung cancer brain metastases. **2022**, 12,	0
121	ZBTB2 links p53 deficiency to HIF -1-mediated hypoxia signaling to promote cancer aggressiveness.	0
120	Regulation of Metastatic Tumor Dormancy and Emerging Opportunities for Therapeutic Intervention. **2022**, 23, 13931	0
119	Biomedical engineered nanomaterials to alleviate tumor hypoxia for enhanced photodynamic therapy. **2022**, 106551	1
118	Pan-cancer analysis of tissue and single-cell HIF-pathway activation using a conserved gene signature. **2022**, 41, 111652	0
117	Extracellular Vesicles in Multiple Myeloma□Cracking the Code to a Better Understanding of the Disease. **2022**, 14, 5575	0
116	Hypoxia Enhances Glioma Resistance to Sulfasalazine-Induced Ferroptosis by Upregulating SLC7A11 via PI3K/AKT/HIF-1□Axis. **2022**, 2022, 1-22	1
115	Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?.	0
114	Heme oxygenase-1 protects against PM2.5 induced endothelial dysfunction through inhibition of HIF1□**2023**, 97, 104024	0
113	Hypoxia alleviating platinum(IV)/chlorin e6-based combination chemotherapeutic-photodynamic nanomedicine for oropharyngeal carcinoma. **2023**, 238, 112627	0
112	Mitochondrial physiology: An overview. **2023**, 1-27	0
111	Effect of Angelica Sinensis extract on the angiogenesis of preovulatory follicles (F1□3) in late-phase laying hens. **2023**, 102, 102415	0
110	Anti-hypoxic Agents for Improving Head and Neck Cancer Therapy. **2022**,	0

109	Chapter 10. Microfluidic Models of the Tumor Microenvironment. **2022**, 252-278	0
108	Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research. 12,	0
107	A self-amplified necrotic targeting theranostic nanoparticle with deep tumor penetration for imaging-guided personalized chemo-photodynamic therapy. **2022**, 140465	0
106	A deubiquitination module essential for T reg fitness in the tumor microenvironment. **2022**, 8,	1
105	Folate receptor-targetable and tumor microenvironment-responsive manganese dioxide-based nano-photosensitizer for enhancing hypoxia alleviation-triggered phototherapeutic effects. **2022**,	0
104	Cancer-specific cytotoxicity of pyridinium-based ionic liquids by regulating hypoxia-inducible factor-1□centric cancer metabolism. **2022**, 248, 114334	1
103	The Role of the Chemokine CXCL12 on the Pathogenesis of Several Diseases. **2022**, 18, 419-426	0
102	PI3K / AKT pathway promotes keloid fibroblasts proliferation by enhancing glycolysis under hypoxia.	0
101	Molecular characterisation of coding regions OF HIF-1a gene in Vechur cattle by cDNA sequencing. **2022**, e12578	0
100	Hypoxia deactivates epigenetic feedbacks via enzyme-derived clicking proteolysis-targeting chimeras. **2022**, 8,	0
99	Hypoxia-induced factor and its role in liver fibrosis. 10, e14299	0
98	ROS-responsive mechanically and electronically controllable conductive hydrogel sensor with NIR modulated photothermal therapy. **2022**, 140729	0
97	A delayed ovulation of Progestin-Primed Ovarian Stimulation (PPOS) by down-regulating the LHCGR/PGR pathway.	0
96	NSD1 promotes esophageal cancer tumorigenesis via HIF1□signaling.	0
95	Systemic Delivery of Divalent Europium from Ligand Screening with Implications to Direct Imaging of Hypoxia. **2022**, 144, 23053-23060	2
94	Visualization of hypoxia in cancer cells from effusions in animals and cancer patients. 12,	1
93	Association of hypoxia-inducible factor 1 expressions with prognosis role as a survival prognostic biomarker in the patients with osteosarcoma: a meta-analysis. 1-8	0
92	Role of STAT3 and NRF2 in Tumors: Potential Targets for Antitumor Therapy. **2022**, 27, 8768	1

91	Prognostic Factors for the Efficiency of Radiation Therapy in Dogs with Oral Melanoma: A Pilot Study of Hypoxia in Intraosseous Lesions. **2023**, 10, 4	0
90	Lactate-dependent chaperone-mediated autophagy induces oscillatory HIF-1 activity promoting proliferation of hypoxic cells. **2022**, 13, 1048-1064.e7	1
89	Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents post hoc analyses of the ASCEND-ND and ASCEND-D trials.	0
88	Head-up tilt does not enhance prostate tumor perfusion or oxygenation in young rats. **2022**, 10,	0
87	Prognostic Role of Vascular Endothelial Growth Factor and Correlation with Oxidative Stress Markers in Locally Advanced and Metastatic Ovarian Cancer Patients. **2023**, 13, 166	1
86	Metabolic Adaptations of Cancer in Extreme Tumor Microenvironments.	0
85	IDH2 stabilizes HIF -1 nduced metabolic reprogramming and promotes chemoresistance in urothelial cancer.	0
84	Cancer plasticity: Investigating the causes for this agility. **2023**, 88, 138-156	0
83	Hypoxia signaling pathway: A central mediator in endocrine tumors. 13,	0
82	Tumor hypoxia: From basic knowledge to therapeutic implications. **2023**, 88, 172-186	0
81	MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression. gutjnl-2022-327924	0
80	Druggable Biomarkers Altered in Clear Cell Renal Cell Carcinoma: Strategy for the Development of Mechanism-Based Combination Therapy. **2023**, 24, 902	0
79	Network Pharmacology Analysis and Experimental Verification on Antiangiogenesis Mechanism of Hedyotis diffusa Willd in Liver Cancer. **2023**, 2023, 1-11	0
78	Ferroptosis in life: To be or not to be. **2023**, 159, 114241	0
77	Expression of HIF-1 and Genes Involved in Glucose Metabolism Is Increased in Cervical Cancer and HPV-16-Positive Cell Lines. **2023**, 12, 33	0
76	Hypoxia signaling and cholesterol/steroidogenic acute regulatory protein 1 axis: interplay and role in alcohol and non-alcohol-related liver diseases. 170-186	0
75	Acidic and hypoxic tumor microenvironment regulation by CaO2-loaded polydopamine nanoparticles. **2022**, 20,	0
74	Hypoxia Affects the Antioxidant Activity of Glutaredoxin 3 in Scylla paramamosain through Hypoxia Response Elements. **2023**, 12, 76	0

73	Metabolic reprogramming by miRNAs in the tumor microenvironment: Focused on immunometabolism. 12,	0
72	Lactate-related metabolic reprogramming and immune regulation in colorectal cancer. 13,	0
71	Hypoxia inducible factor-1 activator munc-18-interacting protein 3 promotes tumour progression in urothelial carcinoma. **2023**, 3,	1
70	NOX Dependent ROS Generation and Cell Metabolism. **2023**, 24, 2086	1
69	Prognostic histological markers in oral tongue squamous cell carcinoma patients treated with (chemo)radiotherapy.	0
68	Glycogen as an Effective Target in Cancer Therapy. **2023**, 1-12	0
67	Mint3-targeted therapy: A novel therapeutic strategy for urothelial carcinoma. **2023**, 3,	0
66	Expression of fructose-1,6-bisphosphatase 1 is associated with [18F]FDG uptake and prognosis in patients with mesial temporal lobe epilepsy.	0
65	Ferroptosis-modulating small molecules for targeting drug-resistant cancer: Challenges and opportunities in manipulating redox signaling.	0
64	Hypercapnic Tissue Gene Expression and Survival in Early-Stage Pancreatic Ductal Adenocarcinoma. Publish Ahead of Print,	0
63	Encoding and Decoding of p53 Dynamics in Cellular Response to Stresses. **2023**, 12, 490	1
62	Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses.	0
61	Hypoxia-inducible lncRNA MIR210HG promotes HIF1□expression by inhibiting miR -93-5p in renal tubular cells.	0
60	Molecular principles of tissue invasion and metastasis. **2023**, 324, C971-C991	0
59	Cancer metabolism within tumor microenvironments. **2023**, 1867, 130330	0
58	3D printing of lithium osteogenic bioactive composite scaffold for enhanced bone regeneration. **2023**, 256, 110641	0
57	The role of metabolic reprogramming of tumor-associated macrophages in shaping the immunosuppressive tumor microenvironment. **2023**, 161, 114504	0
56	l-carvone decreases breast cancer cells adhesion, migration, and invasion by suppressing FAK activation. **2023**, 110480	0

55	Icariin promotes osteogenic differentiation by upregulating alpha-enolase expression. **2023**, 34, 101471	0
54	Insight into the transcription factors regulating Ischemic stroke and glioma in response to shared stimuli. **2023**, 92, 102-127	0
53	L3MBTL3 is induced by HIF-1α and fine tunes the HIF-1α degradation under hypoxia in vitro. **2023**, 9, e13222	0
52	Interactions between non-coding RNAs and HIF-1α in the context of cancer. **2023**, 943, 175535	0
51	The role of metabolic reprogramming of oxygen-induced macrophages in the dynamic changes of atherosclerotic plaques. **2023**, 37,	0
50	HuMSC-EV induce monocyte/macrophage mobilization to orchestrate neovascularization in wound healing process following radiation injury. **2023**, 9,	0
49	An overview of hyperbaric oxygen preconditioning against ischemic stroke. **2023**, 38, 855-872	0
48	Could senescence phenotypes strike the balance to promote tumor dormancy?. **2023**, 42, 143-160	0
47	Cardiomyocyte infection by Trypanosoma cruzi promotes innate immune response and glycolysis activation. 13,	0
46	Down-regulation of ALDOB during metabolic reprogramming mediates malignant behavior in hepatocellular carcinoma and insensitivity to postoperative adjuvant transarterial chemoembolization. **2023**, 137, 303-316	0
45	Microfluidics-enabled Serial Assembly of Lipid-siRNA-sorafenib Nanoparticles for Synergetic Hepatocellular Carcinoma Therapy. **2023**, 35,	0
44	Potential Pathophysiological Pathways in the Complex Relationships between OSA and Cancer. **2023**, 15, 1061	1
43	HDAC8 Deacetylates HIF-1α and Enhances Its Protein Stability to Promote Tumor Growth and Migration in Melanoma. **2023**, 15, 1123	0
42	Review: Mechanisms and perspective treatment of radioresistance in non-small cell lung cancer. 14,	0
41	MicroRNA-223: a key regulator of liver tumour microenvironment. gutjnl-2022-329322	0
40	HIF : a master regulator of nutrient availability and metabolic cross-talk in the tumor microenvironment. **2023**, 42,	0
39	Participation of adhesion molecules in changing cell interactions during metastasis development. **2020**, 15, 27-32	0
38	Exploiting moderate hypoxia to benefit patients with brain disease: Molecular mechanisms and translational research in progress.	0

37	Hypoxia in Skin Cancer: Molecular Basis and Clinical Implications. **2023**, 24, 4430	0
36	Expression Dynamics of CA IX Epitope in Cancer Cells under Intermittent Hypoxia Correlates with Extracellular pH Drop and Cell Killing by Ureido-Sulfonamide CA IX Inhibitors. **2023**, 24, 4595	0
35	Albumin-based smart nanoplatform for ultrasound-mediated enhanced chemo-sonodynamic combination therapy. **2023**, 227, 111794	0
34	Co-expression prognostic-related genes signature base on propofol and sevoflurane anesthesia predict prognosis and immunotherapy response in glioblastoma. **2023**, 55, 778-792	0
33	HIPK2 in Angiogenesis: A Promising Biomarker in Cancer Progression and in Angiogenic Diseases. **2023**, 15, 1566	0
32	Host-Related Factors in the Interplay among Inflammation, Immunity and Dormancy in Breast Cancer Recurrence and Prognosis: An Overview for Clinicians. **2023**, 24, 4974	0
31	Elevated hypoxic inducible factor-1 alpha levels associated with metabolic disorders in children with obesity.	0
30	Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges. 13,	0
29	SIRT3 -dependent delactylation of cyclin E2 prevents hepatocellular carcinoma growth.	0
28	An optimized reporter of the transcription factor hypoxia-inducible factor 1reveals complex HIF-1activation dynamics in single cells. **2023**, 299, 104599	0
27	A comprehensive review on the indazole based derivatives as targeted anticancer agents. **2023**, 1284, 135327	0
26	3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor-on-a-Chip.	0
25	An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines. **2023**, 24, 5648	0
24	Carbonic anhydrase IX-related tumoral hypoxia predicts worse prognosis in breast cancer: A systematic review and meta-analysis. 10,	0
23	High Expression of COA6 Is Related to Unfavorable Prognosis and Enhanced Oxidative Phosphorylation in Lung Adenocarcinoma. **2023**, 24, 5705	0
22	Hypoxia-induced autophagy in triple negative breast cancer: association with prognostic variables, patientssurvival and response to neoadjuvant chemotherapy.	0
21	Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer. **2023**, 24, 5840	0
20	The Clinical Applications of Hypoxia-Inducible Factor-1Alpha (HIF-1 36, 1300-1304	0

19	Biomimetic gene editing system for precise tumor cell reprogramming and augmented tumor therapy. **2023**, 356, 663-677	0
18	Expression of RSUME is Associated With Poor Prognosis in Clear Cell Renal Carcinoma: Involvement of ROS Related Metabolism. **2023**,	0
17	Oxygen-Generating Biomaterials for Translational Bone Regenerative Engineering.	0
16	Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment. **2023**, 24, 6495	0
15	Preoperative contrast-enhanced CT-based radiomics signature for predicting hypoxia-inducible factor 1α expression in retroperitoneal sarcoma. **2023**,	0
14	Hypoxia switches TET1 from being tumor-suppressive to oncogenic.	0
13	Positron emission tomography imaging sheds new light on hypoxia and antitumor therapies.	0
12	Hypoxia Increases ATX Expression by Histone Crotonylation in a HIF-2α Dependent Manner. **2023**, 24, 7031	0
11	HIGD1A inactivated by DNA hypermethylation promotes invasion of kidney renal clear cell carcinoma. **2023**, 245, 154463	0
10	Hallmarks of an Aging and Malignant Tumor Microenvironment and the Rise of Resilient Cell Subpopulations. **2023**, 113-137	0
9	A deep learning and docking simulation-based virtual screening strategy enables the rapid identification of HIF-1α pathway activators from a marine natural product database. 1-23	0
8	Role of Hypoxia in Cancer Therapy: Introduction. **2023**, 245-250	0
7	Hypoxia and Senescence: Role of Oxygen in Modulation of Tumor Suppression. **2023**, 89-117	0
6	Hypoxia and Extracellular Matrix-Major Drivers of Tumor Metastasis. **2023**, 217-244	0
5	HIF1α dependent and independent pathways regulate the expression of PD-L1 in prostate cancer. **2023**, 40,	0
4	Self-adaptive nanoassembly enabling turn-on hypoxia illumination and periphery/center closed-loop tumor eradication. **2023**, 4, 101014	0
3	Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma. **2023**, 24, 7506	0
2	The Involvement of Glucose and Lipid Metabolism Alteration in Rheumatoid Arthritis and Its Clinical Implication. Volume 16, 1837-1852	0

1	Strategic Design of Conquering Hypoxia in Tumor for Advanced Photodynamic Therapy.	0